Novel thiophene sulfoximines, compositions thereof, and methods treating complement-mediated diseases and conditions

ABSTRACT

Disclosed are compounds for treating the symptoms of an acute or chronic disorder mediated by the classical pathway of the complement cascade. Said compounds are of Formula I  
                 
 
or a solvate, hydrate, pharmaceutically acceptable salt, or prodrug thereof; wherein R a , R b , and R c  are defined in the specification, as are A Z, Q, R 1  and R 2 .

CROSS REFERENCE TO RELATED APPLICATIONS

This application claims priority to U.S. Provisional Application forPatent No. 60/662,518, filed Mar. 16, 2005, the entire disclosure ofwhich are hereby incorporated in their entirely.

BACKGROUND OF THE INVENTION

The present invention is in the field of medicinal chemistry. Inparticular, the invention is directed to novel heterocyclic sufloximinesand their use for inhibiting the enzyme C1s, a protease in the classicalpathway of the complement system; and the use of this inhibition totreat or ameliorate acute or chronic disorders in mammals

The immune system of the human body is equipped with several defensemechanisms to respond to bacterial, viral, or parasitic infection andinjury. One such defense mechanism involves the complement system.Complement consists of a complex series of approximately 30 plasma andmembrane protein components, many of which are proteinases. Onceactivated, this system of enzymes non-specifically complements theimmunologically specific effects of antibody by modulating the immuneresponse, lysing target cells, stimulating vascular and other smoothmuscle cells, facilitating the transport of immune complexes, producinganaphylatoxins which cause degranulation of mast cells and release ofhistamine, stimulating chemotaxis (migration) of leukocytes toward thearea of complement activity, activating B lymphocytes and macrophages,and inducing phagocytosis and lysis of cells (Eisen, H. N., Immunology,Harper & Row Publishers, Inc., Hagerstown, Md., p. 512 (1974); Roitt, I.et al., Immunology, Gower Medical Publishing, London, N.Y., pp. 7.1-7.14(1985); U.S. Pat. Nos. 5,472,939 and 5,268,363).

The complement system functions as a “cascade.” The enzyme cascades areinitiated when inactive enzyme precursor molecules are activated,through limited proteolysis, by membrane-bound enzymes. A small fragmentis lost from the enzyme precursor and a nascent membrane binding site isrevealed. The major fragment then binds to the membrane as the nextfunctionally active enzyme of the complement cascade. Since each enzymeis able to activate many enzyme precursors, the system forms anamplifying cascade, resembling the reactions seen in blood clotting andfibrinolysis (Roitt, I. et al., Immunology, Gower Medical Publishing,London, N.Y., pp. 7.1-7.14 (1985)).

The proteins of the complement system form three inter-related enzymecascades, termed the classical, mannan-binding lectin (MBL) andalternative pathways. The classical pathway is usually initiated byantigen-antibody complexes, while the alternative pathway is activatedby specific polysaccharides, often found on bacterial, viral, andparasitic cell surfaces. The MBL pathway is mediated by mannan-bindinglectin binding to the mannose groups found in many microbialcarbohydrates. The classical pathway consists of components C1-C9, whilethe alternative pathway consists of components C3-C9 (excluding C4) andseveral factors, such as Factor B, Factor D, and Factor H.

The sequence of events comprising the classical complement pathwayconsists of three stages: recognition, enzymatic activation, andmembrane attack leading to cell death. The first phase of complementactivation begins with C1. C1 is made up of three distinct proteins: arecognition subunit, C1q, and the serine proteinase subcomponents, C1rand C1s, which are bound together in a calcium-dependent tetramericcomplex, C1r₂s₂. An intact C1 complex is necessary for physiologicalactivation of C1 to result. Activation occurs when the intact C1 complexbinds to immunoglobulin complexed with antigen. This binding activatesC1 s which then cleaves both the C4 and C2 proteins to generate C4a andC4b, as well as C2a and C2b. The C4b and C2a fragments combine to formthe C3 convertase, which in turn cleaves C3 to form C3a and C3b(Makrides, Pharmacol. Rev. 50:59-87 (1998); and U.S. Pat. No.5,268,363). Both the classical and alternative pathways are capable ofindividually inducing the production of the C3 convertase to convert C3to C3b, the generation of which is the central event of the complementpathway. C3b binds to C3b receptors present on neutrophils, eosinophils,monocytes and macrophages, thereby activating the terminal lyticcomplement sequence, C5-C9 (Roitt, I. et al., Immunology, Gower MedicalPublishing, London, N.Y., pp. 7.1-7.14 (1985)).

Complement is designed to fight infection and injury; however, this samemechanism, if inappropriately activated, can cause a significant amountof inflammation and tissue damage as a result of the rapid andaggressive enzyme activity. Complement-induced inflammation and tissuedamage has been implicated in a number of disease states, including: theintestinal inflammation of Crohn's disease which is characterized by thelymphoid infiltration of mononuclear and polymorphonuclear leukocytes(Ahrenstedt et al., New Engl. J. Med. 322:1345-9 (1990)), thermal injury(burns, frostbite) (Gelfand et al., J. Clin. Invest. 70:1170 (1982);Demling et al., Surgery 106:52-9 (1989)), hemodialysis (Deppisch et al.,Kidney Inst. 37:696-706 (1990); Kojima et al., Nippon Jenzo Gakkai Shi31:91-7 (1989)), post pump syndrome in cardiopulmonary bypass (Chenowethet al., Complement. Inflamm. 3:152-165 (1981); Chenoweth et al.,Complement 3:152-165 (1986); Salama et al., N. Engl. J. Med. 318:408-14(1988)), and ischaemia (Huang et al., Science 285:595 (1999); Naka etal., Transplantation 64:1248 (1997); Pemberton et al., J. Immunol.150:5104 (1993); Chavez-Cartaya et al., Transplantation 59:1047 (1995);Hill et al., J. Immunol. 149:1723 (1992); Weisman et al., Science249:146 (1990)). Both complement and leukocytes are reported to beimplicated in the pathogenesis of adult respiratory distress syndrome(Zilow et al., Clin. Exp. Immunol. 79:151-57 (1990); Langlois et al.,Heart Lung 18:71-84 (1989)). Activation of the complement system issuggested to be involved in the development of fatal complications insepsis (Hack et al., Am. J. Med. 86:20-26 (1989)) and causes tissueinjury in animal models of autoimmune diseases such asimmune-complex-induced vasculitis (Cochrane, Springer SeminarImmunopathol. 7:263 (1984)), glomerulonephritis (Couser et al., KidneyInst. 29:879 (1985)), type II collagen-induced arthritis (Watson &Townes, J. Exp. Med. 162:1878 (1985)), and experimental allergicneuritis (Feasby et al., Brain Res. 419:97 (1987)). The complementsystem is also involved in hyperacute allograft and hyperacute xenograftrejection (Knechtle et al., J. Heart Transplant 4(5):541 (1985);Guttman, Transplantation 17:383 (1974); Adachi et al., Trans. Proc.19(1):1145 (1987)). Complement activation during immunotherapy withrecombinant IL-2 appears to cause the severe toxicity and side effectsobserved from IL-2 treatment (Thijs et al., J. Immunol. 144:2419(1990)).

Complement fragments generated by the classical portion of thecomplement cascade have been found to be present in the immune complexesformed against indigenous tissue in autoimmune diseases. Such diseasesinclude, but are not limited to: Hashimoto's thyroiditis,glomerulonephritis and cutaneous lesions of systemic lupuserythematosus, other glomerulonephritides, bullous pemphigoid,dermatitis herpetiformis, Goodpasture's syndrome, Graves' disease,myasthenia gravis, insulin resistance, autoimmune hemolyic anemia,autoimmune thrombocytopenic purpura, and rheumatoid arthritis (Bieseckeret al. J. Exp. Med. 154: 1779 (1981); Biesecker et al., N. Engl. J. Med.306: 264 (1982); Falk et al., Clin. Research 32:503A (Abstract) (1984);Falk et al., J. Clin. Invest. 72:560 (1983); Dahl et al., J. Invest.Dermatol. 82:132 (1984); Dahl et al., Arch. Dermatol. 121:70 (1985);Sanders et al. Clin. Research 33:388A (Abstract) (1985); and U.S. Pat.Nos. 5,268,363 and 4,722,890).

Compounds that potently and selectively inhibit complement will havetherapeutic applications in several acute and chronic immunological andnon-immunological disorders, and a variety of neurodegenerativediseases. Evidence from both human and animal studies shows thatactivation of the classical complement pathway is primarily involved inneurodegenerative diseases of the central nervous system (CNS).Autoimmune diseases in which these inhibitors of the complement cascadesystem will be therapeutically useful include myasthenia gravis (MG),rheumatoid arthritis, and systemic lupus erythematosus.Neurodegenerative diseases in which inhibitors of the complement cascadesystem will be therapeutically useful include the demyelinating disordermultiple sclerosis (MS), the neuropathies Guillain-Barré syndrome (GBS)and Miller-Fisher syndrome (MFS), Alzheimer's disease (AD), andprion-related disease (variant Creutzfeld Jacob disease). Other diseasesand conditions include hereditary and acquired angioedema (in which adeficiency in complement inhibitory protein leads to an activecomplement consumption and repeated episodes of life-threateningangiodema), septic shock, paroxysmal nocturnal hemoglobinuria, organrejection (transplantation), burns (wound healing), brain trauma, softtissue trauma, asthma, platelet storage, hemodialysis,ischemia-reperfusion injury, and cardiopulmonary bypass equipment(Makrides, Pharmacol. Rev. 50:59-87 (1998); Spiegel et al., Strategiesfor Inhibition of Complement Activation in the Treatment ofNeurodegenerative Diseases in: Neuroinflammation: Mechanisms andManagement, Wood (ed.), Humana Press, Inc., Totowa, N.J., Chapter 5, pp.129-176; and U.S. Pat. No. 4,916,219).

A number of strategies have been proposed for the inhibition ofprimarily the classical complement pathway. Efforts to directly inhibitcomplement activation have focused on chemical compounds that inhibitcomplement components such as C1r and C1s. Small peptide inhibitors ofconvertases, such as the C3 and C5 convertases, have also been described(Liszewski and Atkinson, Exp. Opin. Invest. Drugs 7: 323-332 (1998). Sofar, the best studied complement inhibitor for treatment of CNSdisorders is soluble recombinant human complement receptor Type 1(sCR1). sCR1 has proven effective in animal models of CNS diseases andis under investigation for use in man (Fearon, Clin. Exp. Immunol. 86(Suppl. 1): 43-46 (1991)). However, there are several drawbacks to theuse of sCR1 in disorders of the CNS: the agent is expensive, must beadministered systemically, and has a short half-life in vivo. The nextgeneration of complement inhibitors are likely to solve many of thesedrawbacks (Spiegel et al., Strategies for Inhibition of ComplementActivation in the Treatment of Neurodegenerative Diseases in:Neuroinflammation: Mechanisms and Management, Wood (ed.), Humana Press,Inc., Totowa, N.J., Chapter 5, pp. 129-176).

A need continues to exist for non-peptidic compounds that are potentinhibitors of complement, specifically C1s, and which possess greaterbioavailability and fewer side-effects than currently available C1sinhibitors. Accordingly, novel C1s inhibitors, characterized by potentinhibitory capacity, are potentially valuable therapeutic agents for avariety of conditions.

SUMMARY OF THE INVENTION

The present invention relates to a racemic or homochiral compound ofFormula I:

or a solvate, hydrate, pharmaceutically acceptable salt, or prodrugthereof; wherein:Z is —CO—, —SO₂—, —SO₂CH₂—, —COCH₂—, —CONH—, or a direct bond whereinthe carbonyl carbon or the sulfur is bonded to the nitrogen;Q is C₁₋₄ alkyl, halo, amino, C₁₋₆ alkylthio, C₂₋₆ alkenylthio, C₁₋₆alkoxy, trifluoromethyl, methylsulfonyl, or benzylthio;R¹ is hydrogen, C₁₋₄ alkyl, aryl, heteroaryl, benzo fused heteroaryl,benzo fused heterocyclyl, any of which except hydrogen is optionallysubstituted with one or two substituents independently selected from:guanidinyl, halogen, —CF₃, —CN, —NO₂, —NR_(d)COR_(e), —CONR_(d)R_(e),—NR_(d)SO₂R_(e), —SO₂NR_(d)R_(e), —NR_(d)CONHR_(e), —R_(d),—NR_(d)R_(e), —CO₂R_(d), —SO₂R_(d), or heterocyclyl which may besubstituted with one R_(d);R² is hydrogen, halogen, aryl or heteroaryl, wherein the aryl orheteroaryl are optionally substituted with up to three substituentsindependently selected from: C(1-4)alkyl, —NR_(f)R_(g), guanidinyl;A is aryl or heteroaryl;R_(a), R_(b) R_(c), R_(d) R_(e), R_(f) and R_(g) are independentlyhydrogen, C₁₋₄ alkyl, C₆₋₁₀ aryl, C₁₋₄ hydroxyalkyl, C₁₋₄ aminoalkyl,mono(C₁₋₄)alkylamino(C₂₋₆)alkyl, di(C₁₋₄)alkylamino(C₂₋₆)alkyl,carboxy(C₁₋₄)alkyl, cyano, nitro, amino, C₁₋₄ alkoxy, hydroxy, or—CO₂R^(w), whereinR^(w) is hydrogen, hydroxy, C₁₋₄ alkoxy, cyano, C₁₋₄ alkoxycarbonyl,C₁₋₄ alkyl, C₃₋₈ cycloalkyl, phenyl, or benzyl.

The present invention provides a novel class of thienyl sulfoximines.The thienyl sulfoximines of Formula I inhibit the enzyme C1s, a proteasein the classical pathway of the complement system, and thus, can be usedto treat or ameliorate complement-mediated acute or chronic disorders inmammals.

Thus, a first aspect of the present invention is directed to novelcompounds of Formula I.

In a second embodiment, the present invention provides a pharmaceuticalcomposition comprising a compound of Formula I and a pharmaceuticallyacceptable carrier or diluent.

The present invention further provides a method for treating acute andchronic disorders associated with activation of the classical pathway ofthe complement system by administering to a mammal in need of suchtreatment a therapeutically effective amount of a compound of Formula I.These acute and chronic conditions are caused either in whole or in partby inflammation and tissue damage that result from aberrant activationof the complement cascade.

In one embodiment, compounds of Formula I can be administered to amammal to treat complement-mediated inflammation and tissue damage.Examples of conditions that can be treated include intestinalinflammation of Crohn's disease, thermal injury (burns, frostbite), postpump syndrome in cardiopulmonary bypass, and ischaemia (stroke,myocardial infarction, ischaemic colitis, hemorrhagic shock, trauma,post-surgical tissue damage and delayed or impaired function of organ orgraft following transplant).

The complement system is activated in hyperacute allograft andhyperacute xenograft rejection, and in acute humoral rejection mediatedby donor-specific antibodies. Thus, in yet another embodiment, compoundsof Formula I can be administered to a mammal before, during or after thetransplant of an organ or a graft to ameliorate the rejection of suchorgan or graft by the mammal. Grafts can include an allograft orxenograft.

Complement activation during immunotherapy with recombinant IL-2 appearsto cause acute vascular leak syndrome that results in the severetoxicity and side effects observed from IL-2 treatment and otherconditions such as bone marrow transplantation and acute pancreatitis.In another embodiment of the present invention, a compound of Formula Iis administered to a mammal before, during or after treatment of saidmammal with IL-2, bone marrow transplantation, or onset of pancreatitis,in an amount effective to reduce the vascular leak syndrome that causestoxicity and side-effects associated with the treatment or disorders.

In another embodiment, compounds of Formula I can be administered to amammal to treat complement-mediated tissue injury associated withautoimmune diseases. Examples of autoimmune diseases that are treatableaccording to the present invention include Hashimoto's thyroiditis,Addison's disease, glomerulonephritis and cutaneous lesions of systemiclupus erythematosus, other glomerulonephritides, bullous pemphigoid,pemphigus, Goodpasture's syndrome, Graves' disease,immune-complex-induced vasculitis, hemolytic anemia, myasthenia gravis,allergic neuritis, myasthenia gravis, Type I diabetes mellitus,autoimmune hemolytic anemia, autoimmune thrombocytopenic purpura, typeII collagen-induced arthritis, and rheumatoid arthritis. Autoimmunediseases preferred for treatment by inhibitors of the present inventioninclude myasthenia gravis (MG), rheumatoid arthritis, and systemic lupuserythematosus.

Another embodiment of the present invention is directed to administeringa therapeutically effective amount of a compound of Formula I to amammal that has been diagnosed with a neurodegenerative disease.Neurodegenerative diseases in which inhibitors of the complement cascadesystem will be therapeutically useful include the demyelinating disordermultiple sclerosis (MS), the neuropathies Guillain-Barré syndrome (GBS)and Miller-Fisher syndrome (MFS), Alzheimer's disease (AD), and variantCreutzfeldt-Jakob disease.

In another embodiment, compounds of the present invention can beadministered to a mammal to treat complement-mediated complications insepsis, or symptoms of adult respiratory distress syndrome.

Other diseases and conditions that can be treated include hereditary andacquired angioedema, paroxysmal nocturnal hemoglobinuria, brain traumaand other soft tissue trauma, asthma and hemodialysis.

Compounds of Formula I can also be employed in vitro for human organ andgraft storage as well as platelet storage.

DETAILED DESCRIPTION OF THE INVENTION

Compounds useful in the present invention have the general Formula I:

or a solvate, hydrate, pharmaceutically acceptable salt, or prodrugthereof; wherein:Z is —CO—, —SO₂—, —SO₂CH₂—, —COCH₂—, —CONH—, or a direct bond whereinthe carbonyl carbon or the sulfur is bonded to the nitrogen;Q is C₁₋₄ alkyl, halo, amino, C₁₋₆alkylthio, C₂₋₆ alkenylthio,C₁₋₆alkoxy, trifluoromethyl, methylsulfonyl, or benzylthio;R¹ is hydrogen, C₁₋₄ alkyl, aryl, heteroaryl, benzo fused heteroaryl,benzo fused heterocyclyl, any of which except hydrogen is optionallysubstituted with one or two substituents independently selected from:guanidinyl, halogen, —CF₃, —CN, —NO₂, —NR_(d)COR_(e), —CONR_(d)R_(e),—NR_(d)SO₂R_(e), —SO₂NR_(d)R_(e), —NR_(d)CONHR_(e), —R_(d),—NR_(d)R_(e), —CO₂R_(d), —SO₂R_(d), or heterocyclyl which may besubstituted with one R_(d);R² is hydrogen, halogen, aryl or heteroaryl, wherein the aryl orheteroaryl are optionally substituted with up to three substituentsindependently selected from: C(1-4)alkyl, —NR_(f)R_(g), guanidinyl;A is aryl or heteroaryl;R_(a), R_(b) R_(c), R_(d) R_(e), R_(f) and R_(g) are independentlyhydrogen, C₁₋₄ alkyl, C₆₋₁₀ aryl, C₁₋₄ hydroxyalkyl, C₁₋₄ aminoalkyl,mono(C₁₋₄)alkylamino(C₂₋₆)alkyl, di(C₁₋₄)alkylamino(C₂₋₆)alkyl,carboxy(C₁₋₄)alkyl, cyano, nitro, amino, C₁₋₄ alkoxy, hydroxy, or—CO₂R^(w), whereinR^(w) is hydrogen, hydroxy, C₁₋₄ alkoxy, cyano, C₁₋₄ alkoxycarbonyl,C₁₋₄ alkyl, C₃₋₈ cycloalkyl, phenyl, or benzyl.

A preferred group of compounds falling within the scope of the presentinvention includes compounds of Formula I wherein Q is —SC₍₁₋₄₎alkyl,and A is phenyl.

Another preferred group of compounds falling within the scope of thepresent invention includes compounds of Formula I wherein R¹ ishydrogen, C₁₋₄ alkyl, aryl, heteroaryl, benzo fused heteroaryl, benzofused heterocyclyl, any of which except hydrogen is optionallysubstituted with one or two substituents independently selected from:guanidinyl, halogen, —CF₃, —CN, —NO₂, NR_(d)COR_(e), NR_(d)SO₂R_(e),NR_(d)CONHR_(e), R_(d), NH₂, CO₂R_(e), SO₂R_(d), heterocyclyl.

Another preferred group of compounds falling within the scope of thepresent invention includes compounds of Formula I wherein R_(a), R_(b),and R_(c) are hydrogen, and R₁ is selected from hydrogen, C₁₋₄ alkyl,phenyl, pyridyl, imidazolyl, thiazolyl, furanyl, thienyl,benzothiazolyl, pyrazolyl, pyrimidinyl,3,4-Dihydro-2H-benzo[1,4]oxazine, benzimidazolyl, benzofuranyl, indolyl,benzothiophenyl, or 1,3,4 oxadiazolyl, any of which except hydrogen isoptionally substituted with one or two substituents independentlyselected from: guanidinyl, halogen, —CF₃, —CN, —NO₂, NR_(d)COR_(e),NR_(d)SO₂R_(e), NR_(d)CONHR_(e), R_(d), NH₂, CO₂R_(e), SO₂R_(d),heterocyclyl.

Definitions

The term “alkyl” as employed herein by itself or as part of anothergroup refers to both straight and branched chain radicals of up to 12carbons, such as methyl, ethyl, propyl, isopropyl, butyl, t-butyl,isobutyl, pentyl, hexyl, isohexyl, heptyl, 4,4-dimethylpentyl, octyl,2,2,4-trimethylpentyl, nonyl, decyl, undecyl, dodecyl.

The term “alkenyl” is used herein to mean a straight or branched chainradical of 2-20 carbon atoms, unless the chain length is limitedthereto, wherein there is at least one double bond between two of thecarbon atoms in the chain, including, but not limited to, ethenyl,1-propenyl, 2-propenyl, 2-methyl-1-propenyl, 1-butenyl, 2-butenyl, andthe like. Preferably, the alkenyl chain is 2 to 10 carbon atoms inlength, more preferably 2 to 8 carbon atoms in length, most preferably 2to 4 carbon atoms in length.

In all instances herein where there is an alkenyl moiety as asubstituent group, the unsaturated linkage, i.e., the vinylene linkage,is preferably not directly attached to a nitrogen, oxygen or sulfurmoiety.

The term “alkylthio” as employed herein by itself or as part of anothergroup refers to a straight or branched chain radical of 1 to 20 carbonatoms, unless the chain length is limited thereto, bonded to a sulfuratom, including, but not limited to, methylthio, ethylthio,n-propylthio, isopropylthio, and the like. Preferably the alkylthiochain is 1 to 10 carbon atoms in length, more preferably 1 to 8 carbonatoms in length.

The term “alkoxy” as employed herein by itself or as part of anothergroup refers to a straight or branched chain radical of 1 to 20 carbonatoms, unless the chain length is limited thereto, bonded to an oxygenatom, including, but not limited to, methoxy, ethoxy, n-propoxy,isopropoxy, and the like. Preferably the alkoxy chain is 1 to 10 carbonatoms in length, more preferably 1 to 8 carbon atoms in length.

The term “aralkyl” or “arylalkyl” as employed herein by itself or aspart of another group refers to C₁₋₆-alkyl groups as discussed abovehaving an aryl substituent, such as benzyl, phenylethyl or2-naphthylmethyl.

The term “aryl” as employed herein by itself or as part of another grouprefers to monocyclic or bicyclic aromatic groups containing from 6 to 14carbons in the ring portion, preferably 6-10 carbons in the ringportion, such as phenyl, naphthyl or tetrahydronaphthyl.

The term “cycloalkyl” as employed herein by itself or as part of anothergroup refers to cycloalkyl groups containing 3 to 9 carbon atoms.Typical examples are cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl,cycloheptyl, cyclooctyl and cyclononyl.

The term “dialkylamine” as employed herein by itself or as part ofanother group refers to an amino group which is substituted with twoalkyl groups, each having from 1 to 6 carbon atoms.

The term “enantiomer” as employed herein refers to either of a pair ofchemical compounds or salts whose molecular structures have amirror-image relationship to each other

The term “graft” as employed herein by itself or part of another grouprefers to material, especially living tissue or an organ, surgicallyattached to or inserted into a bodily part to replace a damaged part orcompensate for a defect.

The terms “halogen” or “halo” as employed herein by itself or as part ofanother group refers to chlorine, bromine, fluorine or iodine, withchlorine being preferred.

The terms “heterocyclic,” “heterocyclo” or “heterocycle” as employedherein by themselves or as part of larger groups refer to a saturated orwholly or partially unsaturated 3-7 membered monocyclic, or 7-10membered bicyclic ring system, which consists of carbon atoms and fromone to four heteroatoms independently selected from the group consistingof O, N, and S, wherein the nitrogen and sulfur heteroatoms can beoptionally oxidized, the nitrogen can be optionally quaternized, andincluding any bicyclic group in which any of the above-definedheterocyclic rings is fused to a benzene ring, and wherein theheterocyclic ring can be substituted on carbon or on a nitrogen atom ifthe resulting compound is stable. Especially useful are rings containingone oxygen or sulfur, one to three nitrogen atoms, or one oxygen orsulfur combined with one or two nitrogen atoms. Examples of suchheterocyclic groups include piperidinyl, piperazinyl, 2-oxopiperazinyl,2-oxopiperidinyl, 2-oxopyrrolodinyl, 2-oxoazepinyl, azepinyl, pyrrolyl,4-piperidonyl, pyrrolidinyl, pyrazolyl, pyrazolidinyl, imidazolyl,imidazolinyl, imidazolidinyl, pyridyl, pyrazinyl, pyrimidinyl,pyridazinyl, oxazolyl, oxazolidinyl, isoxazolyl, isoxazolidinyl,morpholinyl, thiazolyl, thiazolidinyl, isothiazolyl, quinuclidinyl,isothiazolidinyl, indolyl, quinolinyl, isoquinolinyl, benzimidazolyl,thiadiazoyl, benzopyranyl, benzothiazolyl, benzoxazolyl, furyl,tetrahydrofuryl, tetrahydropyranyl, benzofuranyl, thienyl, benzothienyl,thiamorpholinyl, thiamorpholinyl sulfoxide, thiamorpholinyl sulfone, andoxadiazolyl. Morpholino is the same as morpholinyl.

The term “heteroatom” is used herein to mean an oxygen atom (“0”), asulfur atom (“S”) or a nitrogen atom (“N”). It will be recognized thatwhen the heteroatom is nitrogen, it may form an NR^(y)R^(z) moiety,wherein R^(y) and R^(z) are, independently from one another, hydrogen orC₁ to C₈ alkyl, or together with the nitrogen to which they are bound,form a saturated or unsaturated 5-, 6-, or 7-membered ring.

The term “heteroaryl” as employed herein refers to groups having 5 to 14ring atoms; 6, 10 or 14 π electrons shared in a cyclic array; andcontaining carbon atoms and 1, 2 or 3 oxygen, nitrogen or sulfurheteroatoms (where examples of heteroaryl groups are: thienyl,benzo[b]thienyl, naphtho[2,3-b]thienyl, thianthrenyl, furyl,benzofuranyl, pyranyl, isobenzofuranyl, benzoxazolyl, chromenyl,xanthenyl, phenoxathiinyl, 2H-pyrrolyl, pyrrolyl, imidazolyl, pyrazolyl,pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, indolizinyl, isoindolyl,3H-indolyl, indolyl, indazolyl, purinyl, 4H-quinolizinyl, isoquinolyl,quinolyl, phthalazinyl, naphthyridinyl, quinazolinyl, cinnolinyl,pteridinyl, 4αH-carbazolyl, carbazolyl, β-carbolinyl, phenanthridinyl,acridinyl, perimidinyl, phenanthrolinyl, phenazinyl, isothiazolyl,phenothiazinyl, isoxazolyl, furazanyl and phenoxazinyl groups).

The term “homochiral” as employed herein refers to a chemical compoundor salt consisting of only one enantiomer.

The term “medical device” as employed herein refers to an instrument,apparatus, implement, machine, contrivance, implant, in vitro reagent,or other similar or related article, including a component part, oraccessory which is:

recognized in the official National Formulary, or the United StatesPharmacopoeia, or any supplement to them,

intended for use in the diagnosis of disease or other conditions, or inthe cure, mitigation, treatment, or prevention of disease, in man orother animals, or

intended to affect the structure or any function of the body of man orother animals, and which does not achieve any of its primary intendedpurposes through chemical action within or on the body of man or otheranimals and which is not dependent upon being metabolized for theachievement of any of its primary intended purposes.

Examples of medical devices include, but are not limited to stents,prostheses, artificial organs, and artificial joints.

The term “monoalkylamine” as employed herein by itself or as part ofanother group refers to an amino group which is substituted with onealkyl group having from 1 to 6 carbon atoms.

The expression “prodrug” denotes a derivative of a known direct actingdrug, which derivative has enhanced delivery characteristics andtherapeutic value as compared to the drug, and is transformed into theactive drug by an enzymatic or chemical process. Useful prodrugs arethose where R_(b), R_(c) and/or R⁴ are —CO₂R^(w), where R^(w) is definedabove. See U.S. Pat. No. 5,466,811 and Saulnier et al., Bioorg. Med.Chem. Lett. 4:1985-1990 (1994).

The term “substituted,” as used herein, means that one or more hydrogensof the designated moiety are replaced with a selection from theindicated group, provided that no atom's normal valency is exceeded, andthat the substitution results in a stable compound. When a substituentis keto (i.e., ═O), then 2 hydrogens attached to an atom of the moietyare replaced.

By “stable compound” or “stable formula” is meant herein a compound thatis sufficiently robust to survive isolation to a useful degree of purityfrom a reaction mixture and formulation into an efficacious therapeuticagent.

The term “stent” refers to any device capable of being delivered by acatheter. A stent is routinely used to prevent vascular closure due tophysical anomalies such as unwanted inward growth of vascular tissue dueto surgical trauma. It often has a tubular, expanding lattice-typestructure appropriate to be left inside the lumen of a duct to relievean obstruction. The stent has a lumen wall-contacting surface and alumen-exposed surface. The lumen-wall contacting surface is the outsidesurface of the tube and the lumen-exposed surface is the inner surfaceof the tube. The stent can be polymeric, metallic or polymeric andmetallic, and it can optionally be biodegradable.

By an “efficacious level” of a composition of the invention is meant alevel at which some relief is afforded to the patient who is therecipient of the treatment. By an “abnormal” host inflammatory conditionis meant a level of inflammation in the subject at a site which exceedsthe norm for the healthy medical state of the subject, or exceeds adesired level. By “secondary” tissue damage or toxic effects is meantthe tissue damage or toxic effects which occur to otherwise healthytissues, organs, and the cells therein, due to the presence of aninflammatory response, including as a result of a “primary” inflammatoryresponse elsewhere in the body.

The “animals” referred to herein are preferably mammals and mostpreferably humans, although the invention is not intended to be limitedto such.

Abbreviations: AcOH acetic acid AlMe₃ trimethyl aluminum Boct-butyloxycarbonyl, also tBoc Boc₂O di-tert-butyl dicarbonate ^(t)BuONO2-Methyl-2-nitrosooxy-propane m-CPBA m-chloroperbenzoic acid Cu(OTf)₂copper(II)trifluoromethanesulfonate DCM dichloromethane DIEAdiisopropylethylamine DIC diisopropylcarbonate DME dimethoxyethaneDMAP-resin 4-dimethylaminopyridine - modified resin DMAP4-dimethylaminopyridine DMF dimethylformamide DMSO dimethyl sulfoxideDTNB 5,5′-dithio-bis(2-nitrobenzoic acid) ESI-MS electrospray ionizationmass spectrum Et₂O diethyl ether Et₃N triethylamine EtOAc ethyl acetateHEPES 4-(2-hydroxyethyl)piperazine-1-ethanesulfonic acid HPLC highpressure liquid chromatography LDA lithium diisopropylamine MeOHmethanol NaOMe sodium methoxide NaSMe sodium methanethiolate NMR nuclearmagnetic resonance PCC pyridinium chlorochromate Pd(dppf)Cl₂Dichloro(1,1bis(diphenylphosphino)ferrocene)palladium(II) Pd(PPh₃)₄tetrakistriphenylphosphine Pd⁰ PhI(OAc)₂ iodobenzene diacetate^(i)PrMgCl isopropylmagnesium chloride RP-HPLC reverse phase highpressure liquid chromatography RT room temperature rt retention time TFAtrifluoroacetic acid TBAF tetrabutyl ammonium fluoride TEA triethylamineTHF tetrahydrofuran TLC thin layer chromatography

When any variable occurs more than one time in any constituent or in anyFormula, its definition on each occurrence is independent of itsdefinition at every other occurrence. Also, combinations of substituentsand/or variables are permissible only if such combinations result instable compounds.

The present invention provides a method for treating acute and chronicdisorders associated with activation of the classical pathway of thecomplement system by administering to a mammal in need of such treatmenta therapeutically effective amount of a compound of Formula I.

These acute and chronic conditions include inflammation and tissuedamage that arise as a result of rapid and aggressive enzyme activity ofthe complement cascade. Complement-mediated inflammation and theresultant tissue damage has been implicated in a number of diseasestates including: 1) ischaemia reperfusion damage, such as occurs postmyocardial infarction, post transplant, post surgery and in hemorrhagicshock; 2) antibody-mediated conditions, such as hyperacute allograft andxenograft rejection, organ transplant rejection and auto-immunediseases; and 3) other disease states, such as thermal injury, trauma,adult respiratory distress syndrome (ARDS), sepsis and prion disease.

The compounds of the present invention are believed to inhibit thefunctioning of the protease activity of C1s. This protease-inhibitionactivity results in the inhibition or blocking of a variety ofcomplement-mediated immunological functions. Therefore, compounds ofFormula I can be used to ameliorate a number of disease states inducedby complement-mediated inflammation and tissue damage.

The term “treatment of inflammation” or “treating inflammation” isintended to include the administration of compounds of the presentinvention to a subject for purposes which can include prophylaxis,amelioration, prevention or cure of an inflammatory response. Suchtreatment need not necessarily completely ameliorate the inflammatoryresponse. Further, such treatment can be used in conjunction with othertraditional treatments for reducing the inflammatory condition known tothose of skill in the art.

In one embodiment, compounds of Formula I can be administered to amammal to treat complement-mediated inflammation and tissue damage thatis a consequence of ischaemia/reperfusion injury. Thus, the C1sinhibitors of the present invention can be employed to prevent, or atleast ameliorate, inflammation and tissue damage arising from a stroke,myocardial infarction, hemorrhagic shock, and surgery. In particular,compounds of Formula I can be employed to prevent inflammation oftransplanted tissue and organs.

The compounds of Formula I can also be provided as a preventivetreatment before detection of an inflammatory state, so as to preventthe same from developing in patients at high risk for the same, such as,for example, transplant patients.

The compounds of Formula I can be used to treat chronic or acuteinflammation that is the result of an antibody-mediated reaction, suchas hyperacute allograft and xenograft rejection, organ transplantrejection and auto-immune diseases, which include arthritis, rheumatoidarthritis, multiple sclerosis (MS), type I diabetes, intestinalinflammation of Crohn's disease, systemic lupus erythematosus (lupus),immune-complex-induced vasculitis, restenosis and psoriasis.

The complement system is activated in hyperacute allograft andhyperacute xenograft rejection, and in acute humoral rejection mediatedby donor-specific antibodies. In another embodiment, compounds ofFormula I can be administered to a mammal before, during or after thetransplant of an organ or a graft to ameliorate the rejection of suchorgan or graft by the mammal.

Organ transplant and graft patients undergo concurrent immunotherapy.Complement activation during immunotherapy with recombinant IL-2 appearsto cause acute vascular leak syndrome that results in the severetoxicity and side effects observed from IL-2 treatment and otherconditions such as bone marrow transplantation and acute pancreatitis.Thus, in a further embodiment of the present invention, a compound ofFormula I is administered to a mammal before, during or after treatmentof said mammal with IL-2, bone marrow transplantation, or onset ofpancreatitis, in an amount effective to reduce the vascular leaksyndrome that causes toxicity and side-effects associated with thetreatment or disorders.

Another embodiment of the present invention is directed to administeringa therapeutically effective compound of Formula I to a mammal that hasbeen diagnosed with an autoimmune disease. Autoimmune diseases that aretreatable according to the present invention include Addison's disease,Type I diabetes mellitus, Hashimoto's thyroiditis, glomerulonephritisand cutaneous lesions of systemic lupus erythematosus, otherglomerulonephritides, bullous pemphigoid, dermatitis herpetiformis,Goodpasture's syndrome, Graves' disease, Parkinson's disease, myastheniagravis, insulin resistance, autoimmune hemolytic anemia, autoimmunethrombocytopenic purpura, immune-complex-induced vasculitisglomerulonephritis, type II collagen-induced arthritis, rheumatoidarthritis, and allergic neuritis. Autoimmune diseases preferred fortreatment by inhibitors of the present invention include myastheniagravis (MG), rheumatoid arthritis, and systemic lupus erythematosus.

Another embodiment of the present invention is directed to administeringa therapeutically effective amount of a compound of Formula I to amammal that has been diagnosed with a neurodegenerative disease.Neurodegenerative diseases in which inhibitors of the complement cascadesystem will be therapeutically useful include the demyelinating disordermultiple sclerosis (MS), the neuropathies Guillain-Barré syndrome (GBS)and Miller-Fisher syndrome (MFS), Alzheimer's disease (AD) and variantCreutzfeldt-Jakob disease (vCJD).

In another embodiment, efficacious levels of the C1s inhibitors of theinvention are administered so as to provide therapeutic benefits againstthe secondary harmful inflammatory effects of inflammation.

In an additional embodiment, compounds of the present invention can beadministered to a mammal suffering from the symptoms of ARDS. ARDS is acomplex pulmonary disorder affecting 150,000 people in the U.S. yearlywith a 50% mortality rate. Leukocytes, platelets and the proteolyticpathways of coagulation and complement mediate ARDS. ARDS involvesactivation of the contact activation pathway and depletion of C1inhibitor and may be induced by either sepsis or trauma. Sepsis-inducedARDS results in more severe disseminated intravascular coagulation (DIC)and fibrinolysis, more fibrin degradation products and reduced ATIIIlevels compared to trauma-induced ARDS (Carvalho et al., J. Lab. Clin.Med. 112:270-277 (1988)).

In a further embodiment, compounds of Formula I can be administered to aperson in septic shock. Septic shock is the most common cause of deathof humans in intensive care units in the United States (Parillo et al.,Ann. Int. Med. 113:227-242 (1990); Schmeichel C. J. & McCormick D.,BioTechnol. 10:264-267 (1992)). In recent years aggressive fluidinfusion therapy has been accepted as a primary means of treatment forseptic shock.

The increase in cardiac output and vasodilation in septic shock isattributed to the action of inflammatory mediators. In septic shock,components of the kallikrein-kinin system are depleted, suggestingactivation of this system. This is not the case in cardiogenic shock,suggesting that the kallikrein-kinin system is a key player in septicshock (Martinez-Brotons F. et al., Thromb. Haemostas. 58:709-713(1987)). While the actual events leading to septic shock, DIC andhypotension have not been established, the known interactions amongvarious components of the many physiological systems suggest thatactivation of the contact pathway may lead to a state of septic shock,multi-organ failure, and death (Bone, R. C., Arch. Intern. Med.152:1381-1389 (1992); Colman, R. W., New Engl. J. Med. 320:1207-1209(1989)). The contact activation pathway is also involved in both fibrindeposition and lysis, as well as triggering neutrophil activation,activation of complement and modulation of blood pressure.

Inhibition of the complement cascade is expected to lead to downstreamutilities associated with the contact system of coagulation and thecomplement system. This interaction between components of the complementand coagulation systems at the surface of blood platelets andendothelium can generate inflammatory and chemotactic peptides at sitesof vascular thrombus formation and may contribute to the alteredhemostasis associated with immune disease states. In addition, immunereactions affecting blood platelets and endothelium can lead to plateletaggregation, the secretion of proteolytic enzymes and vasoactive aminesfrom platelet storage granules, and increase adherence of platelets andleukocytes to the endothelial lining of blood vessels.

Other diseases and conditions that can be treated with compounds ofFormula I include hereditary angioedema, paroxysmal nocturnalhemoglobinuria, wound healing, brain trauma, asthma, hemodialysis,infection, dermatosis, inflammatory bowel disease, osteoporosis,osteoarthritis, thermal injury (burns and frostbite), hemolytic anemiaand post pump syndrome in cardiopulmonary bypass.

It has been demonstrated that membrane-uptake of C3b and C5b-9 proteinscan occur spontaneously during incubation of platelets in citratedplasma. Complement activation can also occur during blood collection asa result of exposure to plastic surfaces supporting the C3-convertasereaction. While the implications of complement activation during bloodcollection and in vitro storage for transfusion have not been directlyaddressed, it is nevertheless known that plasma levels of coagulationfactors V and VIII rapidly decline in stored platelet concentrates at arate considerably faster than their decay in cell-free plasma,suggesting consumptive loss. Further, platelet collection and storage isassociated with an increase in vesicular plasma membrane microparticles,a product of C5b-9 initiated platelet secretion. These physiological andenzymatic changes greatly reduce the potential shelf life of storedplatelets, particularly platelet-rich plasma concentrates used fortransfusions, which is generally only 72 hours at best. Furthermore,this interaction of activated C5b-9, platelets, and coagulation factorsin stored platelet concentrates will adversely affect the hemostaticeffectiveness of these units when infused.

In vitro human organ and tissue storage and survival of the transplantedgraft is also adversely affected by the spontaneous activation of thecomplement system, resulting in membrane insertion of the C5b-9 proteinsinto vascular endothelium. Activation of C5 to C5a and C5b can becatalyzed by plastics and other synthetic membranes required to maintainperfusion of vascular beds during in vitro tissue and organ storage. Inaddition, membrane deposition of C5b-9 in vivo has been implicated inthe acute rejection of transplanted tissue due to immune activation ofthe recipient's plasma complement system against the endothelial cellswithin the donor's organ.

Platelet and endothelial cell activation by C5b-9 also has ramificationsin autoimmune disorders and other disease states. The importance ofspontaneous complement activation and the resulting exposure ofplatelets and endothelium to activated C5b-9 to the evolution ofvaso-occlusive disease is underscored by consideration that a) leukocyteinfiltration of the subendothelium, which is known to occur in regionsof atheromatous degeneration and suggests localized generation of C5a atthe vessel wall, is potentially catalyzed by adherent platelets; and b)local intravascular complement activation resulting in membranedeposition of C5b-9 complexes accompanies coronary vessel occlusion andmay affect the ultimate extent of myocardial damage associated withinfarction.

It is therefore an aspect of the present invention to provide a meansand method for the modulation and inhibition of complement-mediatedplatelet and endothelial cell activation in vivo and in vitro. It is afurther aspect of the present invention to provide a means and methodfor increasing the survival and therapeutic efficacy of platelets andtissues or organs collected and stored in vitro.

Preferably, the treatment methods of the invention deliver the C1sinhibitor either by contacting cells of the animal with a C1s inhibitordescribed above or by administering to the animal a C1s inhibitordescribed above.

The inhibitors can be used in vitro or in vivo. They can be administeredby any number of known routes, including orally, intravenously,intramuscularly, subcutaneously, intrathecally, topically,transdermally, and by infusion (Platt et al., U.S. Pat. No. 4,510,130;Badalamente et al., Proc. Natl. Acad. Sci. U.S.A. 86:5983-5987 (1989);Staubli et al., Brain Research 444:153-158 (1988)) and will generally beadministered in combination with a physiologically acceptable carrier(e.g., physiological saline) or diluent. The effective quantity ofinhibitor given will be determined empirically and will be based on suchconsiderations as the particular inhibitor used, the condition of theindividual, and the size and weight of the individual. It is to beexpected that the general end-use application dose range will be about0.01 to 100 mg per kg per day, preferably 0.1 to 75 mg per kg per dayfor an effective therapeutic effect.

Amounts and regimens for the administration of C1s inhibitors andcompositions of the invention can be determined readily by those withordinary skill in the clinical art of treating inflammation-relateddisorders such as arthritis, tissue injury and tissue rejection.Generally, the dosage of the composition of the invention will varydepending upon considerations such as: type of pharmaceuticalcomposition employed; age; health; medical conditions being treated;kind of concurrent treatment, if any; frequency of treatment and thenature of the effect desired; extent of tissue damage; gender; durationof the symptoms; and contraindications, if any, and other variables tobe adjusted by the individual physician. A desired dosage can beadministered in one or more applications to obtain the desired results.Pharmaceutical compositions containing the C1s inhibitors of theinvention can be provided in unit dosage forms.

In one embodiment, dosing will be by intravenous injection or short-terminfusion. In a further embodiment, the C1s inhibitors of the presentinvention will be administered orally, in the form of a tablet, pill,lozenge, troche or capsule. To achieve optimal therapeutic effect,maintenance dosing may be required. Such maintenance dosing may be givenrepeatedly during the course of a day by, for instance, repeatedindividual injections, repeated oral dosing, or by introduction of acontinuous drip infusion. Effective dosages can be readily determined byone of ordinary skill in the art through routine trials establishingdose response curves.

Pharmaceutical Compositions

Pharmaceutical compositions for treating a complement-mediated diseasestate, comprising a compound of Formula I in an amount effective toinhibit C1 s protease function in a mammal and a pharmaceuticallyacceptable carrier or diluent, are within the scope of the presentinvention.

Pharmaceutical compositions comprising an effective amount of the C1 sinhibitors of the invention, in combination with any conventionalpharmaceutically acceptable carrier or diluent, are included in thepresent invention.

For medicinal use, the pharmaceutically acceptable acid addition salts,those salts in which the anion does not contribute significantly totoxicity or pharmacological activity of the organic cation, arepreferred. The acid addition salts are obtained either by reaction of anorganic base of Formula I with an organic or inorganic acid, preferablyby contact in solution, or by any of the standard methods detailed inthe literature available to any practitioner skilled in the art.Examples of useful organic acids are carboxylic acids such as maleicacid, acetic acid, tartaric acid, propionic acid, fumaric acid,isethionic acid, succinic acid, cyclamic acid, pivalic acid and thelike; useful inorganic acids are hydrohalide acids such as HCl, HBr, andHI; sulfuric acid; phosphoric acid and the like. Preferred acids forforming acid addition salts include HCl and acetic acid.

The pharmaceutical compositions of the invention can be administered toany animal that can experience the beneficial effects of the compoundsof the invention. Foremost among such animals are humans, although theinvention is not intended to be so limited.

The pharmaceutical compositions of the present invention can beadministered by any means that achieve their intended purpose. Forexample, administration can be by parenteral, subcutaneous, intravenous,intramuscular, intraperitoneal, transdermal, buccal, or ocular routes.Alternatively, or concurrently, administration can be by the oral route.The dosage administered will be dependent upon the age, health, andweight of the recipient, kind of concurrent treatment, if any, frequencyof treatment, and the nature of the effect desired.

In addition to the pharmacologically active compounds, the newpharmaceutical preparations can contain suitable pharmaceuticallyacceptable carriers comprising excipients and auxiliaries thatfacilitate processing of the active compounds into preparations that canbe used pharmaceutically.

The pharmaceutical preparations of the present invention aremanufactured in a manner that is, itself, known, for example, by meansof conventional mixing, granulating, dragee-making, dissolving, orlyophilizing processes. Thus, pharmaceutical preparations for oral usecan be obtained by combining the active compounds with solid excipients,optionally grinding the resulting mixture and processing the mixture ofgranules, after adding suitable auxiliaries, if desired or necessary, toobtain tablets or dragee cores.

Suitable excipients are, in particular, fillers such as saccharides, forexample, lactose or sucrose, mannitol or sorbitol, cellulosepreparations and/or calcium phosphates, for example, tricalciumphosphate or calcium hydrogen phosphate, as well as binders, such as,starch paste, using, for example, maize starch, wheat starch, ricestarch, potato starch, gelatin, tragacanth, methyl cellulose,hydroxypropylmethylcellulose, sodium carboxymethylcellulose, and/orpolyvinyl pyrrolidone. If desired, disintegrating agents can be added,such as, the above-mentioned starches and also carboxymethyl-starch,cross-linked polyvinyl pyrrolidone, agar, or alginic acid or a saltthereof, such as, sodium alginate. Auxiliaries are, above all,flow-regulating agents and lubricants, for example, silica, talc,stearic acid or salts thereof, such as, magnesium stearate or calciumstearate, and/or polyethylene glycol. Dragee cores are provided withsuitable coatings that, if desired, are resistant to gastric juices. Forthis purpose, concentrated saccharide solutions can be used, which mayoptionally contain gum arabic, talc, polyvinyl pyrrolidone, polyethyleneglycol, and/or titanium dioxide, lacquer solutions and suitable organicsolvents or solvent mixtures. In order to produce coatings resistant togastric juices, solutions of suitable cellulose preparations, such as,acetylcellulose phthalate or hydroxypropylmethyl-cellulose phthalate,are used. Dye stuffs or pigments can be added to the tablets or drageecoatings, for example, for identification or in order to characterizecombinations of active compound doses.

Other pharmaceutical preparations, which can be used orally, includepush-fit capsules made of gelatin, as well as soft, sealed capsules madeof gelatin and a plasticizer, such as, glycerol or sorbitol. Thepush-fit capsules can contain the active compounds in the form ofgranules that may be mixed with fillers such as lactose, binders such asstarches, and/or lubricants such as talc or magnesium stearate and,optionally, stabilizers. In soft capsules, the active compounds arepreferably dissolved or suspended in suitable liquids, such as, fattyoils or liquid paraffin. In addition, stabilizers may be added.

Suitable formulations for parenteral administration include aqueoussolutions of the active compounds in water-soluble form, for example,water-soluble salts, alkaline solutions and cyclodextrin inclusioncomplexes. Especially preferred salts are hydrochloride and acetatesalts. One or more modified or unmodified cyclodextrins can be employedto stabilize and increase the water solubility of compounds of thepresent invention. Useful cyclodextrins for this purpose are disclosedin U.S. Pat. Nos. 4,727,064, 4,764,604, and 5,024,998.

In addition, suspensions of the active compounds as appropriate oilyinjection suspensions can be administered. Suitable lipophilic solventsor vehicles include fatty oils, for example, sesame oil, or syntheticfatty acid esters, for example, ethyl oleate or triglycerides orpolyethylene glycol-400 (the compounds are soluble in PEG-400). Aqueousinjection suspensions can contain substances that increase the viscosityof the suspension, for example, sodium carboxymethyl cellulose,sorbitol, and/or dextran. Optionally, the suspension may also containstabilizers.

When employed as thrombin inhibitors, the compounds of the presentinvention may be administered in an effective amount within the dosagerange of about 0.1 to about 500 mg/kg, preferably between about 0.1 andabout 10 mg/kg body weight, on a regimen in single or 2-4 divided dailydoses.

Compounds of Formula I may be prepared by a variety of methods.Exemplary synthetic routes for generating sulfoximines of the inventionare described below.

EXAMPLE 1a General Procedure for Preparation of Sulfoximines

A solution of 3-bromo-2-chloro-thiophene (1-1) is treated with lithiumdiisopropyl amine (LDA). Formylation with DMF is followed bycondensation with hydroxylamine and subsequent water elimination usingphthalic anhydride (Wang, E., Lin, G. Tetrahedron Lett 39, 4047-4050(1998)) gives 4-bromo-5-chloro-thiophene-2-carbonitrile (1-2). Treatmentwith isopropyl magnesium chloride followed by a sulfinic methyl ester,such as meta-bromo benzene sulfinic methyl ester, gives the sulfoxide(1-3) (Andersen, K. K. et al. J. Am. Chem. Soc. 86, 5637 (1964)). It isrecognized, by those skilled in the art, that different sulfinic estersmay be used, such as phenyl, naphthyl, pyridyl, imidazolyl, thiazolyl,furanyl, thienyl, benzothiazolyl, pyrazolyl, pyrimidinyl,benzimidazolyl, benzofuranyl, indolyl, or benzothiophenyl any of whichis optionally substituted. Sulfoxide (1-3) is oxidized to sulfoximine(1-4) by a substituted sulfonylimino iodinane. Reactions were carriedout in the presence of an aprotic solvent such as acetonitrile, a lewisacid such as copper (II) trifluoromethane sulfonate, under inertatmosphere such as argon or nitrogen, at room temperature (Lacote, E. etal. Synlett 2002, 28, 116-118).

Reaction of sulfoximine (1-4) with a nucleophile, Q-M, where M is ametal such as an alkali, allows replacement of the chloro functionality;examples include other halogens, alkyl groups, alkoxides, andalkylthiols. Concomitant conversion of the nitrile to the imidate estermay be observed with certain nucleophiles such as sodiummethanethiolate. If simultaneous removal of a para-nitro phenol from asulfoximine is desired, three equivalents of sodium methanethiolate maybe used (Cren, S. et al Tetrahedron Lett. 43, 2749-2751 (2002)).Subsequent treatment of the nitrile with sodium methoxide to form theimidate, followed by treatment of the imidate with a solution ofmethanolic ammonia/ammonium formate reveals the carboxamidinefunctionality. Protection with tert-butlyoxycarbonyl, or other suitableprotecting group gives product (1-5) or, where R¹ is removed, product(1-6). Sulfoximine (1-6) may be further reacted with an appropriateelectrophile to give products (1-7, 1-8, and 1-9).

Products 1-6 through 1-9 may be further derivatized at the R¹, R¹, or Qpositions, followed by acid mediated removal of the carboxamidineprotecting group. Palladium mediated cross coupling with an appropriateboronic ester is an example of R¹ derivatization, giving products offormula 1-10.

EXAMPLE 1b General Synthesis of Sulfonylimino Iodinanes

The sulfonylimino iodinane used above was made from the condensation ofa sulfonamide with iodobenzene diacetate using a base, such as potassiumhydroxide, in a solvent such as methanol at 0° C. (Ronald E. W. et al;J. Am. Chem. Soc. 106(17); 4922-4926 (1984)).

EXAMPLE 1c General Procedure for the Synthesis of Sulfinic Methyl Esters

The sulfinic methyl ester used in Example 1a was generated by theoxidation of an aryl thiol, first with PCC (Salehi, P. et al, SyntheticCommunications, 31(18), 2777-2781 (2001)), and then with bromine. Asolution of a bromine substituted benzenethiol is treated withpyridinium chlorochromate to give bis-bromophenyldisulfide. Oxidationwith bromine in methanol (Resek, J. E. et al, Tetrahedron Lett. 36,7051-7054 (1995)), followed by aqueous workup, givesbromo-benzenesulfinic acid methyl ester. It is recognized, by thoseskilled in the art, that different aryl thiols may be used, such asphenyl, naphthyl, pyridyl, imidazolyl, thiazolyl, furanyl, thienyl,benzothiazolyl, pyrazolyl, pyrimidinyl, benzimidazolyl, benzofuranyl,indolyl, or benzothiophenyl any of which is optionally substituted.

EXAMPLE 2 General Procedure for Preparation of Sulfoximines

A solution of 4-Bromo-5-nitro-thiophene-2-carbonitrile (2-1) is treatedwith an optionally substituted aryl or heteroaryl thiol to affordthioether (2-2). Reaction with iron and ammonium chloride (Stanetty, P.and Kremslehner, M., Heterocycles 48: 259 (1998)), followed bytert-butyl nitrite and copper (II) bromide gives the bromide (2-3) ((seeDoyle; Siegfried; Dellaria, J. Org. Chem. 42: 2426 (1977)). Oxidationwith hydrogen peroxide followed by treatment with a substitutedsulfonylimino iodinane and copper (II) triflate gives the sulfoximine(2-4). Reaction with a metallated nucleophile displaces the bromide togive sulfoximine (2-5). Cleavage of the sulfonamide with a suitablereagent, such as sodium methane thiolate, followed by treatment withtrimethyl aluminum and ammonium chloride gives the carboxamidine(Garigipati, R., Tetrahedron Lett. 31: 1969 (1990)), which is thenprotected to give the product (2-6), which may be further derivatized atthe sulfoximine, Q, or R² positions prior to acid catalyzed deprotectionof the carboxamidine. Alternatively, the sulfoximine (2-5) may bereacted with sodium methoxide, followed by a methanolic solution ofammonia and ammonium formate to give the carboxamidine as the product(2-7). Persons skilled in the art recognize that any examplessynthesized in racemic form may be separated into the correspondingenantiomers using a high performance liquid chromatograph equipped witha chiral separation column.

EXAMPLE 34-[S-(3-Bromophenyl)-N-(2-nitrobenzene-sulfonyl)sulfoxamino]-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

EXAMPLE 3a [N-(2-Nitrobenzene-sulfonylimino)]phenyl iodinane

A suspension of 2-nitro-benzenesulfonamide (2.50 g, 12.4 mmol) inmethanol (50 mL) was treated with solid potassium hydroxide (1.35 g,30.9 mmol) and stirred at room temperature for 10 min. During this timethe mixture turned clear then returned to a cloudy suspension. Themixture was cooled to 0° C., slowly treated with iodobenzene diacetate(3.38 g, 12.4 mmol), stirred at 0° C. for 10 min., and stirred at roomtemperature for 4 h. Solids were filtered, quickly washed with coldmethanol, and dried under high vac to afford[N-(2-nitrobenzene-sulfonylimino)]phenyl iodinane (3.40 g, 68%) as anoff-white solid. The crude material was used directly in the nextreaction.

EXAMPLE 3b4-[(3-Bromo-benzene)-N-(2-nitro-benzenesulfonyl)sulfoximino]-5-chloro-thiophene-2-carbonitrile

A solution of4-(3-bromo-benzenesulfinyl)-5-chloro-thiophene-2-carbonitrile ((Example24: step e) 200 mg, 0.558 mmol) in acetonitrile (3 mL) was treated with[N-(2-nitrobenzene-sulfonylimino)]phenyl iodinane ((Example 3: step a)451 mg, 1.12 mmol). The flask was flushed with argon. The suspension wastreated with copper (II) triflate (80.8 mg, 0.279 mmol) and stirred atroom temperature for 2 h. The excess[N-(2-nitrobenzene-sulfonylimino)]phenyl iodinane was removed byfiltering the mixture through Celite. The filter cake was washed withethyl acetate, and the filtrate was washed with water, dried over MgSO₄,and concentrated in vacuo. Silica gel chromatography (25% EtOAc/hexanesto 40% EtOAc/hexanes raised in 5% increments) afforded4-[(3-bromo-benzene)-N-(2-nitro-benzenesulfonyl)sulfoximino]-5-chloro-thiophene-2-carbonitrile(101 mg, 33%) as a white solid. ¹H NMR (CDCl₃): δ 8.176 (t, 1H, J=2.0Hz), 8.110-8.081 (m, 1H), 8.078 (s, 1H), 8.072-8.040 (m, 1H),7.869-7.837 (m, 1H), 7.720 (ddd, 2H, J=2.8 Hz, J=1.6 Hz), 7.701-7.655(m, 1H), 7.512 (t, 1H, J=8.0 Hz).

EXAMPLE 3c4-[(3-Bromo-benzene)-N-(2-nitro-benzenesulfonyl)sulfoximino]-5-chloro-thiophene-2-formamidemethyl ester

A solution of4-[(3-bromo-benzene)-N-(2-nitrobenzene-sulfonyl)sulfoximino]-5-chloro-thiophene-2-carbonitrile((Example 3: step b) 20.0 mg, 0.037 mmol) in tetrahydrofuran (2 mL) wascooled to −78° C. and treated dropwise with sodium thiomethoxide (87.0μL of a 0.5 M solution in methanol, 0.044 mmol). The solution stirred−78° C. for 1 h and at room temperature for 20 min. Excess sodiumthiomethoxide was quenched with 2 drops of glacial acetic acid. Thesolvents were removed in vacuo to afford4-[(3-bromo-benzene)-N-(2-nitro-benzenesulfonyl)sulfoximino]-5-chloro-thiophene-2-formamidemethyl ester. The crude material was used directly in the next reaction.C₁₉H₁₆BrN₃O₆S₄: 590.51 (M+1) found 589.8/591.8.

EXAMPLE 3d4-[S-(3-Bromophenyl)-N-(2-nitrobenzene-sulfonyl)sulfoxamino]-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

A solution of4-[(3-bromo-benzene)-N-(2-nitro-benzenesulfonyl)sulfoximino]-5-chloro-thiophene-2-formamidemethyl ester ((Example 3: step c) 21.6 mg, 0.036 mmol) in methanol (5mL) was treated with ammonium formate (23.1 mg, 0.366 mmol) and ammonia(2 mL of a 2M solution in methanol). The reaction was stirred at roomtemperature for 17 h. Minimal conversion to product (6%) was seen,therefore ammonia (100 μL of 7M solution in methanol) was added, and thereaction was heated to 40° C. for 12 h. Solvents were removed in vacuo.Preparatory HPLC (10-50% acetonitrile in 0.1% TFA/water over 30 min.)afforded4-[S-(3-bromophenyl)-N-(2-nitrobenzene-sulfonyl)sulfoxamino]-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate (15.8 mg, 75%) as a colorless glassy solid. ¹H NMR(CD₃OD): δ 8.394 (s, 1H), 8.201 (t, 1H, J=2.0 Hz), 8.066 (d, 1H, J=8.0Hz), 7.944 (d, 2H, J=8.0 Hz), 7.814 (d, 2H, J=6.0 Hz), 7.750-7.698 (m,1H), 7.585 (t, 1H, J=8.0 Hz), 2.695 (s, 3H). C₁₈H₁₅BrN₄O₅S₄: 575.50(M+1) found 574.8/576.9.

EXAMPLE 44-[S-(3-Bromophenyl)-N-(3-acetamidobenzene-sulfonyl)sulfoxamino]-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

A solution of 4-[S-(3-Bromophenyl)-N-sulfonyl-3-analinesulfoximino]-5-methylsulfanyl-thiophene-2-carbamic acid tert-butyl ester((Example 34: step b) 10.0 mg, 0.015 mmol) in CH₂Cl₂ (1 mL) was treatedwith triethylamine (4.3 μL, 0.031 mmol) and acetic anhydride (1.7 μL,0.019 mmol). The reaction was stirred at room temperature for 4.5 h.Solvents were evaporated in vacuo. The residue was taken up in CH₂Cl₂(1.5 mL) and treated with trifluoroactic acid (250 μL) at roomtemperature for 1 h. The solvents were evaporated in vacuo. PreparatoryHPLC (10-50% acetonitrile in 0.1% TFA/water over 30 min.) afforded4-[S-(3-bromophenyl)-N-(3-acetamidobenzene-sulfonyl)sulfoxamino]-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate (6.8 mg, 75%) as a colorless glassy solid. ¹H NMR(CD₃OD): δ 8.348 (s, 1H), 8.260 (t, 1H, J=2.0 Hz), 8.073 (t, 1H, J=2.0Hz), 7.990 (d, 1H, J=8.0 Hz), 7.902 (d, 1H, J=8.0 Hz), 7.633 (d, 1H,J=8.0 Hz), 7.536 (t, 2H, J=8.0 Hz), 7.429 (t, 1H, J=8.0 Hz), 2.687 (s,3H), 2.179 (s, 3H). C₂₀H₁₉BrN₄O₄S₄: 587.56 (M+1) found 586.9/588.9.

EXAMPLE 54-[S-(3-Bromophenyl)-N-(3-{N,N-bismethanesulfonyl}aminobenzene-sulfonyl)sulfoxamino]-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

A solution of 4-[S-(3-Bromophenyl)-N-sulfonyl-3-analinesulfoximino]-5-methylsulfanyl-thiophene-2-carbamic acid tert-butyl ester((Example 34: step b) 10.0 mg, 0.015 mmol) in CH₂Cl₂ (1 mL) was treatedwith triethylamine (4.3 μL, 0.031 mmol) and methanesulfonyl chloride(1.4 μL, 0.019 mmol). The reaction was stirred at room temperature for1.5 h. Solvents were evaporated in vacuo. The residue was taken up inCH₂Cl₂ (1.5 mL) and treated with trifluoroacetic acid (250 μL) at roomtemperature for 1.5 h. Solvents were evaporated in vacuo. PreparatoryHPLC (10-50% acetonitrile in 0.1% TFA/water over 30 min.) afforded4-[S-(3-bromophenyl)-N-(3-{N,N-bismethanesulfonylamino}benzene-sulfonyl)sulfoxamino]-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate (7.0 mg, 72%) as a colorless glassy solid. ¹H NMR(CD₃OD): δ 8.346 (s, 1H), 8.139 (t, 1H, J=2.0 Hz), 8.026-7.986 (m, 2H),7.941 (d, 1H, J=8.0 Hz), 7.907 (d, 1H, J=8.0 Hz), 7.742 (d, 1H, J=8.0Hz), 7.635 (t, 1H, J=8.0 Hz), 7.562 (t, 1H, J=8.0 Hz), 3.512 (s, 6H),2.711 (s, 3H). C₂₀H₂₁BrN₄O₇S₆: 701.70 (M+1) found 700.9/702.8.

EXAMPLE 64-[S-(3-Bromophenyl)-N-(3-ureidobenzene-sulfonyl)sulfoxamino]-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

A solution of 4-[S-(3-Bromophenyl)-N-sulfonyl-3-analinesulfoximino]-5-methylsulfanyl-thiophene-2-carbamic acid tert-butyl ester((Example 34: step b) 20.0 mg, 0.031 mmol) in CH₂Cl₂ (2 mL) was treatedwith pyridine (3.0 μL, 0.037 mmol) and p-nitrophenyl chloroformate (6.2mg, 0.031 mmol). The reaction was stirred at room temperature for 40min. Triethylamine (17.3 μL, 0.124 mmol) and ammonia (124 μL of a 0.5Msolution in dioxane, 0.062 mmol) were added, and the reaction wasstirred at room temperature for 15 h. The reaction was diluted withCH₂Cl₂ and washed with saturated aqueous NaHCO₃ until the aqueous layerno longer appears yellow. The organic layer was dried over MgSO₄ andconcentrated in vacuo. The residue was taken up in CH₂Cl₂ (3 mL) andtreated with trifluoroacetic acid (0.5 mL) at room temperature for 1 h.Solvents were evaporated in vacuo. Preparatory HPLC (10-50% acetonitrilein 0.1% TFA/water over 30 min.) afforded4-[S-(3-bromophenyl)-N-(3-ureidobenzene-sulfonyl)sulfoxamino]-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate (14.9 mg, 82%) as a colorless glassy solid. ¹H NMR(CD₃OD): δ 8.311 (s, 1H), 8.093 (t, 1H, J=2.0 Hz), 8.067 (t, 1H, J=2.0Hz), 7.989 (d, 1H, J=8.0 Hz), 7.898 (d, 1H, J=2.0 Hz), 7.535 (t, 1H,J=8.0 Hz), 7.456 (dt, 2H, J=8.0 Hz, J=1.6 Hz), 7.408-7.328 (m, 2H),2.688 (s, 3H). C₂₀H₂₁BrN₄O₇S₆: 588.55 (M+1) found 587.8/589.8.

EXAMPLE 74-[S-(3-Bromophenyl)-N-(3-methanesulfonamidobenzene-sulfonyl)sulfoxamino]-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

A solution of 4-[S-(3-Bromophenyl)-N-sulfonyl-3-analinesulfoximino]-5-methylsulfanyl-thiophene-2-carbamic acid tert-butyl ester((Example 34: step b) 10.0 mg, 0.015 mmol) in CH₂Cl₂ (1 mL) was treatedwith triethylamine (2.6 μL, 0.019 mmol) and methanesulfonyl chloride(1.3 μL, 0.017 mmol). The reaction was stirred at room temperature for16 h. Solvents were evaporated in vacuo. The residue was taken up inCH₂Cl₂ (2 mL) and treated with trifluoroacetic acid (0.5 mL) at roomtemperature for 1 h. Solvents were evaporated in vacuo. Preparatory HPLC(10-50% acetonitrile in 0.1% TFA/water over 30 min.) afforded4-[S-(3-bromophenyl)-N-(3-methanesulfonamidobenzene-sulfonyl)sulfoxamino]-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate (6.2 mg, 64%) as a colorless glassy solid. ¹H NMR(CD₃OD): δ 8.330 (s, 1H), 8.139 (t, 1H, J=2.0 Hz), 8.033 (d, 1H, J=8.0Hz), 7.938 (d, 1H, J=8.0 Hz), 7.786 (t, 1H, J=2.0 Hz), 7.575 (t, 2H,J=8.0 Hz), 7.484 (t, 1H, J=8.0 Hz), 7.415 (d, 1H, J=8.0 Hz), 3.057 (s,3H), 2.709 (s, 3H). C₁₉H₁₉BrN₄O₅S₅: 623.61 (M+1) found 622.7/624.8.

EXAMPLE 84-[S-(3-Bromophenyl)-N-{3-(5-methyl-[1,3,4]oxadiazol-2-yl)-benzene-sulfonyl}sulfoxamino]-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

A solution of4-[S-(3-bromophenyl)-sulfoxamino]-5-methylsulfanyl-thiophene-2-carbamicacid tert-butyl ester ((Example 24: step j) 20.0 mg, 0.041 mmol) intoluene (4 mL) was treated with triethylamine (13.6 μL, 0.100 mmol) and3-(5-methyl-[1,3,4]oxadiazol-2-yl)-benzenesulfonyl chloride (12.6 mg,0.049 mmol). The reaction was heated to 50° C. for 36 h. No conversionto product was seen at this time. Dimethyl-pyridin-4-yl-amine (DMAP,110.0 mg, 0.082 mmol) was added, and the reaction was stirred at 50° C.for an additional 24 h. The reaction was diluted with ethyl acetate andwashed with water, and the aqueous layer was extracted with ethylacetate. The combined organic layers were dried over MgSO₄ andconcentrated in vacuo. The residue was taken up in CH₂Cl₂ (4 mL) andtreated with trifluoroacetic acid (1 mL) at room temperature for 1.5 h.The solvents were removed in vacuo. Preparatory HPLC (10-50%acetonitrile in 0.1% TFA/water over 30 min.) afforded4-[S-(3-bromophenyl)-N-{3-(5-methyl-[1,3,4]oxadiazol-2-yl)-benzene-sulfonyl}sulfoxamino]-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate (14.0 mg, 56%) as a colorless glassy solid. ¹H NMR(CD₃OD): δ 8.406 (t, 1H, J=1.2 Hz), 8.378 (s, 1H), 8.246 (d, 1H, J=8.0Hz), 8.135 (t, 1H, J=2.0 Hz), 8.095 (d, 1H, J=8.0 Hz), 8.035 (d, 1H,J=8.0 Hz), 7.915 (d, 1H, J=8.0 Hz), 7.758 (t, 1H, J=8.0 Hz), 7.562 (t,1H, J=8.0 Hz), 2.689 (s, 3H), 2.681 (s, 3H). C₁₉H₁₉BrN₄O₅S₅: 612.57(M+1) found 611.9/613.9.

EXAMPLE 94-[S-(3-Bromophenyl)-N-{3-(oxazol-5-yl-benzene-sulfonyl)}sulfoxamino]-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

A solution of4-[S-(3-bromophenyl)-sulfoxamino]-5-methylsulfanyl-thiophene-2-carbamicacid tert-butyl ester ((Example 24: step j) 20.0 mg, 0.041 mmol) intoluene (4 mL) was treated with triethylamine (13.6 μL, 0.100 mmol) and3-oxazol-5-yl-benzenesulfonyl chloride (11.9 mg, 0.049 mmol). Thereaction was heated to 50° C. for 36 h. No conversion to product wasseen at this time. Dimethyl-pyridin-4-yl-amine (DMAP, 10.0 mg, 0.082mmol) was added, and the reaction was stirred at 50° C. for anadditional 24 h. The reaction was diluted with ethyl acetate and washedwith water, and the aqueous layer was extracted with ethyl acetate. Thecombined organic layers were dried over MgSO₄ and concentrated in vacuo.The residue was taken up in CH₂Cl₂ (4 mL) and treated withtrifluoroacetic acid (1 mL) at room temperature for 1.5 h. The solventswere removed in vacuo. Preparatory HPLC (10-50% acetonitrile in 0.1%TFA/water over 30 min.) afforded4-[S-(3-bromophenyl)-N-{3-(oxazol-5-yl-benzene-sulfonyl}sulfoxamino]-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate (5.7 mg, 20%) as a colorless glassy solid. ¹H NMR(CD₃OD): δ 8.355 (s, 1H), 8.348 (s, 1H), 8.128 (t, 1H, J=2.0 Hz), 8.088(t, 1H, J=2.0 Hz), 8.026 (d, 1H, J=8.0 Hz), 7.975 (d, 1H, J=8.0 Hz),7.916-7.865 (m 2H), 7.674 (s, 1H), 7.639 (t, 1H, J=8.0 Hz), 7.551 (t,1H, J=8.0 Hz), 2.680 (s, 3H). C₁₉H₁₉BrN₄O₅S₅: 597.55 (M+1) found596.9/598.8.

EXAMPLE 104-[S-[3-(2-amino-4-guanidino-6-methyl-phenyl)phenyl]-N-(4-ureidobenzene-sulfonyl)sulfoxamino]-5-methylsulfanyl-thiophene-2-carboxamidinebistrifluoroacetate

EXAMPLE 10a 4-[S-([6-Methyl-4-(2-trimethylsilanyl-ethoxycarbonylamino)-biphenyl-2-yl]-carbamic acid 2-trimethylsilanyl-ethylester)-N-sulfony-4-urido-benzenesulfoximino]-5-methylsulfanyl-thiophene-2-carbamic acid tert-butyl ester

A solution of4-[S-([6-Methyl-4-(2-trimethylsilanyl-ethoxycarbonylamino)-biphenyl-2-yl]-carbamicacid 2-trimethylsilanyl-ethyl ester)-N-sulfony-4-analinesulfoximino]-5-methylsulfanyl-thiophene-2-carbamic acid tert-butyl ester((Example 48) 26.5 mg, 0.027 mmol) in CH₂Cl₂ (2 mL) was treated withpyridine (2.6 μL, 0.033 mmol) and p-nitrophenyl chloroformate (5.5 mg,0.027 mmol). The reaction was stirred at room temperature for 30 min.Triethylamine (15.1 μL, 0.109 mmol) and ammonia (108.7 μL of a 0.5Msolution in dioxane, 0.054 mmol) were added, and the reaction wasstirred at room temperature for 45 min. The reaction was diluted withCH₂Cl₂ and washed with saturated aqueous NaHCO₃ until the aqueous layerno longer appeared yellow. The organic layer was dried over MgSO₄ andconcentrated in vacuo to afford the product4-[S-([6-Methyl-4-(2-trimethylsilanyl-ethoxycarbonylamino)-biphenyl-2-yl]-carbamicacid 2-trimethylsilanyl-ethyl ester)-N-sulfony-4-urido-benzenesulfoximino]-5-methylsulfanyl-thiophene-2-carbamic acid tert-butyl ester(21.0 mg, 76%) as a pale yellow solid. C₄₃H₅₉N₇O₁₀S₄Si₅: 1018.40 (M+1)found 917.9 (M+1-benzyloxycarbonyl).

EXAMPLE 10b4-[S-([6-Methyl-biphenyl-2,4-diamine)-N-sulfony-4-ureidobenzene-sulfonyl)sulfoximino]-5-methylsulfanyl-thiophene-2-carbamicacid tert-butyl ester

A4-[S-([6-Methyl-4-(2-trimethylsilanyl-ethoxycarbonylamino)-biphenyl-2-yl]-carbamicacid 2-trimethylsilanyl-ethyl ester)-N-sulfony-4-urea-benzenesulfoximino]-5-methylsulfanyl-thiophene-2-carbamic acid tert-butyl ester((Example 10: step a) 21.0 mg, 0.021 mmol) in tetrahydrofuran (3 mL) washeated to 50° C. and treated with tetrabutylammonium fluoride (62.0 μLas a 1M solution in tetrahydrofuran, 0.063 mmol). The reaction wasstirred at 50° C. for 2.5 h. Solvents were removed in vacuo. The residuewas taken up in ethyl acetate and washed well with water. The organiclayer was dried over MgSO₄ and concentrated in vacuo to afford theproduct4-[S-([6-Methyl-biphenyl-2,4-diamine)-N-sulfony-4-ureidobenzene-sulfonyl)sulfoximino]-5-methylsulfanyl-thiophene-2-carbamicacid tert-butyl ester (17.1 mg, 112%, some salt remained) as a light tansolid. C₄₃H₅₉N₇O₁₀S₄Si₅: 729.92 (M+1) found 730.0.

EXAMPLE 10c4-[S-[3-(2-Amino-4-guanidino-6-methyl-phenyl)phenyl]-N-(4-ureidobenzene-sulfonyl)sulfoxamino]-5-methylsulfanyl-thiophene-2-carboxamidinebistrifluoroacetate

A 4-[S-([6-Methyl-biphenyl-2,4-diamine)-N-sulfony-4-urea-benzenesulfoximino]-5-methylsulfanyl-thiophene-2-carbamic acid tert-butyl ester((Example 10: step b) 17 mg, 0.023 mmol) in 5% acetic acid/methanol (2mL) was treated with1,3-bis(tert-butoxycarbonyl)-2-methyl-2-thiopseudourea (6.8 mg, 0.023mmol) and heated to 50° C. for 30 min. Solvents were removed in vacuo.The residue was taken up in CH₂Cl₂ (2 mL) and treated withtrifluoroacetic acid (0.5 mL) at room temperature for 1.5 h. Solventswere removed in vacuo. Preparatory HPLC (10-50% acetonitrile in 0.1%TFA/water over 30 min.) afforded4-[S-[3-(2-amino-4-guanidino-6-methyl-phenyl)phenyl]-N-(4-ureidobenzene-sulfonyl)sulfoxamino]-5-methylsulfanyl-thiophene-2-carboxamidinebistrifluoroacetate (8.2 mg, 52%) as a colorless glassy solid. ¹H NMR(CD₃OD): δ 8.350 (d, 1H, J=4.0 Hz), 8.029 (d, 1H, J=8.0 Hz), 8.000 (d,1H, J=1.2 Hz), 7.790 (t, 1H, J=8.0 Hz), 7.722 (dd, 2H, J=2.0 Hz, J=9.2Hz), 7.646 (d, 1H, J=7.6 Hz), 7.497 (dd, 2H, J=2.0 Hz, J=8.8 Hz), 7.670(d, 1H, J=2.4 Hz), 7.630 (t, 1H, J=1.2 Hz), 2.650 (d, 3H, J=1.6 Hz),1.978 (d, 3H, J=4.4 Hz). C₂₇H₂₉N₉O₄S₄: 671.84 (M+1) found 672.1.

EXAMPLE 114-[S-(3-Bromophenyl)-N-p-tolyl-formamide]-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

A solution of4-[S-(3-bromophenyl)-sulfoxamino]-5-methylsulfanyl-thiophene-2-carbamicacid tert-butyl ester (Example 24: step j) 20.0 mg, 0.041 mmol) intetrahydrofuran (1 mL) was treated with diisopropylethylamine (100 μL,0.574 mmol) and 1-isocyanato-4-methyl benzene (400 μL of a 0.25 Msolution in tetrahydrofuran, 0.751 mmol) at room temperature for 2 h.The reaction was diluted with EtOAc (50 mL) and was washed with citricacid (3×10 mL), NaHCO₃ (2×10 mL), and brine (20 mL). The organic layerwas dried over Na₂SO₄ and concentrated in vacuo. The residue was takenup in CH₂Cl₂ (3 mL) and treated with trifluoroacetic acid (3 mL) at roomtemperature for 2 h. Solvents were evaporated in vacuo. Preparatory HPLC(10-55% acetonitrile in 0.1% TFA/water over 40 min.) afforded the titlecompound (5.2 mg, 25%) as a colorless glassy solid. ¹H NMR (CD₃OD): δ8.43 (s, 1H), 8.394 (s, 1H), 8.16 (d, H, J=8.0 Hz), 7.92 (d, 1H, J=8.0Hz), 7.58 (t, 1H, J=8.0 Hz), 7.34 (d, 2H, J=8.0 Hz), 7.09 (d, 2H, J=8.8Hz), 2.72 (s, 3H), 2.29 (s, 3H). C₂₀H₁₉BrN₄O₂S₃: 523.49 (M+1); found:522.7/524.6.

EXAMPLE 124-[S-(3-Bromophenyl)-N-benzamide]-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

A solution of4-[S-(3-bromophenyl)-sulfoxamino]-5-methylsulfanyl-thiophene-2-carbamicacid tert-butyl ester (Example 24: step j) 14.0 mg, 0.029 mmol) intetrahydrofuran (2 mL) was cooled to 0° C. and treated with pyridine(160 μL, 2 mmol) and benzoyl chloride (150 μL of a 0.2M solution intetrahydrofuran, 0.030 mmol) for 1 h. Because no conversion to productwas seen under these conditions, the reaction was warmed to roomtemperature and stirred for 1 h. The reaction was treated withadditional benzoyl chloride (750 μL, 0.150 mmol) over 3 h and allowed tostir at room temperature for 16 h. The reaction was diluted with EtOAc(50 mL) and was washed with citric acid (3×10 mL), NaHCO₃ (2×10 mL), andbrine (20 mL). The organic layer was dried over Na₂SO₄ and concentratedin vacuo. The residue was taken up in CH₂Cl₂ (3 mL) and treated withtrifluoroacetic acid (3 mL) for 2 h. Solvents were removed in vacuo.Preparatory HPLC of the residue (10-55% acetonitrile in 0.1% TFA/waterover 40 min.) afforded the title compound (4.7 mg, 34%) as a colorlessglassy solid. ¹H NMR (CD₃OD): δ 8.48 (s, 1H), 8.36 (t, 1H, J=1.6 Hz),8.24-8.21 (m, 3H), 7.96 (d, 1H, J=8.0 Hz), 7.66-7.60 (m, 2H), 7.55-7.50(m, 2H), 2.70 (s, 3H). C₁₉H₁₆BrN₃O₂S₃: 494.45 (M+1); found: 493.9/495.9.

EXAMPLE 134-[S-(3-Bromophenyl)-N-3-nitro-benzamide]-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

A solution of4-[S-(3-bromophenyl)-sulfoxamino]-5-methylsulfanyl-thiophene-2-carbamicacid tert-butyl ester (Example 24: step j) 50.0 mg, 0.102 mmol) intetrahydrofuran (3 mL) was treated with diisopropylethyl amine (175 μL,1.00 mmol) and 3-nitrobenzoyl chloride (1.00 mL as a 0.5 M solution inCH₂Cl₂, 0.500 mmol). The reaction was stirred at room temperature for 30min. The reaction was diluted with EtOAc (50 mL) and was washed withcitric acid (3×10 mL), NaHCO₃ (2×10 mL), and brine (20 mL). The organiclayer was dried over Na₂SO₄ and concentrated in vacuo. A portion of theresidue (10 mg) was chromatographed on silica gel (10-50% EtOAc in Hex)to afford4-[S-(3-bromophenyl)-N-3-nitro-benzamide]-5-methylsulfanyl-thiophene-2-tertbutyl ester. The residue was taken up in CH₂Cl₂ (3 mL) and treated withtrifluoroacetic acid (3 mL) at room temperature for 2 h.

Preparatory HPLC (10-55% acetonitrile in 0.1% TFA/water over 40 min.)afforded the title compound (3.5 mg) as a colorless glassy solid. ¹H NMR(CD₃OD): δ 8.49 (s, 1H), 8.37 (t, 1H, J=2.0 Hz), 8.23 (d, 1H, J=8.0 Hz),8.16 (dt, 1H, J=8.0 Hz, J=1.2 Hz), 8.04 (dd, 1H, J=2.0 Hz, J=2.0 Hz),7.98 (d, 1H, J=8.0 Hz), 7.63 (t, 1H, J=8.0 Hz), 7.60 (t, 1H, J=8.0 Hz),7.47 (d, 1H, J=8.0 Hz), 2.71 (s, 3H). C₁₉H₁₅BrN₄O₄S₃: 539.45 (M+1);found: 538.8/540.8.

EXAMPLE 144-[S-(3-Bromophenyl)-N-3-amino-benzamide]-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

A solution of4-[S-(3-bromophenyl)-N-3-nitro-benzamide]-5-methylsulfanyl-thiophene-2-tertbutyl ester (Example 13: step intermediate) 20 mg, 0.03 mmol) intetrahydrofuran (1 mL), ethanol (2 mL), and water (1 mL) was treatedwith sodium dithionite (52 mg, 0.3 mmol) at RT for 2 h. The reaction wasdiluted with EtOAc (50 mL) and was washed with citric acid (3×10 mL),NaHCO₃ (2×10 mL), and brine (20 mL). The organic layer was dried overNa₂SO₄ and concentrated in vacuo. The residue was taken up in CH₂Cl₂ (3mL) and treated with trifluoroacetic acid (3 mL) for 1 h. Solvents wereevaporated in vacuo. Preparatory HPLC (10-55% acetonitrile in 0.1%TFA/water over 40 min.) afforded the title compound (7 mg, 35%) as acolorless glassy solid. ¹H NMR (CD₃OD): 6.9.01 (dd, 1H, J=2.0 Hz, J=2.0Hz), 8.60 (d, 1H, J=7.6 Hz), 8.50 (d, 1H, J=8.0 Hz), 8.49 (s, 1H), 8.375(t, 1H, J=2.0 Hz), 8.235 (d, 1H, J=8.0 Hz), 7.983 (d, 1H, J=8.0 Hz),7.803 (t, 1H, J=8.0 Hz), 7.644 (t, 1H, J=8.0 Hz), 2.730 (s, 3H).C₁₉H₁₇BrN₄O₂S₃: 509.47 (M+1); found: 508.8/510.9.

EXAMPLE 154-[S-(3-Bromophenyl)-N-(phenylmethane-sulfonyl)sulfoxamino]-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

A solution of4-[S-(3-bromophenyl)-sulfoxamino]-5-methylsulfanyl-thiophene-2-carbamicacid tert-butyl ester (Example 24: step j) 13.0 mg, 0.027 mmol) inCH₂Cl₂ (3 mL) was treated with triethylamine (175 μL, 1 mmol) andphenyl-methanesulfonyl chloride (0.2M in DCM, 300 μL, 0.6 mmol) at roomtemperature for 2 h. The reaction was diluted with EtOAc (50 mL) and waswashed with citric acid (3×10 mL), NaHCO₃ (2×10 mL), and brine (20 mL).The organic layer was dried over Na₂SO₄ and concentrated in vacuo. Theresidue was taken up in CH₂Cl₂ (3 mL) and treated with trifluoroaceticacid (3 mL) at room temperature for 1 h. Solvents were removed in vacuo.Preparatory HPLC (10-55% acetonitrile in 0.1% TFA/water over 40 min.)afforded the title compound (8 mg, 57%) as a colorless glassy solid. ¹HNMR (CD₃OD): δ 8.30 (s, 1H), 8.20 (t, 1H, J=1.6 Hz), 8.02 (d, 1H, J=8.4Hz), 7.95 (d, 1H, J=8.0 Hz), 7.58 (t, 1H, J=8.0 Hz), 7.48-7.44 (m, 2H),7.400-7.36 (m, 3H), 4.56 (s, 2H), 2.74 (s, 3H). C₁₉H₁₈BrN₃O₃S₄: 544.53(M+1); found: 543.9/545.8.

EXAMPLE 164-[S-(3-Bromophenyl)-N-(methanesulfonyl)-sulfoxamino]-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

A solution of4-[S-(3-bromophenyl)-sulfoxamino]-5-methylsulfanyl-thiophene-2-carbamicacid tert-butyl ester (Example 24: step j) 13.0 mg, 0.027 mmol) inCH₂Cl₂ (3 mL) was treated with triethylamine (175 μL, 1 mmol) andmethanesulfonyl chloride (0.2 M in DCM, 200 μL, 0.4 mmol) at roomtemperature for 3 h. The reaction was diluted with EtOAc (50 mL) and waswashed with citric acid (3×10 mL), NaHCO₃ (2×10 mL), and brine (20 mL).The organic layer was dried over Na₂SO₄ and concentrated in vacuo. Theresidue was taken up in CH₂Cl₂ (3 mL) and treated with trifluoroaceticacid (3 mL) at room temperature for 1 h. Solvents were removed in vacuo.Preparatory HPLC (10-55% acetonitrile in 0.1% TFA/water over 40 min.)afforded the title compound (7 mg, 58%) as a colorless glassy solid. ¹HNMR (CD₃OD): δ 8.38 (s, 1H), 8.26 (t, 1H, J=1.6 Hz), 8.10 (d, 1H, J=8.0Hz), 7.96 (d, 1H, J=8.0 Hz), 7.60 (t, 1H, J=8.0 Hz), 3.19 (s, 3H), 2.75(s, 3H). C₁₃H₁₄BrN₃O₃S₄: 468.44 (M+1); found: 467.8/469.8.

EXAMPLE 174-[S-(3-Bromophenyl)-N-({2-aminophenyl}methane-sulfonyl)sulfoxamino]-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

EXAMPLE 17a4-[S-(3-Bromophenyl)-N-({2-nitrophenyl}methane-sulfonyl)sulfoxamino]-5-methylsulfanyl-thiophene-2-tertbutyl ester

A solution of4-[S-(3-bromophenyl)-sulfoxamino]-5-methylsulfanyl-thiophene-2-carbamicacid tert-butyl ester (Example 24: step j) 20.0 mg, 0.041 mmol) intetrahydrofuran (3 mL) was treated with diisopropylethylamine (60.0 μL,0.344 mmol) and (2-nitrophenyl)methanesulfonyl chloride (240 μL of a 0.2M solution in DCM, 0.120 mmol) at room temperature for 6 h. The reactionwas treated with additional 2-nitrophenylmethanesulfonyl chloride (240μL of a 0.2 M solution in DCM, 0.120 mmol) and was stirred for 16 h. Thereaction was diluted with EtOAc (50 mL) and was washed with citric acid(3×10 mL), NaHCO₃ (2×10 mL), and brine (20 mL). The organic layer wasdried over Na₂SO₄ and concentrated in vacuo. Silica gel chromatography(10-60% EtOAc in hexanes) afforded4-[S-(3-Bromophenyl)-N-({2-nitrophenyl}methane-sulfonyl)sulfoxamino]-5-methylsulfanyl-thiophene-2-tertbutyl ester (20 mg, 0.03 mmol) as an off-white solid. C₂₄H₂₅BrN₄O₇S₄:689.65 (M+1); found: 688.6/690.6.

EXAMPLE 17b4-[S-(3-Bromophenyl)-N-({2-aminophenyl}methane-sulfonyl)sulfoxamino]-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

A solution of4-[S-(3-bromophenyl)-N-({2-nitrophenyl}methane-sulfonyl)sulfoxamino]-5-methylsulfanyl-thiophene-2-tertbutyl ester (Example 17: step a; 20.0 mg, 0.029 mmol) in tetrahydrofuran(3 mL) and water (1 mL) was treated with aqueous sodium dithionite (0.5mL of a 0.5 M solution, 0.250 mmol) and stirred at room temperature for1 h. The reaction was diluted with ethyl acetate (30 mL) and washed withwater (2×10 mL). The organic layer was dried over Na₂SO₄ andconcentrated in vacuo. A portion of the residue (4.0 mg, 0.006 mmol) wastaken up in CH₂Cl₂ (3 mL) and treated with trifluoroacetic acid (3 mL)at room temperature for 2 h. Solvents were evaporated in vacuo.Preparatory HPLC of the residue (10-55% acetonitrile in 0.1% TFA/waterover 40 min.) afforded the title compound (3 mg, 70%) as a colorlessglassy solid. ¹H NMR (CD₃OD): δ 8.33 (s, 1H), 8.24 (t, 1H, J=1.6 Hz),8.04 (d, 1H, J=8.4 Hz), 7.97 (d, 1H, J=8.0 Hz), 7.60 (t, 1H, J=8.0 Hz),7.36 (dd, 1H, J=7.6 Hz, J=1.2 Hz), 7.32 (dt, 1H, J=2.0 Hz, J=7.6 Hz),7.08 (dd, 1H, J=0.8 Hz, J=8.0 Hz), 7.03 (dt, 1H, J=1.2 Hz, J=7.2 Hz),4.66 (s, 2H), 2.75 (s, 3H). C₁₉H₁₉BrN₄O₃S₄: 559.55 (M+1); found:558.7/560.7.

EXAMPLE 184-[S-[3-(2-Amino-4-guanidino-6-methyl-phenyl)phenyl]-N-(3-ureidobenzene-sulfonyl)sulfoxamino]-5-methylsulfanyl-thiophene-2-carboxamidinebistrifluoroacetate

EXAMPLE 18a4-[S-(3-Bromophenyl)-N-(sulfonyl-3-nitrobenzene)-sulfoximino]-5-chloro-thiophene-2-carbonitrile

A solution of4-(3-bromo-benzenesulfinyl)-5-chloro-thiophene-2-carbonitrile (Example24: step e; 347 mg, 1 mmol), (N-(3-nitrosulfonylbenzene)imino)phenyliodinane (prepared analogously to(N-(4-nitrosulfonylbenzene)imino)phenyl iodinane in Example 24: step f;450 mg, 1.2 mmol), and copper triflate (36 mg, 0.1 mmol) in acetonitrile(4 mL) was stirred for 30 min at RT. An additional 80 mg of(N-(3-nitrosulfonylbenzene)imino)phenyl iodinane was added and after 30min of stirring, the reaction was partitioned between EtOAc (100 mL) andNaHCO₃ (30 mL). The layers were separated and the organic layer waswashed with water (3×20 mL) and brine (30 mL). The organic solution wasdried over Na₂SO₄, concentrated in vacuo, and the residue was purifiedvia silica gel flash chromatography to yield the product contaminatedwith sulfoxide starting material. Recrystallization from DCM-Hexanesyielded the product (410 mg, 75%). ¹H NMR (CDCl₃): δ 8.91 (t, 1H, J=2.0Hz), 8.42 (ddd, 1H, J=1.0, 2.0, 8.1 Hz), 8.34 (ddd, 1H, J=1.2, 1.6, 8.0Hz), 8.11 (t, 1H, J=2.0 Hz), 8.06 (s, 1H), 7.97 (ddd, 1H, J=1.0, 1.8,8.1 Hz), 7.74 (ddd, 1H, J=1.0, 1.8, 8.1 Hz), 7.68 (t, 1H, J=8.0 Hz),7.43 (t, 1H, J=8.0 Hz).

EXAMPLE 18b4-[S-(3-Bromophenyl)-N-(sulfonyl-3-nitrobenzene)-sulfoximino]-5-methylsulfanyl-thiophene-2-carbamicacid tert-butyl ester

To a solution of4-[S-(3-bromophenyl)-N-(sulfonyl-3-nitrobenzene)-sufloximino]-5-chloro-thiophene-2-carbonitrile(Example 18: step a; 410 mg, 0.75 mmol) in THF at -78° C. was added asolution of NaSMe (0.5M, 3 mL, 1.5 mmol) in MeOH. The reaction asallowed to warm to RT over 30 min and was stirred for an additional hrat RT. Ethyl acetate (100 mL) and aqueous NaHCO₃ (30 mL) were added andthe layers were separated. The organic layer was washed with water (10mL), brine (10 mL), and was dried over Na₂SO₄. The solution wasconcentrated and the residue was dissolved in methanolic ammonia (7N, 40mL) and THF (10 mL). Ammonium formate (200 mg) was added and thereaction was heated at 40° C. for 16 h. The solvent was removed in vacuoand the residue was dissolved in 1:1 dioxane/MeOH (20 mL).Di-tert-butyldicarbonate (6.6 g, 30 mmol) and DIEA (5 mL) were added andthe reaction was stirred for 4 h at RT. EtOAc (100 mL) and citric acid(1M, 30 mL) were added and the layers were separated. The organic layerwas washed with citric acid (3×30 mL), NaHCO₃ (30 mL), brine (50 mL),and was dried over Na₂SO₄. Concentration of the solution followed bysilica gel flash chromatography (5-40% EtOAc in hexanes) yielded theproduct (325 mg, 64%). ¹H NMR (CDCl₃): δ ¹H NMR (CDCl₃): δ 8.77 (t, 1H,J=2.0 Hz), 8.37 (ddd, 1H, J=1.0, 2.2, 8.2 Hz), 8.30 (ddd, 1H, J=1.0,1.6, 8.0 Hz), 8.10 (t, 1H, J=2.0 Hz), 8.01 (s, 1H), 7.97 (ddd, 1H,J=1.0, 1.8, 8.1 Hz), 7.73 (ddd, 1H, J=1.0, 1.8, 8.1 Hz), 7.67 (t, 1H,J=8.0 Hz), 7.41 (t, 1H, J=8.0 Hz), 2.55 (s, 3H), 1.50 (s, 9H).C₂₃H₂₃BrN₄O₇S₄: 675.0 (M+1); found: 674.6/676.6.

EXAMPLE 18c4-[S-([6-Methyl-4-(2-trimethylsilanyl-ethoxycarbonylamino)-biphenyl-2-yl]-carbamicacid 2-trimethylsilanyl-ethyl ester)-N-sulfonyl-3-nitro-benzenesulfoximino]-5-methylsulfanyl-thiophene-2-carbamic acid tert-butyl ester

A solution of4-[S-(3-Bromophenyl)-N-(sulfonyl-3-nitrobenzene)-sulfoximino]-5-methylsulfanyl-thiophene-2-carbamicacid tert-butyl ester (325 mg, 0.48 mmol), di-Teoc-pinacolboronate(Example 18: step b; 403 mg, 0.75 mmol), and saturated NaHCO₃ (2 mL) indimethoxyethane (4 mL) was sparged with argon for 10 min, andtetrakis(triphenylphosphine)palladium (0) (80 mg, 0.072 mmol) was added.The solution was heated to 80° C. for 8 h. The solution was partitionbetween EtOAc (60 mL) and water (20 mL) and the layers were separated.The organic layer was washed with water (20 mL), brine (20 mL) and wasdried over Na₂SO₄. Concentration of the solvent followed by silica gelflash chromatography yielded the product (227 mg, 48%). ¹H NMR (CDCl₃):δ 8.81 (m, 1H), 8.37 (m, 1H), 8.30 (m, 1H), 7.70-8.05 (m, 3H), 7.66 (m,2H), 7.51 (m, 1H), 7.27 (m, 2H), 6.65 (s, 1H), 5.98 (br m, 1H), 4.27 (m,2H), 4.09 (m, 2H), 2.57 (br d, 3H), 1.97 (br d, 3H), 1.51 (s, 9H), 1.06(m, 2H), 0.90 (m, 2H), 0.07 (s, 9H), −0.04 (s, 9H). C₄₂H₅₆N₆O₁S₄Si₂:1005.2 (M+1); found: 904.9 ((M+1)-Boc).

EXAMPLE 18d4-[S-([6-Methyl-4-(2-trimethylsilanyl-ethoxycarbonylamino)-biphenyl-2-yl]-carbamicacid 2-trimethylsilanyl-ethyl ester)-N-sulfonyl-3-analinesulfoximino]-5-methylsulfanyl-thiophene-2-carbamic acid tert-butyl ester

The procedure outlined in Example 33: step b was followed using4-[S-([6-Methyl-4-(2-trimethylsilanyl-ethoxycarbonylamino)-biphenyl-2-yl]-carbamicacid 2-trimethylsilanyl-ethyl ester)-N-sulfonyl-3-nitro-benzenesulfoximino]-5-methylsulfanyl-thiophene-2-carbamic acid tert-butyl ester((Example 18: step c) 114 mg, 0.11 mmol), iron powder (100 mg, 2 mmol),saturated ammonium chloride (1 mL), ethanol (4 mL) and dioxane (1 mL).Analogous workup followed by purification by silica gel flashchromatography yielded the product (75 mg, 68%) as a colorless glassysolid. C₄₂H₅₈N₆O₉S₄Si₂: 975.3 (M+1); found: 975.1.

EXAMPLE 18e4-[S-([6-Methyl-4-(2-trimethylsilanyl-ethoxycarbonylamino)-biphenyl-2-yl]-carbamicacid 2-trimethylsilanyl-ethylester)-N-sulfonyl-3-ureidobenzene-sulfonyl)sulfoximino]-5-methylsulfanyl-thiophene-2-carbamicacid tert-butyl ester

A solution of p-nitrophenyl chloroformate (0.2 M, 385 uL, 0.077 mmol)was added to a 0° C. solution of4-[S-([6-Methyl-4-(2-trimethylsilanyl-ethoxycarbonylamino)-biphenyl-2-yl]-carbamicacid 2-trimethylsilanyl-ethyl ester)-N-sulfonyl-3-analine sulfonylsulfoximino]-5-methylsulfanyl-thiophene-2-carbamic acid tert-butyl ester((Example 18: step d) 75 mg, 0.077 mmol) and pyridine (20 μL, 0.231mmol) in CH₂Cl₂ (2 mL). The reaction was stirred at room temperature for30 min and the reaction was divided into two portions. Ammonia (5 mL ofa 0.5M solution in dioxane, 2.5 mmol) was added and the reaction wasstirred at room temperature for 45 min. The reaction was diluted withEtOAc and was washed with saturated aqueous NaHCO₃ until the aqueouslayer no longer appeared yellow. The organic layer was dried over Na₂SO₄and concentrated in vacuo to afford the title product (35 mg, 76%) as apale yellow glass which was used without further purification.C₄₃H₅₉N₇O₁₀S₄Si₅: 1018.3 (M+1); found: 918.1 ((M+1)-Boc).

EXAMPLE 18f4-[S-[3-(2-Amino-4-guanidino-6-methyl-phenyl)phenyl]-N-(3-ureidobenzene-sulfonyl)sulfoximino]-5-methylsulfanyl-thiophene-2-carboxamidinebistrifluoroacetate

A solution of-[S-([6-Methyl-4-(2-trimethylsilanyl-ethoxycarbonylamino)-biphenyl-2-yl]-carbamicacid 2-trimethylsilanyl-ethylester)-N-sulfonyl-3-ureidobenzene-sulfonyl)sulfoximino]-5-methylsulfanyl-thiophene-2-carbamicacid tert-butyl ester (Example 18: step e) 35.0 mg, 0.035 mmol) intetrahydrofuran (2 mL) was heated to 50° C. and treated withtetrabutylammonium fluoride (1M in THF, 350 μL, 0.35 mmol). The reactionwas stirred at 50° C. for 30 min. The residue was taken up in ethylacetate (30 mL) and was washed with water (5×10 mL). The organic layerwas dried over Na₂SO₄ and concentrated in vacuo. C₃₁H₃₅N₇O₆S₄: 730.2(M+1); Found: 730.0. The residue was dissolved in 5% acetic acid inmethanol (2 mL) was treated with1,3-bis(tert-butoxycarbonyl)-2-methyl-2-thiopseudourea (11.6 mg, 0.04mmol) and heated to 40° C. for 12 h. C₄₂H₅₃N₉O₉S₄: 972.3 (M+1); found:972.1. Solvents were removed in vacuo, the residue was taken up inCH₂Cl₂ (2 mL) and treated with trifluoroacetic acid (0.5 mL) at roomtemperature for 1.5 h. Solvents were removed in vacuo. Preparatory HPLC(10-50% acetonitrile in 0.1% TFA/water over 30 min.) afforded4-[S-[3-(2-amino-4-guanidino-6-methyl-phenyl)phenyl]-N-(3-ureidobenzene-sulfonyl)sulfoxamino]-5-methylsulfanyl-thiophene-2-carboxamidinebistrifluoroacetate (6.3 mg) as a colorless glassy solid. ¹H NMR(CD₃OD): δ 8.36 (m, 1H), 8.15 (m, 1H), 8.00 (m, 1H), 7.99 (m, 1H), 7.75(m, 1H), 7.63 (m, 1H), 7.44 (m, 2H), 7.37 (m, 1H); 6.65 (s, 1H), 6.61(m, 1H), 2.66 (br d, 3H), 1.96 (br d, 3H). C₂₇H₂₉N₉O₄S₄: 672.8 (M+1)found: 673.1.

EXAMPLE 19 4-[S-(3-Bromo-benzenesulfonyl)-N-(m-sulfonyl benzoicacid)-sulfoxamino]-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

EXAMPLE 19a 3-Sulfamoyl-benzoic acid tert-butyl ester

Sulfuric acid (conc., 498 μL, 9.06 mmol) was added to a suspension ofMgSO₄ (4.36 g, 36.22 mmol) in CH₂Cl₂ (36 mL). The reaction mixture wasstirred for 15 minutes, treated with 3-chlorosulfonyl-benzoic acid(Aldrich, 2 g, 9.06 mmol) and 2-methyl-propan-2-ol (anhydrous, 4.33 mL,45.27 mmol), capped tightly, and stirred overnight at room temperature.The next day, the mixture was cooled to 0° C., treated with 7N NH₃ inmethanol (Aldrich, 40 mL) dropwise, and stirred for 30 minutes. Thesolvents were removed in vacuo and the crude was dissolved in ethylacetate and saturated NaHCO₃. The organic layer was washed withsaturated NaHCO₃, water, and brine, dried over MgSO₄, filtered, andconcentrated in vacuo to afford the title compound as a white solid (1g, 42.9% yield). ¹H-NMR (CDCl₃): δ 8.51-8.53 (m, 1H), 8.20-8.21 (m, 1H),8.08-8.11 (m, 1H), 7.57-7.62 (m, 1H), 5.09 (bs, 2H), and 1.61 (s, 9H).

EXAMPLE 19b (N-(m-Sulfonyl benzoic acid tert-butylester)imino)phenyliodinane

Potassium hydroxide (141 mg, 2.52 mmol) was added to a solution of3-sulfamoyl-benzoic acid tert-butyl ester (Example 19: step a, 259 mg,1.01 mmol) in methanol (anhydrous, 4 mL). The reaction mixture wasstirred for 30 minutes at room temperature, cooled to 0° C., and purgedwith argon. Iodobenzenediacetate (Aldrich, 324 mg, 1.01 mmol) was addedand the reaction mixture was stirred overnight at room temperature.Water (30 mL) was added to the reaction mixture until a precipitateformed. The mixture was cooled in the refrigerator for 3 hours, and thenthe solids were filtered and dried overnight to afford the titlecompound as a yellow solid (237 mg, 51% yield).

EXAMPLE 19c 4-[S-(3-Bromophenyl)-N-(m-sulfonyl benzoic acid tert-butylester)sufoxamino]-5-methylsulfanyl-thiophene-2-carbonitrile

Copper (II) trifluoromethanesulfonate (Aldrich, 8.6 mg, 0.024 mmol) wasadded to a suspension of4-(3-bromo-benzenesulfinyl)-5-chloro-thiophene-2-carbonitrile (Example24: step e, 82.8 mg, 0.24 mmol) and (N-(m-sulfonyl benzoic acidtert-butyl ester)imino)phenyliodinane (Example 19: step b, 219.5 mg,0.48 mmol) in acetonitrile (anhydrous, 1 mL) under argon. The reactionmixture was stirred at RT under argon overnight, concentrated in vacuo,diluted in ethyl acetate, and washed with brine. The organic layer wasdried over magnesium sulfate, filtered, concentrated in vacuo, andpurified by column chromatography (silica gel, 40-50% ethylacetate/hexanes) to afford the title compound as a white solid (47.9 mg,33.3% yield). ¹H-NMR (CDCl₃): δ 8.54-8.56 (m, 1H), 8.12-8.22 (m, 3H),8.01-8.04 (m, 2H), 7.83-7.87 (m, 1H), 7.48-7.61 (m, 2H), 1.63 (s, 9H).

EXAMPLE 19d 4-[S-(3-Bromophenyl)-N-(m-sulfonyl benzoic acid tert-butylester)-sulfoxamino]-5-methylsulfanyl-thiophene-2-carboximidic acidmethyl ester

Sodium thiomethoxide solution (0.1M in methanol, 955 μL, 0.096 mmol) wasadded to a −78° C. solution of 4-[S-(3-bromophenyl)-N-(m-sulfonylbenzoic acid tert-butylester)sufoxamino]-5-methylsulfanyl-thiophene-2-carbonitrile (Example 19:step c, 47.9 mg, 0.080 mmol) in THF (anhydrous, 3 mL) under argon. Thereaction mixture was warmed to room temperature, stirred overnight, andconcentrated in vacuo. The residue was diluted with ethyl acetate andwashed with saturated NaHCO₃, water, and brine. The organic layer wasdried over magnesium sulfate, filtered, and concentrated in vacuo toafford the title compound as a yellow oil (51.4 mg, quantitative).¹H-NMR (CDCl₃): δ 8.54-8.55 (m, 1H), 8.12-8.18 (m, 3H), 8.00-8.04 (m,1H), 7.75-7.82 (m, 2H), 7.41-7.57 (m, 2H), 3.85-3.90 (m, 3H), 2.59 (s,3H), and 1.62 (s, 9H).

EXAMPLE 19e 4-[S-(3-Bromo-benzenesulfonyl)-N-(m-sulfonyl benzoic acidtert-butylester)-sulfoxamino]-5-methylsulfanyl-thiophene-2-carboxamidine

Ammonium formate (Aldrich, 25.1 mg, 0.398 mmol) was added to a solutionof 4-[S-(3-bromophenyl)-N-(m-sulfonyl benzoic acid tert-butylester)-sulfoxamino]-5-methylsulfanyl-thiophene-2-carboximidic acidmethyl ester (Example 19: step d, 51.4 mg, 0.080 mmol) in 2.0 M NH₃ inmethanol (anhydrous, 4 mL) under argon. The reaction mixture was heatedto 40° C. for 4.5 hours, and then stirred overnight at RT. Ammoniumformate (25.1 mg, 0.398 mmol) was added, and then the reaction washeated to 40° C. for 2 hours. Another five equivalents of ammoniumformate were added, and then the reaction mixture was heated for twohours more. The reaction was cooled to room temperature, diluted withTHF (0.5 mL) and TEA (0.5 mL), and concentrated in vacuo to afford thetitle compound as a yellow oil (50.2 mg, quantitative). ESI-MS (m/z):Calcd. for C₂₃H₂₄BrN₃O₅S₄: 573.9 (M-tert-butyl); found: 573.9.

EXAMPLE 19f 4-[S-(3-Bromo-benzenesulfonyl)-N-(m-sulfonyl benzoicacid)-sulfoxamino]-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

Trifluoroacetic acid (2.5 mL) was added to a 0° C. suspension of4-[S-(3-bromo-benzenesulfonyl)-N-(m-sulfonyl benzoic acid tert-butylester)-sulfoxamino]-5-methylsulfanyl-thiophene-2-carboxamidine (Example19: step e, 50.2 mg, 0.080 mmol) and Et₃SiH (31.8 μL, 0.199 mmol) inCH₂Cl₂ (5 mL). The reaction mixture was stirred at 0° C. for 1 hour,then warmed to RT and stirred for 4 hours. The solvents were removed invacuo to afford a brown oil which was purified by preparatory HPLC(10-80% acetonitrile/0.1% trifluoroacetic acid in water over 30 minutes)to afford the title compound as a white solid (28.2 mg, 61.7% yield).¹H-NMR (CD₃OD): δ 8.37-8.39 (m, 1H), 8.32 (s, 1H), 8.20-8.23 (m, 1H),8.05-8.11 (m, 2H), 7.99-8.02 (m, 1H), 7.89-7.92 (m, 1H), 7.52-7.66 (m,2H), and 2.67 (s, 3H). ESI-MS (m/z): Calcd. for C₁₉H₂₃BrN₃O₅S₄: 573.9(M+1); found: 573.8.

EXAMPLE 20 4-[S-(3-Bromo-benzenesulfonyl)-N-(p-sulfonyl benzoicacid)-sulfoxamino]-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

EXAMPLE 20a 4-Sulfamoyl-benzoic acid tert-butyl ester

The procedure as in Example 19: step a was followed using4-chlorosulfonyl-benzoic acid (2 g, 9.06 mmol), MgSO₄ (4.36 g, 36.22mmol), H₂SO₄ (conc., 498 μL, 9.06 mmol), 2-methyl-propan-2-ol(anhydrous, 4.33 mL, 45.27 mmol), and CH₂Cl₂ (36 mL). Analogous workupwas followed by column chromatography (silica gel, 50-100% ethylacetate/hexanes) to afford the title compound as a white solid (500 mg,21.5% yield). ¹H-NMR (CDCl₃): δ 8.12 (d, 2H, J=8.8 Hz), 7.97 (d, 2H,J=8.8 Hz), 4.90 (bs, 2H), 1.61 (s, 9H).

EXAMPLE 20b (N-(p-Sulfonyl benzoic acid tert-butylester)imino)phenyliodinane

The procedure as in Example 19: step b was followed using4-sulfamoyl-benzoic acid tert-butyl ester (Example 20: step a, 379 mg,1.47 mmol), KOH (207 mg, 3.68 mmol), iodobenzenediacetate (474 mg, 1.47mmol), and methanol (anhydrous, 5.89 mL) to afford a yellow solid (514mg, 75.9% yield).

EXAMPLE 20c 4-[S-(3-Bromophenyl)-N-(p-sulfonyl benzoic acid tert-butylester)sufoxamino]-5-methylsulfanyl-thiophene-2-carbonitrile

The procedure as in Example 19: step c was followed using4-(3-bromo-benzenesulfinyl)-5-chloro-thiophene-2-carbonitrile (80 mg,0.231 mmol), (N-(p-sulfonyl benzoic acid tert-butylester)imino)phenyliodinane (Example 20: step b, 212 mg, 0.462 mmol),Cu(OTf)₂ (8.35 mg, 0.023 mmol), and acetonitrile (anhydrous, 1 mL).Analogous work up was followed by column chromatography (silica gel,20-30% ethyl acetate/hexanes) to afford the title compound as a whitesolid (92 mg, 66.2% yield). ¹H-NMR (CDCl₃): δ 8.17-8.18 (m, 1H),8.10-8.14 (m, 2H), 8.00-8.05 (m, 4H), 7.84-7.88 (m, 1H), 7.49-7.54 (m,1H), 1.62 (s, 9H).

EXAMPLE 20d 4-[S-(3-Bromophenyl)-N-(p-sulfonyl benzoic acid tert-butylester)-sulfoxamino]-5-methylsulfanyl-thiophene-2-carboximidic acidmethyl ester

The procedure as in Example 19: step d was followed using4-[S-(3-bromophenyl)-N-(p-sulfonyl benzoic acid tert-butylester)sufoxamino]-5-methylsulfanyl-thiophene-2-carbonitrile (Example 20:step c, 92 mg, 0.153 mmol), 0.1M NaSMe in methanol (1.83 mL, 0.183mmol), and THF (anhydrous, 3 mL). The reaction mixture was warmed to RTand stirred overnight. The next day, the reaction mixture was cooled to−78° C. and 0.1M NaSMe in methanol (764 μL, 0.076 mmol) was added. Thereaction mixture was stirred for 2 hours at −78° C., quenched withsaturated NaHCO₃, and extracted into ethyl acetate. The organic layerwas washed with saturated NaHCO₃, water, and brine, dried over magnesiumsulfate, filtered, and concentrated in vacuo to afford the titlecompound as a yellow oil (47.7 mg, 48% yield). ESI-MS (m/z): Calcd. forC₂₄H₂₅BrN₂O₆S₄: 645.0 (M+1); found: 644.7.

EXAMPLE 20e 4-[S-(3-Bromo-benzenesulfonyl)-N-(p-sulfonyl benzoic acidtert-butylester)-sulfoxamino]-5-methylsulfanyl-thiophene-2-carboxamidine

The procedure as in Example 19: step e was followed using4-[S-(3-bromophenyl)-N-(p-sulfonyl benzoic acid tert-butylester)-sulfoxamino]-5-methylsulfanyl-thiophene-2-carboximidic acidmethyl ester (Example 20: step d, 47.7 mg, 0.074 mmol), ammonium formate(25 mg, 0.396 mmol), and 2.0 M NH₃ in methanol (anhydrous, 5 ml). Thereaction mixture was heated to 40° C. for 6 hours, then stirredovernight at RT. THF (0.5 mL) and TEA (0.5 mL) were added and thesolvents were removed in vacuo to afford the title compound as a yellowoil (46.6 mg, quantitative). ESI-MS (m/z): Calcd. for C₂₃H₂₄BrN₃O₅S₄:630.0 (M+1); found: 529.8.

EXAMPLE 20f 4-[S-(3-Bromo-benzenesulfonyl)-N-(p-sulfonyl benzoicacid)-sulfoxamino]-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

The procedure as in Example 19: step f was followed using4-[S-(3-bromo-benzenesulfonyl)-N-(p-sulfonyl benzoic acid tert-butylester)-sulfoxamino]-5-methylsulfanyl-thiophene-2-carboxamidine (Example20: step e, 46.6 mg, 0.074 mmol), Et₃SiH (29.5 μL, 0.185 mmol),trifluoroacetic acid (2.5 mL), and CH₂Cl₂ (5 mL). The crude was purifiedby preparatory HPLC (10-80% acetonitrile/0.1% trifluoroacetic acid inwater over 30 minutes) to afford the title compound as a white solid(1.3 mg, 3.1% yield). ¹H-NMR (CD₃OD): δ 8.32 (s, 1H), 8.10-8.15 (m, 3H),8.02-8.06 (m, 1H), 7.91-7.96 (m, 3H), 7.54-7.60 (m, 1H), 2.70 (s, 3H).ESI-MS (m/z): Calcd. for C₁₉H₁₆BrN₃O₅S₄: 573.9 (M+1); found: 573.8.

EXAMPLE 214-[S-(3-Bromophenyl)-N-(2-pyridinesulfonyl)-sulfoxamino]-5-methylsulfanyl-thiophene-2-carboxamidinebis trifluoroacetate

EXAMPLE 21a4-[S-(3-Bromophenyl)-N-(2-pyridinesulfonyl)sulfoxamino]-5-methylsulfanyl-thiophene-2-carbamicacid tert-butyl ester

Pyridine-2-sulfonyl chloride (Combiblocks, 14.1 mg, 0.066 mmol) wasadded to a suspension of4-[S-(3-bromophenyl)-sulfoxamino]-5-methylsulfanyl-thiophene-2-carbamicacid tert-butyl ester (Example 24: step j, 26.9 mg, 0.055 mmol) andtriethylamine (Aldrich, 22.9 μL, 0.16 mmol) in CH₂Cl₂ (36 mL). Thereaction mixture was stirred overnight at room temperature and thenadditional pyridine-2-sulfonyl chloride (Combiblocks, 35.2 mg, 0.16mmol) and TEA (Aldrich, 68.8 μL, 0.49 mmol) were added. After stirringfor 3 days, the mixture was concentrated in vacuo to afford the titlecompound as a red oil (8.66 mg, 25% yield). ESI-MS (m/z): Calcd. forC₂₃H₂₃BrN₄O₅S₄: 530.9 (M-Boc); found: 530.9.

EXAMPLE 21b4-[S-(3-Bromophenyl)-N-(2-pyridinesulfonyl)-sulfoxamino]-5-methylsulfanyl-thiophene-2-carboxamidinebis trifluoroacetate

Trifluoroacetic acid (2 mL) was added to4-[S-(3-bromophenyl)-N-(sulfonyl2-pyridyl)sulfoxamino]-5-methylsulfanyl-thiophene-2-carbamic acidtert-butyl ester (Example 21: step a, 8.66 mg, 0.014 mmol) in CH₂Cl₂ (2mL) at room temperature. The reaction mixture was stirred for 2 hours,concentrated in vacuo, and purified by preparatory HPLC (10-80%acetonitrile/0.1% trifluoroacetic acid in water over 30 minutes) toafford the title compound as a white solid (1.4 mg, 19.2% yield). ¹H-NMR(CD₃OD): δ 8.63-8.65 (m, 1H), 8.41 (s, 1H), 8.16-8.17 (m, 1H), 8.01-8.06(m, 2H), 7.95-7.98 (m, 1H), 7.92 (dm, 1H, J=8.0 Hz), 7.62-7.66 (m, 1H),7.56 (t, 1H, J=8.0 Hz), and 2.69 (s, 3H). ESI-MS (m/z): Calcd. forC₁₇H₁₅BrN₄O₃S₄: 530.9 (M+1); found: 530.9.

EXAMPLE 22 Synthesis of 4-[S-(3-Bromophenyl)-N-(m-sulfonylpyridyl)-sulfoxamino]-5-methylsulfanyl-thiophene-2-carboxamidine bistrifluoroacetate

EXAMPLE 22a 4-[S-(3-Bromophenyl)-N-(m-sulfonylpyridyl)sulfoxamino]-5-methylsulfanyl-thiophene-2-carbamic acidtert-butyl ester

The procedure as in Example 21: step a was followed using4-[S-(3-bromophenyl)-sulfoxamino]-5-methylsulfanyl-thiophene-2-carbamicacid tert-butyl ester (Example 24: step j, 27.8 mg, 0.057 mmol),pyridine-3-sulfonyl chloride hydrochloride (Chemical Synthesis Services,51 mg, 0.24 mmol), TEA (94.8 μL, 0.68 mmol), and CH₂Cl₂ (2 mL).Analogous workup afforded the title compound as a red oil (10.7 mg, 30%yield). ESI-MS (m/z): Calcd. for C₂₃H₂₃BrN₄O₅S₄: 530.9 (M-Boc); found:530.9.

EXAMPLE 22b4-[S-(3-Bromo-benzenesulfonyl)-N-(3-pyridine-sulfonyl)-sulfoxamino]-5-methylsulfanyl-thiophene-2-carboxamidinebistrifluoroacetate

The procedure as in Example 21: step b was followed using4-[S-(3-bromophenyl)-N-(m-sulfonylpyridyl)sulfoxamino]-5-methylsulfanyl-thiophene-2-carbamic acidtert-butyl ester (Example 22: step a, 10.7 mg, 0.017 mmol), TFA (2 mL),and CH₂Cl₂ (2 mL). Analogous workup and purification afforded the titlecompound as a white solid (4.3 mg, 47.8% yield). ¹H-NMR (CD₃OD): δ8.95-9.04 (m, 1H), 8.75-8.85 (m, 1H), 8.39 (s, 1H), 8.27-8.33 (m, 1H),8.05-8.19 (m, 2H), 7.95-7.98 (m, 1H), 7.57-7.70 (m, 2H), and 2.72 (s,3H). ESI-MS (m/z): Calcd. for C₁₇H₁₅BrN₄O₃S₄: 530.9 (M+1); found: 530.9.

EXAMPLE 23 Synthesis of4-[S-(3-Bromophenyl)-N-(phenyl)-sulfoxamino]-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

EXAMPLE 23a4-[S-(3-Bromophenyl)-N-(phenyl)sulfoxamino]-5-methylsulfanyl-thiophene-2-carbamicacid tert-butyl ester

4-[S-(3-Bromophenyl)-sulfoxamino]-5-methylsulfanyl-thiophene-2-carbamicacid tert-butyl ester (Example 24: step j, 10 mg, 0.020 mmol), phenylboronic acid (Aldrich, 4.97 mg, 0.041 mmol), [1,10]phenanthroline(Aldrich, 3.78 mg, 0.021 mmol), and copper (II) acetate (Aldrich, 3.70mg, 0.020 mmol) were stirred in CH₂Cl₂ (1 mL) over 3 days at roomtemperature. The mixture was concentrated in vacuo and purified bypreparatory thin layer chromatography (silica gel, 30-40% ethylacetate/hexanes) to afford the title compound as a white solid (4.1 mg,35% yield). ¹H-NMR (CDCl₃): δ 8.24-8.27 (m, 1H), 8.01-8.06 (m, 1H), 7.88(s, 1H), 7.65-7.70 (m, 1H), 7.33-7.38 (m, 1H), 7.10-7.20 (m, 4H),6.92-6.97 (m, 1H), 2.55 (s, 3H) and 1.52 (s, 9H).

EXAMPLE 23b4-[S-(3-Bromophenyl)-N-(phenyl)-sulfoxamino]-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

The procedure as in Example 19: step f was followed using4-[S-(3-bromophenyl)-N-(phenyl)sulfoxamino]-5-methylsulfanyl-thiophene-2-carbamicacid tert-butyl ester (Example 23: step a, 4.1 mg, 0.072 mmol), TFA (2mL), and CH₂Cl₂ (2 mL). Analogous workup and purification afforded thetitle compound as a white solid (1.7 mg, 50% yield). ¹H-NMR (CD₃OD): δ8.34 (s, 1H), 8.29-8.31 (m, 1H), 8.13 (dm, 1H, J=8.0 Hz), 7.84 (dm, 1H,J=8.0 Hz), 7.51 (t, 1H, J=8.0 Hz), 7.11-7.19 (m, 4H), 6.92-6.97 (m, 1H),and 2.69 (s, 3H). ESI-MS (m/z): Calcd. for C₁₈H₁₆BrN₃OS₃: 466.0 (M+1);found: 465.9.

EXAMPLE 244-[S-(3-Bromophenyl)-sulfoximino]-5-methylsulfanyl-thiophene-2-carbamicacid tert-butyl ester

EXAMPLE 24a 4-Bromo-5-chloro-thiophene-2-carbaldehyde

To a −78° C. solution of 3-bromo-2-chloro-thiophene (10.03 g, 50.79mmol) in THF (anhydrous, 100 mL) was added lithium diisopropyl amidesolution (Aldrich, 2.0M in heptane/THF/ethylbenzene, 38.1 mL, 76.20mmol) dropwise over 45 minutes under argon. The reaction mixture wasstirred for one hour at −78° C., treated with DMF (Aldrich, anhydrous,19.7 mL, 254.40 mmol), stirred for 15 minutes at −78° C., warmed to roomtemperature, and stirred for 45 minutes. Aqueous citric acid was addedand the reaction mixture was stirred for 5 minutes. The mixture wasdiluted with ethyl acetate and was washed with saturated NaHCO₃, water,and brine. The organic layer was dried over magnesium sulfate, filtered,concentrated in vacuo, and purified by column chromatography (silicagel, 1-3% ethyl acetate/hexanes) to afford the title compound as ayellow solid (10.63 g, 92.8% yield).

EXAMPLE 24b 4-Bromo-5-chloro-thiophene-2-carbonitrile

Hydroxylamine hydrochloride (Aldrich, 4.91 g, 70.66 mmol) andtriethylamine (anhydrous, 11.2 mL, 80.36 mmol) were added to a 0° C.solution of 4-bromo-5-chloro-thiophene-2-carbaldehyde (Example 24: stepa, 10.63 g, 47.14 mmol) in acetonitrile (anhydrous, 250 mL). Thereaction mixture was warmed to room temperature and stirred for 1 hour.Phthalic anhydride was added and the reaction mixture was heated to 80°C. overnight. The mixture was cooled to room temperature, diluted withethyl acetate (400 mL), and washed with aqueous citric acid, saturatedNaHCO₃, water, and brine. The organic layer was dried over magnesiumsulfate, filtered, concentrated in vacuo, and purified by columnchromatography (silica gel, 5% ethyl acetate/hexanes) to afford thetitle compound as a pale yellow solid (9.76 g, 93% yield). ¹H-NMR(CDCl₃): δ 7.47 (s, 1H).

EXAMPLE 24c bis-3-Bromophenyldisulfide

Pyridinium chlorochromate (Aldrich, 11.2 g, 51.96 mmol) was addedportionwise to a 0° C. solution of 3-bromo-benzenethiol (Aldrich, 6.14mL, 51.92 mmol) in CH₂Cl₂ (100 mL). The reaction was stirred at roomtemperature for 1 hour and then quenched with silica gel for 10 minutes.The slurry was filtered through Celite, which was subsequently washedwith hexanes (250 mL). The filtrate was concentrated in vacuo to affordthe title compound as a brown oil (8.9 g, 91% yield).

EXAMPLE 24d 3-Bromo-benzenesulfinic acid methyl ester

Bromine (Aldrich, 3.65 mL, 71.03 mmol) was added dropwise over 30minutes to a room temperature solution of bis-3-bromophenyldisulfide(Example 24: step c, 8.9 g, 23.66 mmol) and sodium carbonate (Aldrich,12.54 g, 118.31 mmol) in methanol (anhydrous, 100 mL). The reactionmixture was stirred overnight and then concentrated in vacuo. Theresidue was diluted with ethyl acetate (300 mL) and was washed withsaturated NaHCO₃, water, and brine. The organic layer was dried overmagnesium sulfate, filtered, concentrated in vacuo, and purified bycolumn chromatography (silica gel, 10-15% ethyl acetate/hexanes) toafford the title compound as a pale yellow oil (9.8 g, 88% yield).¹H-NMR (CDCl₃): δ 7.87-7.77 (m, 1H), 7.71 (dm, 1H, J=7.9 Hz), 7.65 (dm,1H, J=7.8 Hz), 7.45 (t, 1H, J=7.8 Hz), and 3.53 (s, 3H).

EXAMPLE 24e4-(3-Bromo-benzenesulfinyl)-5-chloro-thiophene-2-carbonitrile

Isopropyl magnesium chloride solution (Aldrich, 2.0 M in THF, 2.92 mL,5.84 mmol) was added dropwise over 1.5 hours to a −78° C. suspension of4-bromo-5-chloro-thiophene-2-carbonitrile (Example 24: step b, 1 g, 4.49mmol) in THF (anhydrous, 20 mL) under argon. The reaction mixture wastreated with 3-bromo-benzenesulfinic acid methyl ester solution (Example24: step d, 1 g, 4.49 mmol, 10 mL of THF) in one portion at −78° C. andthen stirred overnight at room temperature. Saturated ammonium chloridesolution was added to the mixture and stirred for 30 minutes at roomtemperature. The reaction mixture was diluted with ethyl acetate andwashed with water and brine. The organic layer was dried over magnesiumsulfate, filtered, concentrated in vacuo, and purified by columnchromatography (silica gel, 15-25% ethyl acetate/hexanes) to afford thetitle compound as a light yellow solid (1.33 g, 85% yield). ¹H-NMR(CDCl₃): δ 7.86-7.88 (m, 1H), 7.69 (dm, 1H, =7.9 Hz), 7.64 (dm, 1H,J=7.9 Hz), 7.62 (s, 1H), 7.42 (t, 1H, J=7.9 Hz).

EXAMPLE 24f (N-(p-Nitrosulfonylbenzene)imino)phenyl iodinane

Potassium hydroxide (Aldrich, 5.95 g, 106.09 mmol) was added to asuspension of 4-nitro-benzenesulfonamide (Aldrich, 8.85 g, 42.4 mmol) inmethanol (anhydrous, 100 mL). After stirring for 30 minutes, thereaction mixture was purged with argon and then treated with iodobenzenediacetate (Aldrich, 13.67 g, 42.4 mmol). The reaction mixture wasstirred overnight at room temperature and then the solids were filteredand dried overnight in a vacuum oven to afford the title compound as ayellow solid (15.32 g, 89% yield).

EXAMPLE 24g4-[S-(3-Bromophenyl)-N-(sulfonyl-p-nitrobenzene)-sufloximino]-5-Chloro-thiophene-2-carbonitrile

Copper (II) trifluoromethanesulfonate (Aldrich, 278 mg, 0.77 mmol) wasadded to a suspension of4-(3-bromo-benzenesulfinyl)-5-chloro-thiophene-2-carbonitrile (Example24: step e, 1.33 g, 3.84 mmol) and(N-(p-nitrosulfonylbenzene)imino)phenyl iodinane (Example 24: step f,1.86 g, 4.60 mmol) at room temperature under argon. The reaction mixturewas stirred at room temperature for 2 hours, and then filtered. Theisolated solid was washed with water, dissolved in THF (50 mL), andconcentrated in vacuo to afford the title compound as a light yellowsolid (1.89 g, 90% yield). ¹H-NMR (CDCl₃): δ 8.33-8.37 (m, 2H),8.15-8.20 (m, 3H), 8.04 (s, 1H), 8.01 (dm, 1H, J=8.1. Hz), 7.87 (dm, 1H,J=8.0 Hz), 7.52 (t 1H, J=8.1 Hz).

EXAMPLE 24h4-[S-(3-Bromophenyl)-sulfoximino]-5-methylsulfanyl-thiophene-2-carboximidicacid methyl ester

Sodium thiomethoxide solution (1.0 M in methanol, 2.00 mL, 2.00 mmol)was added dropwise over 1 hour to a −78° C. suspension of4-[S-(3-bromophenyl)-N-(sulfonyl-p-nitrobenzene)-sufloximino]-5-methylsulfanyl-thiophene-2-carbonitrile(Example 24: step g, 1.03 g, 1.88 mmol) in THF (anhydrous, 10 mL) underargon. The reaction was warmed to room temperature and stirredovernight. Additional sodium thiomethoxide solution (1.0 M in methanol,4.0 mL) was added dropwise over 6 hours at room temperature under argon.Saturated sodium bicarbonate solution (15 mL) was added and the mixturewas stirred for 15 minutes at room temperature. The mixture was dilutedwith ethyl acetate, and then washed with water and brine. The organiclayer was dried over magnesium sulfate, filtered, and concentrated invacuo to afford the title compound as a yellow oil (764 mg,quantitative). ESI-MS (m/z): Calcd. for C₁₃H₁₃BrN₂O₂S₃: 404.9 (M+1);found: 404.9.

EXAMPLE 24i4-[S-(3-Bromophenyl)-sulfoximino]-5-methylsulfanyl-thiophene-2-carboxamidine

A mixture of ammonium formate (Aldrich, 238 mg, 3.77 mmol) and4-[S-(3-bromophenyl)-sulfoximino]-5-methylsulfanyl-thiophene-2-carboximidicacid methyl ester (Example 24: step h, 764 mg, 1.88 mmol) in 2.0 M NH₃in methanol (anhydrous, 10 mL) and was heated to 40° C. for 7 hours,then stirred overnight at room temperature under argon. The reactionmixture was treated with THF (0.5 mL) and TEA (0.5 mL) and concentratedin vacuo to afford a yellow oil (680 mg, quantitative). ESI-MS (m/z):Calcd. for C₁₂H₁₂BrN₃OS₃: 389.9 (M+1); found: 389.9.

EXAMPLE 24j4-[S-(3-Bromophenyl)-sulfoximino]-5-methylsulfanyl-thiophene-2-carbamicacid tert-butyl ester

Di-tert-butyl dicarbonate (Aldrich, 1.14 g, 5.23 mmol) andN,N-ethyldiisopropyl-amine (910 μL, 5.22 mmol) were added at roomtemperature to a suspension of4-[S-(3-bromophenyl)-sulfoximino]-5-methylsulfanyl-thiophene-2-carboxamidine(Example 24: step 1,680 mg, 1.88 mmol) in THF (anhydrous, 15 mL). Thereaction mixture was stirred overnight at room temperature. Additionaldi-tert-butyl dicarbonate (1.14 g, 5.23 mmol) and DIEA (910 μL, 5.22mmol) were added and the mixture was stirred overnight. Methanol (2 mL),water (1 mL), di-tert-butyl dicarbonate (1.14 g, 5.23 mmol), and DIEA(910 μL, 5.22 mmol) were added and the mixture was stirred overnight.The mixture was concentrated in vacuo and purified by columnchromatography (silica gel, 50% ethyl acetate/hexanes) to afford thetitle compound as a light yellow solid (300 mg, 35% yield). ¹H-NMR(CDCl₃/CD₃OD): δ 8.18-8.19 (m, 1H), 7.99 (dm, 1H, J=7.9 Hz), 7.93 (s,1H), 7.70 (dm, 1H, J=8.0 Hz), 7.38 (t, 1H, J=8.0 Hz), 2.56 (s, 3H), and1.50 (s, 9H).

EXAMPLE 254-[S-(3-Bromophenyl)-N-Tosylsulfoximino]-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

EXAMPLE 25a (N-(p-Toluenesulfonyl)imino)phenyliodinane

Diacetoxyiodobenzene (12.88 g, 40 mmol) was added to a solution of KOH(5.61 g, 100 mmol) and p-toluenesulfonamide (6.85 g, 40 mmol) inmethanol (160 mL) at 8° C. A yellow color developed within 1 minute. Thecooling bath was removed, and the solution was allowed to warm to RTwith stirring for 3 hours. Water (180 mL) was added and the reaction wasrefrigerated overnight. The precipitate was collected by filtration anddried overnight in a vacuum dessicator to yield 10 g (66%) of a lightyellow solid which was used with out further purification orcharacterization.

EXAMPLE 25b 4-Bromo-5-nitro-thiophene-2-carbaldehyde

A 5-L, three-neck, round bottom flask was equipped with a mechanicalstirrer and temperature probe and charged with3-bromothiphenecarboxyaldehyde (360.0 g, 1.884 mmol) and H₂SO₄ (1.5 L).The flask was cooled to 0° C. using an ice/NaCl bath. In a separateround-bottom flask, KNO₃ (209.5 g, 2.076 mol) was dissolved in H₂SO₄ (1L). This solution was transferred to an addition funnel and added to thethiophene over a 2 hour period while maintaining the internaltemperature below 4° C. After 30 minutes from the end of the addition,the reaction was complete by TLC analysis (2:1 heptane/EtOAc). A 20 Lglass carboy was charged with approximately 10 kg of ice and equippedwith a pneumatic stirrer. The reaction mixture was poured slowly intothe ice and washed with H₂O (3L), then heptane (3L) and dried in avacuum oven to yield the title compound as a tan solid (426.2 g, 96%).¹H-NMR (CDCl₃): δ 9.9 (1H, s), 8.8 (s, 1H).

EXAMPLE 25c 4-Bromo-5-nitro-thiophene-2-carbaldehyde oxime

A 12-L three neck, round bottom flask equipped with mechanical stirring,a temperature probe and a reflux condenser was charged with4-Bromo-5-nitro-thiophene-2-carbaldehyde (Example 25: step b, 426.0 g,1.805 mol), absolute ethanol (4L) and pyridine (189.9 mL, 2.35 mol).Hydroxylamine hydrochloride (163.3 g, 2.35 mol) was added in one portionand the mixture was heated. The mixture became a slurry at 27° C.,turned clear at 50° C. and was refluxed at 80° C. for 1.5 hour. TLCanalysis showed reaction completion (2:1 heptane/EtOAc). The cooledreaction mixture was concentrated in vaccuo then dried azeotrophicallyusing toluene (1L). The resulting moist solids were transferred to a10-L glass carboy and stirred with H₂O (3L). After 1 hour, the solidswere isolated by filtration, rinsed with H₂O (3L) and heptane (3L), thendried in vacuum oven to give the desired title compound as a brownpowder (441.65 g, 97%). ¹H-NMR (DMSO): δ 13.0 (1H, br s), 8.1 (1H, s),7.8 (1H, s).

EXAMPLE 25d 4-Bromo-5-nitro-thiophene-2-carbonitrile

A 5-L, three neck, round bottom flask equipped with a temperature probe,mechanical stirrer, and a reflux condenser was charged with4-Bromo-5-nitro-thiophene-2-carbaldehyde oxime (Example 25: step c;441.0 g, 1.76 mol). Acetic anhydride (2.5 L) was added causing anendothermic reaction from 22° C. to 17° C. The resulting yellow slurrywas heated to reflux. At 100° C. the reaction became a black solution.After 2 hours at 130° C., TLC analysis (2:1 heptane/EtOAc) showedreaction completion and the heat was removed. The mixture wastransferred to a rotary evaporator and concentrated to dryness. Theresidue was diluted with CH₂Cl₂ (3L), and H₂O (3L). The layers wereseparated and the organic layer was washed with H₂O (3L), dried overMgSO₄, and concentrated to give the desired title compound as a tansolid (350.85 g, 86%). ¹H-NMR (DMSO): δ 8.3 (1H, s).

EXAMPLE 25e 4-(3-Bromo-benzenesulfinyl)-5-nitro-thiophene-2-carbonitrile

A 12-L, three neck, round bottom flask equipped with a mechanicalstirrer and temperature probe was charged with4-Bromo-5-nitro-thiophene-2-carbonitrile (Example 25: step d; 273 g,1.174 mol), 3-bromothiophenol (127 mL, 1.232 mol) and THF (4L). A coldwater bath was added. Triethylamine (172 mL, 1.232 mol) was charged to a250 mL addition funnel and added dropwise to the mixture over 45 min,resulting in a temperature increase from 16.9° C. to 22.3° C. After 1hour, the reaction was complete and transferred in portions to a 5-Lrotary evaporator bulb and concentrated to dryness under vacuum. Thesolids were transferred to a 10-L glass carboy, diluted with EtOAc (2L)and satd. NaHCO₃ (2L) and stirred vigorously. The resulting solidprecipitate was removed by filtration, washed with H₂O (1L) and dried ina vacuum oven resulting in the title compound as a bright yellow powder(241.56 g, 60%). ¹H-NMR (DMSO): δ 8.0 (1H, s), 7.8 (1H, d), 7.6 (1H, d),7.3 (1H, t), 7.1 (1H, s).

EXAMPLE 25f 5-Amino-4-(3-bromo-phenylsulfanyl)-thiophene-2-carbonitrile

4-(3-Bromo-benzenesulfinyl)-5-nitro-thiophene-2-carbonitrile (Example25: step e; 5.20 g, 15.33 mmol) was dissolved into EtOH (45 mL) andacetic acid (5 mL). The reaction was heated to 50° C. and then iron(4.28 g, 76.69 mmol) was added and the reaction was allowed to heat withstirring overnight. The reaction mixture was filtered through celitewhich was washed with MeOH and EtOAc to ensure that the product does notremain on the celite. The filtrate was concentrated and then dissolvedinto EtOAC and washed with brine. The organic layer was dried (MgSO₄)and concentrated. The crude reaction mixture was purified by flashcolumn (20% EtOAc in Hexanes) resulting in the desired product as abrown oil (1.5 g, 32%). ¹H-NMR (CDCl₃): δ 7.38 (1H, s), 7.31-7.29 (1H,m), 7.18 (1H, t, J=1.8, Hz), 7.14 (1H, t, J=7.9 Hz), 6.99-6.96 (1H, m),5.06 (2H, br s).

EXAMPLE 25g 5-Bromo-4-(3-bromo-phenylsulfanyl)-thiophene-2-carbonitrile

Copper (II) bromide (0.54 g, 2.43 mmol) was dissolved in acetonitrile(10 mL). To this solution was added t-butylnitrite (388 μL, 3.26 mmol),slowly while warming to 50° C. A brown gas formed in the reaction flaskand was continued to heat at 50° C. for 30 minutes. To this reactionmixture was added a solution of5-Amino-4-(3-bromo-phenylsulfanyl)-thiophene-2-carbonitrile (Example 25:step f; 0.50 g, 1.63 mmol) in acetonitrile (2 mL). The reaction washeated to 80° C. for 30 minutes. The reaction mixture was concentratedand then purified by flash column chromatography (100% hexane to 20%EtOAc in hexane). The product was isolated as a yellow solid (246 mg,40%). ¹H-NMR (CDCl₃): δ 7.45-7.43 (2H, m), 7.33 (1H, s), 7.33 (1H, s),7.24-7.19 (1H, m).

EXAMPLE 25h 5-Bromo-4-(3-bromo-benzenesulfinyl)-thiophene-2-carbonitrile

To a solution of5-Bromo-4-(3-bromo-phenylsulfanyl)-thiophene-2-carbonitrile (Example 25:step g; 292 mg, 0.78 mmol) in AcOH (3 mL), 30% H₂O₂ (85 μL, 0.94 mmol)was added slowly and warmed to 50° C. for 2 hours. The reaction wasconcentrated and then dissolved in EtOAc and washed with water. Theorganic layer was dried (MgSO₄) and concentrated. The compound was usedwithout further purification. ¹H-NMR (CDCl₃): δ7.87-7.85 (1H, m), 7.64(2H, t, J=10.1, Hz), 7.57 (1H, s), 7.41 (1H, t, 7.91 Hz).

EXAMPLE 25i5-Bromo-4-[S-(3-Bromophenyl)-N-Tosylsulfoximino]-thiophene-2-carbonitrile

To a solution of5-Bromo-4-(3-bromo-benzenesulfinyl)-thiophene-2-carbonitrile (Example25: step h; 322 mg, 0.95 mmol) and(N-(p-Toluenesulfonyl)imino)phenyliodinane (Example 3: step a; 388 mg,1.04 mmol) in acetonitrile (4 mL) was added copper (II)trifluoromethanesulfonate (34.4 mg, 0.095 mmol). The reaction turnedpale green and was stirred at RT overnight. The reaction mixture wasconcentrated and then dissolved in EtOAc and filtered to remove coppersalts. Purification by flash column chromatography (10% EtOAc in Hexane)yielded the desired product as a white solid (182 mg, 34%). ¹H-NMR(CDCl₃): δ 8.18 (1H, t, J=1.9 Hz), 8.02-8.00 (1H, m), 8.01 (1H, s),7.86-7.82 (4H, m), 7.48 (1H, t, J=8.1 Hz), 7.31 (1H, m), 2.43 (3H, s).

EXAMPLE 25j4-[S-(3-Bromophenyl)-N-Tosylsulfoximino]-5-methylsulfanyl-thiophene-2-carbonitrile

To a solution of4-[S-(3-Bromophenyl)-N-Tosylsulfoximino]-5-bromo-thiophene-2-carbonitrile(Example 25: step i; 50 mg, 0.090 mmol) in THF (3 mL) was added 1.0 MNaSMe in EtOH at −78° C. slowly and stirred for 2 hours. The reactionwas purified by prep plate TLC (50% EtOAc in hexanes). The desiredcompound was isolated as a solid (11 mg, 23%). ¹H-NMR (CDCl₃): δ 8.43(1H, d, J=1.4 Hz), 8.12 (1H, t, J=1.82 Hz), 7.99-7.96 (1H, m), 7.83-7.79(3H, m), 7.77-7.76 (1H, d, J=1.53 Hz), 7.48 (1H, t, J=8.0 Hz), 7.30 (1H,m), 2.45 (3H, s), 2.43 (3H, s).

EXAMPLE 25k4-[S-(3-Bromophenyl)-N-Tosylsulfoximino]-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

To a solution of4-[S-(3-Bromophenyl)-N-Tosylsulfoximino]-5-methylsulfanyl-thiophene-2-carbonitrile(Example 25: step j; 5 mg, 0.009 mol) in MeOH (300 μL) and DCM (10 μL)was added sodium methoxide (2 μL, 0.009 mol) and stirred at RT for 10minutes. The reaction was complete by ESI-MS (m/z): Calcd. ForC₂₀H₁₉BrN₂O₄S₄: 557.9; found: 558.9, resulting in the formation of4-[S-(3-Bromophenyl)-N-Tosylsulfoximino]-5-methylsulfanyl-thiophene-2-carboximidicacid methyl ester. To the4-(4-Toluenesulfonyl-3-Bromo-benzenesulfoxamine)-5-methylsulfanyl-thiophene-2-carboximidicacid methyl ester intermediate formed, was added ammonia in methanol(7N) (2 μL, 0.009 mol) and the reaction was stirred for 2 hours. To thiswas added ammonium formate (NH₄HCO₂) (6 mg, 0.09 mol) and the reactionwas stirred an additional 13 hours. The solvents were removed in vacuofollowed by C₁₈-HPLC (5-60% CH₃CN/0.1% TFA water over 20 minutes). Thefinal compound was isolated as a solid (1.8 mg, 30%). ¹H-NMR (CD₃OD): δ8.29 (1H, s), 8.08 (1H, t, J=1.90 Hz), 8.04-8.01 (1H, m), 7.93-7.91 (1H,m), 7.71 (2H, d, J=8.3 Hz), 7.56 (1H, d, J=8.1 Hz), 7.32 (2H, d, J=7.96Hz), 2.71 (3H, s), 2.43 (3H, s).

EXAMPLE 264-(3-Bromo-benzenesulfoxamine)-5-methylsulfanyl-thiophene-2-carboxamidine

EXAMPLE 26a4-(3-Bromo-benzenesulfoximine)-5-methylsulfanyl-thiophene-2-carboamide

To4-[S-(3-Bromophenyl)-N-Tosylsulfoximino]-5-methylsulfanyl-thiophene-2-carbonitrile(Example 25: step j, 47 mg, 0.09 mmol) was added concentrated H₂SO₄ (1mL) and then stirred at RT for 24 hours. The reaction was complete byESI-MS (m/z): Calcd. For C₁₂H₁₁BrN₂O₂S₃: 389.9; found: 391.0. Thereaction was quenched by slowly adding water with stirring until thewater was clear followed with extraction with EtOAc. The organic layerwas dried and concentrated in vacuo followed by purification by flashcolumn chromatography (50% Hexane/EtOAc to 100% EtOAc) which yielded thetitle compound (20 mg, 67%). ¹H-NMR (CDCl₃): δ 8.12 (1H, t, J=1.9 Hz),7.95-7.92 (1H, m), 7.81 (1H, s), 7.65-7.62 (1H, m), 7.32 (1H, t, J=7.93Hz), 2.45 (3H, s).

EXAMPLE 26b4-(3-Bromo-benzenesulfoximine)-5-methylsulfanyl-thiophene-2-carboxamidine

A solution of trimethyl aluminum (2.0 M in toluene) (1.54 mL, 3.07 mmol)was added to ammonium chloride (164 mg, 3.07 mmol) in toluene (500 μL)while under argon with stirring for 10 minutes. This was then added to4-(3-Bromo-benzenesulfoximine)-5-methylsulfanyl-thiophene-2-carboamide(Example 26: step a; 30 mg, 0.77 mmol) and then the reaction was heatedto 80° C. for 2 hours. The reaction was then quenched by pouring into aslurry of silica in DCM and stirring for 10 minutes. The reaction wasthen filtered and washed with 30% MeOH in DCM. The filtrate wasconcentrated in vacuo and redissolved in 10% MeOH in DCM and thenfiltered again to remove silica. The filtrate was then purified byC₁₈-HPLC (5-60% CH₃CN/0.1% TFA water over 30 minutes) resulting in theisolation of the title compound (5.4 mg, 19%). ¹H-NMR (CD₃OD): δ 8.29(1H, s), 8.26-8.25 (1H, m), 8.10-8.08 (1H, m), 7.84-7.81 (1H, m), 7.50(1H, t, J=7.9 Hz), 2.69 (3H, s).

EXAMPLE 274-(3-Bromo-benzenesulfoxamineacetamide)-5-methylsulfanyl-thiophene-2-carboxamidine

EXAMPLE 27a4-(3-Bromo-benzenesulfoximine)-5-methylsulfanyl-thiophene-2-carbamicacid tert-butyl ester

To a solution of4-(3-Bromo-benzenesulfoximine)-5-methylsulfanyl-thiophene-2-carboxamidine(Example 26: step b; 17 mg, 0.31 mmol) was added DIEA (27 μL, 0.16 mmol)and Boc₂O (20 mg, 0.09 mmol) in DMF (500 μL). The reaction was stirredat RT for 12 hours. Solvent was removed in vacuo and triturated withhexane to remove Boc₂O resulting in the desired product (14 mg, 70%).¹H-NMR (CDCl₃): δ 8.24-8.23 (1H, m), 8.05-8.02 (1H, d, J=7.9 Hz), 7.87(1H, s), 7.71-7.69 (1H, d, J=7.0 Hz), 7.41-7.36 (1H, t, J=7.8 Hz), 2.93(3H, s), 1.52 (9H, s).

EXAMPLE 27b4-(3-Bromo-benzenesulfoximineacetamide)-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

To a solution of4-(3-Bromo-benzenesulfoximine)-5-methylsulfanyl-thiophene-2-carbamicacid tert-butyl ester (Example 27: step a; 1.3 mg, 0.0027 mmol) in AcOH(50 μL) was added acetic anhydride (0.4 μL, 0.0039 mmol) and thereaction was stirred at 45° C. for 2 hours. The reaction was purified byC₁₈-HPLC (5-80% CH₃CN/0.1% TFA water over 40 minutes) resulting in theisolation of the title compound (0.7 mg, 59%). ¹H-NMR (CD₃OD): δ 8.36(1H, s), 8.25-8.24 (1H, m), 8.09-8.06 (1H, d, J=8.0 Hz), 7.91-7.88 (1H,d, J=7.9 Hz), 7.58-7.54 (1H, t, J=7.9), 2.72 (3H, s), 2.23 (3H, s).

EXAMPLE 285-Bromo-4[S-(3-Bromophenyl)-N-Tosylsulfoximino]-thiophene-2-carboxamidinetrifluoroacetate

5-Bromo-4-[S-(3-Bromophenyl)-N-Tosylsulfoximino]-thiophene-2-carbonitrile(Example 25: step i; 10 mg, 0.018 mmol), and ammonium formate (excess)were stirred at RT in MeOH (400 μL). To this was added sodium methoxide(1 mg, 0.019 mmol) and the reaction was stirred at RT overnight. Thereaction was purified by C₁₈-HPLC (5-80% CH₃CN/0.1% TFA water over 40minutes) resulting in the isolation of the title compound (7.9 mg, 70%).¹H-NMR (CD₃OD): δ 8.36 (1H, s), 8.13 (1H, s), 8.06-8.04 (1H, d, J=9.70Hz), 7.94-7.95 (1H, d, J=6.91 Hz), 7.74-7.72 (2H, d, J=8.28 Hz), 7.59(1H, t, J=10.1 Hz), 7.34-7.32 (2H, d, J=8.86 Hz). ESI-MS (m/z): Calcd.For C₁₈H₁₅Br₂N₃O₃S₃: 574.86; found: 575.9.

EXAMPLE 294-[S-[3-(2-Tolylphenyl)phenyl]-N-Tosylsulfoximino]-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

EXAMPLE 29a:4-[S-[3-(2-Tolylphenyl)phenyl]-N-Tosylsulfoximino]-5-methylsulfanyl-thiophene-2-carbonitrile

5-Bromo-4-[S-(3-Bromophenyl)-N-Tosylsulfoximino]-thiophene-2-carbonitrile(Example 25: step i; 188 mg, 0.36 mmol) was dissolved into DMF (3.5 mL)and cooled to −30° C. To this was added sodium methanesulfinate (36 mg,0.36 mmol) as a solution in MeOH and the reaction was stirred at −30° C.for 2 hours. The reaction was then warmed to 0° C. for 4 hours and thenwarmed to RT overnight. TLC analysis indicated spots nearly identical,UV HPLC analysis showed shift in retention time. The crude reactionmixture was purified by flash column chromatography (20% EtOAc/Hexanes)resulting in the title compound as a clear glassy solid (124 mg, 66%).ESI-MS (m/z): Calcd. For C₁₉H₁₅BrN₂O₅S₄: 557.9; found: 558.7.

EXAMPLE 29b4[S-(3-Bromophenyl)-N-Tosylsulfoximino]-5-methylsulfanyl-thiophene-2-formamidemethyl ester

4-[S-[3-(2-Tolylphenyl)phenyl]-N-Tosylsulfoximino]-5-methylsulfanyl-thiophene—2-carbonitrile(Example 29: step a; 124 mg, 0.24 mmol) was dissolved in THF (5 mL).This was cooled to −78° C. followed by the slow addition of sodiumthiomethoxide (0.5 M in MeOH, 720 μL, 0.36 mmol). The reaction wasstirred at −78° C. for 2 hours and then warmed to RT overnight. Thereaction was used with out purification In the next step. ESI-MS (m/z):Calcd. For C₂₀H₁₉BrN₂O₄S₄: 557.94; found: 560.9.

EXAMPLE 29c4-(S-(3-Bromophenyl)-N-Tosylsulfoximino)-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

The crude reaction mixture of5-Methylsulfonyl-4[S-(3-Bromophenyl)-N-Tosylsulfoximino]-thiophene-2-formamidemethyl ester (Example 29: step b; 0.22 mmol) was concentrated to removeTHF, dissolved in ammonia in methanol (2.0 M, 1.5 mL, 3 mmol). To thiswas added ammonium formate (14 mg, 0.22 mmol). The reaction was stirredat 30° C. for 2 days. ESI-MS (m/z): Calcd. For C₁₉H₁₈BrN₃O₃S₄: 542.94;found: 545.5.

EXAMPLE 29d4-(S-(3-Bromophenyl)-N-Tosylsulfoximino)-5-methylsulfanyl-thiophene-2-carbamicacid-tert-butyl ester

To a solution of4-(S-(3-Bromophenyl)-N-Tosylsulfoximino)-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate (Example 29: step c; 124 mg, 0.23 mmol) in THF (5 mL)was added DIEA (0.72 μL, 0.046 mmol) and Boc₂O (60.2 mg, 0.27 mmol). Thereaction was stirred at RT for 12 hours. The reaction was not completetherefore it was heated to 40° C. for 8 hours. The reaction wasconcentrated and purified by flash column chromatography (40%EtOAc/Hexanes) to isolate the title compound as a solid (86 mg, 59%).ESI-MS (m/z): Calcd. For C₂₄H₂₆BrN₃O₅S₄: 642.9; found: 645.6.

EXAMPLE 29e4-[S-[3-(2-Tolylphenyl)phenyl]-N-Tosylsulfoximino]-5-methylsulfanyl-thiophene-2-carbamicacid tert-butyl ester

A solution of4-(S-(3-Bromophenyl)-N-Tosylsulfoximino)-5-methylsulfanyl-thiophene-2-carbamicacid-tert-butyl ester (Example 29: step d; 35.5 mg, 0.055 mmol), o-tolylboronic acid (15 mg, 0.110 mmol) and 2M Na₂CO₃ (220 μL, 0.44 mmol) wasdissolved in Acetonitrile (1 mL). Argon gas was bubbled through thereaction mixture and then tetrakis(triphenylphosphine)palladium (0) (13mg, 0.011 mmol) was added and the reaction was heated to 80° C. for 2hours. The reaction mixture was dissolved in EtOAc and washed withbrine. The organic layer was separated and dried with MgSO₄ andconcentrated in vacuo. The reaction was purified by preparative thinlayer chromatography (25% EtOAc/Hexane) resulting in the title compound(17 mg). ESI-MS (m/z): Calcd. For C₃H₃₃N₃O₅S₄: 655.1; found: 655.8.

EXAMPLE 29f4-[S-[3-(2-Tolylphenyl)phenyl]-N-Tosylsulfoximino]-5-methylsulfanyl-thiophene-2-amidinetrifluoroacetate

4-[S-[3-(2-Tolylphenyl)phenyl]-N-Tosylsulfoximino]-5-methylsulfanyl-thiophene-2-carbamicacid-tert-butyl ester (Example 29: step e; 17 mg, 0.03 mmol) wasdissolved in 50% TFA/DCM (1 mL) and stirred for 1 hour. The reaction wasconcentrated in vacuo and purified by C₁₈-HPLC (10-80% CH₃CN/0.1% TFAwater over 30 minutes) resulting in the isolation of the title compound(7.6 mg, 46%). ¹H-NMR (CD₃OD): δ 8.28 (1H, s), 8.03-8.00 (1H, m),7.94-7.93 (1H, m), 7.74-7.70 (4H, m), 7.32-7.26 (5H, m), 7.19-7.16 (1H,d, J=7.11 Hz), 2.67 (3H, s), 2.39 (3H, s), 2.20 (3H, s).

EXAMPLE 304-[S-(3-Bromophenyl)-N-Nosylsulfoximino]-5-methylsulfanyl-thiophene-2-amidinetrifluoroacetate

EXAMPLE 30a 4-[S-(3-Bromophenyl)-N-Nosylsulfoximino]-5-methanesulfonyl-thiophene-2-carbonitrile

4-[S-(3-Bromophenyl)-N-Nosylsulfoximino]-5-chloro-thiophene-2-carbonitrile(Example 24: step g; 67.4 mg, 0.12 mmol) was dissolved in DMF (2 mL) andcooled to −30° C. To this was added 1M sodium methanesulfonyl in MeOH(140 μL, 0.14 mmol) and the reaction was stirred for one hour. Thereaction was monitored by analytical C₁₈-HPLC (10-80% CH₃CN/0.1% TFAwater over 8 minutes) which shows the conversion of starting material atrt=3.37 to product at rt=3.26. The reaction was concentrated, dissolvedin EtOAc and washed with brine. The organic layer was dried with MgSO₄and concentrated followed by preparative TLC purification (30%EtOAc/Hexanes). The title compound was isolated as a white solid (31 mg,44%). ¹H-NMR (CD₃OD): δ 8.38-8.36 (2H, d, J=9.0 Hz), 8.24 (1H, t, J=1.8Hz), 8.18-8.16 (3H, m), 8.13-8.15 (1H, d, J=7.0 Hz), 7.87-7.84 (1H, d,J=7.5 Hz), 7.51 (1H, t, J=8.0 Hz), 3.70 (3H, s).

EXAMPLE 30b4-[S-(3-Bromophenyl)-N-Nosylsulfoximino]-5-methylsulfanyl-thiophene-2-carboximidicacid methyl ester

4-[S-(3-Bromophenyl)-N-Nosylsulfoximino]-5-methanesulfonyl-thiophene-2-carbonitrile (Example 30: step a; 31 mg, 0.049 mmol) wasdissolved in THF (2 mL) and cooled to −78° C. To this was added 0.5 Msodium thiomethoxide in MeOH (120 μL, 0.059 mmol) slowly and stirred for1 hour at −78° C. and then for 1 hour at RT. The reaction was quenchedwith MeOH and AcOH then dissolved into EtOAc and washed with sat.NaHCO₃. The organic layer was dried (MgSO₄) and then concentrated. Thedesired product was obtained without further purification as a yellowsolid (30 mg, 90%). ESI-MS (m/z): Calcd. For C₁₉H₁₆BrN₃O₆S₄: 588.9;found: 591.8.

EXAMPLE 30c4-[S-(3-Bromophenyl)-N-Nosylsulfoximino]-5-methylsulfanyl-thiophene-2-amidinetrifluoroacetate

4-[S-(3-Bromophenyl)-N-Nosylsulfoximino)-5-methylsulfanyl-thiophene-2-carboximidicacid methyl ester (Example 30: step b; 28 mg, 0.047 mmol) was dissolvedin MeOH (4 mL) and to this was added ammonium formate (29 mg, 0.47 mmol)and 2M ammonia in MeOH (2 mL). The reaction was stirred at RT for 24hours followed by purification by C₁₈-HPLC (10-100% CH₃CN/0.1% TFA waterover 30 minutes) resulting in the title compound as a white solid (2.3mg, 10%). ¹H-NMR (CD₃OD): δ 8.39-8.35 (3H, m), 8.13-8.10 (3H, m),8.07-8.05 (1H, d, J=7.0 Hz), 7.96-7.93 (1H, d, J=8.0 Hz), 7.59 (1H, t,J=8.0 Hz), 2.73 (3H, s).

EXAMPLE 31 4-[S-(3-Bromophenyl)-N-sulfonyl-3-nitro-benzenesulfoximino]-5-methylsulfanyl-thiophene-2-amidine trifluoroacetate

EXAMPLE 31a 4-[S-(3-Bromophenyl)-N-sulfonyl-3-nitro-benzenesulfoximino]-5-methylsulfanyl-thiophene-2-carbamic acid tert-butyl ester

To a solution of4-[S-(3-Bromophenyl)-sulfoximino]-5-methylsulfanyl-thiophene-2-carbamicacid tert-butyl ester (Example 24: step j; 94 mg, 0.139 mmol) in DCM (4mL, and still slightly cloudy) was added triethylamine (39 μL, 0.28mmol) and 3-nitrobenzene sulfonyl chloride (37 mg, 0.16 mmol). Thisreaction stirred at RT for several days. ESI-MS (m/z): Calcd. ForC₂₃H₂₃BrN₄O₇S₄: 673.9; found: 676.5.

EXAMPLE 31b 4-[S-(3-Bromophenyl)-N-sulfonyl-3-nitro-benzenesulfoximino]-5-methylsulfanyl-thiophene-2-amidine trifluoroacetate

4-[S-(3-Bromophenyl)-N-sulfonyl-3-nitro-benzenesulfoximino]-5-methylsulfanyl-thiophene-2-carbamic acid tert-butyl ester(Example 31: step a; 10 mg, 0.01 mmol) was dissolved in 50% TFA/DCM (2mL) and stirred at RT for 1 hour. The reaction was purified by C₁₈-HPLC(10-100% CH₃CN/0.1% TFA water over 30 minutes) resulting in the titlecompound as a white solid (6.2 mg, 73%). ¹H-NMR (CD₃OD): δ 8.59-8.58(1H, m), 8.49-8.47 (1H, d, J=7.25 Hz), 8.37 (1H, s), 8.30-8.27 (1H, d,J=6.9 Hz), 8.15-8.14 (1H, m), 8.07-8.05 (1H, d, J=9.0 Hz), 7.95-7.93(1H, d, J=9.0 Hz), 7.83 (1H, t, J=8.0 Hz), 7.58 (1H, t, J=8.0 Hz), 2.71(3H, s).

EXAMPLE 324-[S-(3-Bromophenyl)-N-sulfonyl-3-N-(5-Methanesulfonyl-4-methyl-thiazol-2-yl)-acetamidesulfoximino]-5-methylsulfanyl-thiophene-2-amidine trifluoroacetate

EXAMPLE 32a4-[S-(3-Bromophenyl)-N-sulfonyl-3-N-(5-Methanesulfonyl-4-methyl-thiazol-2-yl)-acetamidesulfoximino]-5-methylsulfanyl-thiophene-2-carbamic acid tert-butyl ester

To a solution of4-[S-(3-Bromophenyl)-sulfoximino]-5-methylsulfanyl-thiophene-2-carbamicacid tert-butyl ester (Example 24: step j; 13 mg, 0.019 mmol), in DCM (1mL) was added Et₃N (5 μL, 0.038 mmol) and2-Acetylamino-4-methyl-thiazole-5-sulfonyl chloride (5.9 mg, 0.024mmol). The reaction was stirred at RT for 24 hours followed bypurification by preparative TLC (40% EtOAc/Hexane) resulting in thetitle compound. ESI-MS (m/z): Calcd. For C₂₃H₂₆BrN₅O₆S₅: 706.9; found:709.6.

EXAMPLE 32b4-[S-(3-Bromophenyl)-N-sulfonyl-3-N-(5-Methanesulfonyl-4-methyl-thiazol-2-yl)-acetamidesulfoximino]-5-methylsulfanyl-thiophene-2-amidine trifluoroacetate

4-[S-(3-Bromophenyl)-N-sulfonyl-3-N-(5-Methanesulfonyl-4-methyl-thiazol-2-yl)-acetamidesulfoximino]-5-methylsulfanyl-thiophene-2-carbamic acid tert-butyl ester(Example 32, step a) was treated with 50% TFA/DCM (2 mL) and stirred for1 hour. The reaction was concentrated and purified by C₁₈-HPLC (10-100%CH₃CN/0.1% TFA water over 30 minutes) resulting in the title compound asa clear glass (2.4 mg). ¹H-NMR (CD₃OD): δ 8.37 (1H, s), 8.14 (1H, t,J=1.8 Hz), 8.05 (1H, d, J=9.0 Hz), 7.94 (1H, d, J=9.8 Hz), 7.58 (1H, t,J=8.0 Hz), 2.70 (3H, s), 2.50 (3H, s), 2.24 (3H, s).

EXAMPLE 334-[S-(3-Bromophenyl)-N-sulfonyl-4-aminophenylsulfoximino]-5-methylsulfanyl-thiophene-2-amidinetrifluoroacetate

EXAMPLE 33a 4-[S-(3-Bromophenyl)-N-sulfonyl-4-nitro-benzenesulfoximino]-5-methylsulfanyl-thiophene-2-carbamic acid tert-butyl ester

To a solution of4-[S-(3-Bromophenyl)-N-Nosylsulfoximino]-5-methylsulfanyl-thiophene-2-amidinetrifluoroacetate (Example 30: step c; 70 mg, 0.12 mmol) in THF (5 mL)and DIEA (42 μL, 0.24 mmol) was added Boc₂O (53 mg, 0.24 mmol) and thereaction was stirred at RT for 12 hours. The reaction was concentrated,dissolved in EtOAc and washed with saturated NaHCO₃ The organic layerwas dried (MgSO₄) and concentrated resulting in desired product. ¹H-NMR(CD₃OD): δ 8.30 (2H, d, J=8.8 Hz), 8.18 (2H, d, J=8.8 Hz), 8.01 (1H, s),7.99 (1H, 8.0 Hz), 7.79 (1H, d, J=7.2 Hz), 7.44 (1H, t, J=8.0 Hz), 2.59(3H, s), 1.53-1.46 (9H, m).

EXAMPLE 33b 4-[S-(3-Bromophenyl)-N-sulfonyl-4-amino-benzenesulfoximino]-5-methylsulfanyl-thiophene-2-carbamic acid tert-butyl ester

To a solution of 4-[S-(3-Bromophenyl)-N-sulfonyl-4-nitro-benzenesulfoximino]-5-methylsulfanyl-thiophene-2-carbamic acid tert-butyl ester(Example 33: step a; 15 mg, 0.02 mmol) in MeOH (1 mL) and H₂O (1 mL) wasadded NH₄Cl (11.6 mg, 0.22 mmol) and Fe (12.2 mg, 0.22 mmol). Thereaction was heated to 80° C. for 1 hour and was then filtered through apad of celite and washed with DCM and EtOAc. The combined filtrates wereconcentrated. ESI-MS (m/z): Calcd. For C₂₃H₂₅BrN₄O₅S₄: 643.9; found:646.5.

EXAMPLE 33c4-[S-(3-Bromophenyl)-N-sulfonyl-4-aminophenylsulfoximino]-5-methylsulfanyl-thiophene-2-amidinetrifluoroacetate

4-[S-(3-Bromophenyl)-N-sulfonyl-4-amino-benzenesulfoximino]-5-methylsulfanyl-thiophene-2-carbamic acid tert-butyl ester(Example 33: step b) was dissolved in DCM (1 mL) and TFA (1 m/L) andstirred at RT for 1 hour. The reaction was concentrated and purified byC₁₈-HPLC (10-100% CH₃CN/0.1% TFA water over 30 minutes) resulting in thetitle compound as a yellow solid (5.9 mg). ¹H-NMR (CD₃OD): δ 8.23 (1H,s), 8.08 (1H, s), 7.98 (1H, d, J=7.1 Hz), 7.89 (1H, d, J=9.8 Hz), 7.52(1H, t, J=8.0 Hz), 7.47-7.44 (2H, m), 6.58-6.56 (2H, m), 2.67 (3H, s).

EXAMPLE 34 4-[S-(3-Bromophenyl)-N-sulfonyl-3-analinesulfoximino]-5-methylsulfanyl-thiophene-2-amidine trifluoroacetate

EXAMPLE 34a 4-[S-(3-Bromophenyl)-N-sulfonyl-3-nitro-benzenesulfoximino]-5-methylsulfanyl-thiophene-2-carbamic acid tert-butyl ester

To a solution of4-[S-(3-Bromophenyl)-sulfoximino]-5-methylsulfanyl-thiophene-2-carbamicacid tert-butyl ester (Example 24: step j; 58 mg, 0.11 mmol) in THF (5mL) and TEA (35 μL, 0.24 mmol) was added 3-nitrobenzene sulfonylchloride(53 mg, 0.24 mmol) and the reaction was stirred at RT for 5 hours. Thereaction was concentrated, and purified by preparative TLC (30%EtOAc/Hexane). ESI-MS (m/z): Calcd. For C₂₃H₂₃BrN₄O₇S₄: 673.9; found:674.5.

EXAMPLE 34b 4-[S-(3-Bromophenyl)-N-sulfonyl-3-analinesulfoximino]-5-methylsulfanyl-thiophene-2-carbamic acid tert-butyl ester

To a solution of 4-[S-(3-Bromophenyl)-N-sulfonyl-3-nitro-benzenesulfoximino]-5-methylsulfanyl-thiophene-2-carbamic acid tert-butyl ester(Example 34: step a; 20 mg, 0.03 mmol) in MeOH (1 mL) was and H₂O (1 mL)was added NH₄C₁ (15.5 mg, 0.29 mmol) and Fe (16.6 mg, 0.29 mmol). Thereaction was heated to 80° C. for 1 hour and was then filtered through apad of celite and washed with DCM and EtOAc. The combined filtrates wereconcentrated. ESI-MS (m/z): Calcd. For C₂₃H₂₅BrN₄O₅S₄: 643.9; found:646.6.

EXAMPLE 34c 4-[S-(3-Bromophenyl)-N-sulfonyl-3-analinesulfoximino]-5-methylsulfanyl-thiophene-2-amidine trifluoroacetate

4-[S-(3-Bromophenyl)-N-sulfonyl-4-amino-benzenesulfoximino]-5-methylsulfanyl-thiophene-2-carbamic acid tert-butyl ester(Example 34: step b) was dissolved in DCM (1 mL) and TFA (1 mL) andstirred at RT for 1 hour. The reaction was concentrated and purified byC₁₈-HPLC (10-80% CH₃CN/0.1% TFA water over 30 minutes) resulting in thetitle compound as a clear glass (1.1 mg). ¹H-NMR (CD₃OD): δ 8.28 (1H,s), 8.15 (1H, s), 8.03 (1H, d, J=7.0 Hz), 7.93 (1H, d, J=9.9 Hz), 7.56(1H, t, J=10.2 Hz), 7.25-7.15 (3H, m), 6.93 (1H, d, J=7.8 Hz), 2.70 (3H,s).

EXAMPLE 354-[S-(3-Bromophenyl)-N-(6-cyano-3-pyridinecarboxamido)-sulfoxamino]-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

EXAMPLE 35a4-[S-(3-Bromophenyl)-N-(6-cyano-3-pyridinecarboxamido)-sulfoxamino]-5-methylsulfanyl-thiophene-2-carbamicacid tert-butyl ester

6-Cyano nicotinic acid (18 mg, 0.118 mmol), DIC (18.5 μL, 0.118 mmol),and DMAP (29 mg, 0.236 mmol) were dissolved in DCM (1 ml). The mixturewas stirred for 10 min and then transferred to a solution of4-[S-(3-bromophenyl)-sulfoxamino]-5-methylsulfanyl-thiophene-2-carbamicacid tert-butyl ester (29 mg, 0.059 mmol, as prepared in Example 24:step j) in THF. After 12 h at RT, another portion of 6-cyano nicotinicacid (37 mg, 0.236 mmol) was activated with DIC (37 μL, 0.236 mmol) andDMAP (58 mg, 0.472 mmol) in DCM (2 mL) for 10 min and then transferredto the reaction mixture. The final mixture was stirred for another 48 hat RT. The reaction mixture was evaporated in vacuo and the residue waspurified using preparative TLC (2×1000μ, 1:1 EtOAc/Hexanes) to provide10 mg4-[S-(3-bromophenyl)-N-(6-cyano-3-pyridinecarboxamido)-sulfoxamino]-5-methylsulfanyl-thiophene-2-carbamicacid tert-butyl ester.

EXAMPLE 35b4-[S-(3-Bromophenyl)-N-(6-cyano-3-pyridinecarboxamido)-sulfoxamino]-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

4-[S-(3-bromophenyl)-N-(6-cyano-3-pyridinecarboxamido)-sulfoxamino]-5-methylsulfanyl-thiophene-2-carbamicacid tert-butyl ester (4 mg, 0.0065 mmol, as prepared in Example 35:step a) was treated with TFA (50% in DCM) for 1 h at RT. The reactionmixture was evaporated in vacuo and the residue was purified usingRP-HPLC to give 2.0 mg of the title compound4-[S-(3-bromophenyl)-N-(6-cyano-3-pyridinecarboxamido)-sulfoxamino]-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate as a white solid. ¹H-NMR (CD₃OD): δ 9.45-9.46 (m, 1H),8.69 (dd, 1H, J=2.1, 8.1 Hz), 8.52 (s, 1H), 8.35-8.37 (m, 1H), 8.23 (dm,1H, J=8.1 Hz), 8.04 (dd, 1H, J=0.8, 8.1 Hz), 7.98 (dm, 1H, J=8.0 Hz),7.64 (t, 1H, J=8.0 Hz), and 2.73 (s, 3H). ESI-MS (m/z): Calcd. forC₁₉H₁₄BrN₅O₂S₃: 520 (M+1); found: 519.9.

EXAMPLE 364-[S-(3-Bromophenyl)-N-(acyl-3-pyridine-4-carboxamide)-sulfoxamino]-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

To4-[S-(3-bromophenyl)-N-(6-cyano-3-pyridinecarboxamido)-sulfoxamino]-5-methylsulfanyl-thiophene-2-carbamicacid tert-butyl ester (4 mg, 0.0065 mmol, as prepared in Example 35:step a) in an ice bath was added concentrated H₂SO₄ (1 mL). The reactionwas slowly warmed up to 60° C. for 1 hr. The mixture was diluted withMeOH (2 mL) and H₂O (7 mL) and purified using RP-HPLC to provide 1.8 mgof the titled compound4-[S-(3-bromophenyl)-N-(acyl-3-pyridine-4-carboxamide)-sulfoxamino]-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate. ¹H-NMR (CD₃OD): δ 9.36-9.40 (m, 1H), 8.67-8.72 (m,1H), 8.51 (s, 1H), 8.36-8.38 (m, 1H), 8.22-8.28 (m, 2H), 7.96-8.00 (m,1H), 7.61-7.67 (m, 1H), and 2.72 (s, 3H). ESI-MS (m/z): Calcd. forC₁₉H₁₆BrN₅O₃S₃: 538 (M+1); found: 537.9.

EXAMPLE 374-[S-(3-Bromophenyl)-N-(sulfonyl-3-phenylcarbonitrile)-sulfoxamino]-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

4-[S-(3-Bromophenyl)-sulfoxamino]-5-methylsulfanyl-thiophene-2-carbamicacid tert-butyl ester (10 mg, 0.02 mmol, as prepared in Example 24: stepj) was dissovled in THF in a microwave tube and to it was added2,6-lutidine (5 μL, 0.044 mmol) and 3-cyano-benzenesulfonyl chloride(5.6 mg, 0.028 mmol). The tube was sealed and heated in a microwave ovenat 110° C. for 20 min. The reaction mixture was allowed to cool,concentrated in vacuo, and then chromatographed using preparative TLC(1000 μm, 1:1 EtOAc/hexanes) to give an oily residue. A portion of thismaterial was immediately treated with 50% TFA in DCM for 1 h at RT andthe resulting mixture was purified on RP-HPLC to provide 1 mg of thetitled compound4-[S-(3-bromophenyl)-N-(sulfonyl-3-phenylcarbonitrile)-sulfoxamino]-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate. ¹H-NMR (CD₃OD): δ 8.38 (s, 1H), 8.14-8.19 (m, 3H),7.94-8.04 (m, 3H), 7.57-7.77 (m, 2H), and 2.72 (s, 3H). ESI-MS (m/z):Calcd. for C₁₉H₁₅BrN₄O₃S₄: 554.9 (M+1); found: 554.8.

EXAMPLE 384-[S-(3-Bromophenyl)-N-(sulfonyl-3-benzamide)-sulfoxamino]-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

EXAMPLE 38a 3-(1-Methyl-1-phenyl-ethylcarbamoyl)-benzenesulfonylchloride

3-Chlorosulfonyl-benzoyl chloride (1 g, 4.2 mmol) was dissolved in DCM(10 mL) and cooled in an ice bath. To the solution was added1-methyl-1-phenyl-ethylamine (0.9 g, 3.8 mmol) and 2,6-lutidine (1 mL,8.4 mmol). The mixture was allowed to warm up to RT and stirred for 4 h.The reaction mixture was diluted with EtOAc (100 mL) and washed with 1NHCl (2×75 mL) and brine. The organic layer was dried (MgSO₄) andevaporated in vacuo to provide 1.37 g (98%) of3-(1-methyl-1-phenyl-ethylcarbamoyl)-benzenesulfonyl chloride as a tansolid. ¹H-NMR (CDCl₃): δ 8.40 (t, 1H, J=1.7 Hz), 8.15-8.18 (m, 2H), 7.72(t, 1H, J=7.8 Hz), 7.46-7.50 (m, 2H), 7.36-7.41 (m, 2H), 7.27-7.32 (m,1H), 6.56 (br s, 1H), and 1.87 (s, 6H).

EXAMPLE 38b4-[S-(3-Bromophenyl)-N-(sulfonyl-3-benzamide)-sulfoxamino]-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

4-[S-(3-Bromophenyl)-sulfoxamino]-5-methylsulfanyl-thiophene-2-carbamicacid tert-butyl ester (33 mg, 0.067 mmol, as prepared in Example 24:step j), 3-(1-methyl-1-phenyl-ethylcarbamoyl)-benzenesulfonyl chloride(68 mg, 0.20 mmol, as prepared in Example 38: step a), and 2,6-lutidine(25 μL, 0.21 mmol) were dissolved in THF (4 mL) and then warmed up to50° C. After 48 h, the reaction mixture was diluted with EtOAc (50 mL)and then washed with saturated NaHCO₃. The organic layer was dried(MgSO₄) and then evaporated in vacuo to give a residue that was treatedwith 50% TFA in DCM for 2 h at RT. The volatiles were removed in vacuoand the crude product was purified using RP-HPLC (CH₃CN/H₂O gradient) toprovide 2.0 mg of the title compound4-[S-(3-bromophenyl)-N-(sulfonyl-3-benzamide)-sulfoxamino]-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate. ¹H-NMR (CD₃OD): δ 8.81 (m, 1H), 8.55 (s, 1H), 8.28 (t,1H, J=1.7 Hz), 8.13-8.18 (m, 2H), 8.04-8.06 (m, 1H), 7.90-7.92 (m, 1H),7.54-7.60 (m, 2H), and 2.70 (s, 3H). ESI-MS (m/z): Calcd. forC₁₉H₁₇BrN₄O₄S₄: 573.9 (M+1); found: 573.9.

EXAMPLE 394-[S-(3-Bromophenyl)-N-(sulfonyl-3-trifluoromethylbenzene)-sulfoxamino]-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

The title compound was prepared following the same procedure describedfor Example 38: step b. Reaction of4-[S-(3-bromophenyl)-sulfoxamino]-5-methylsulfanyl-thiophene-2-carbamicacid tert-butyl ester (10 mg, 0.02 mmol, as prepared in Example 24: stepj), 3-trifluoromethyl-benzenesulfonyl chloride (10 mg, 0.04 mmol), and2,6-lutidine (25 μL, 0.21 mmol) in THF (2 mL), followed by analogouswork up and purification as described in Example 38: step b, provided4.5 mg of the title compound4-[S-(3-bromophenyl)-N-(sulfonyl-3-trifluoromethylbenzene)-sulfoxamino]-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate. ¹H-NMR (CD₃OD): δ 8.37 (s, 1H), 8.15-8.19 (m, 2H),8.09-8.11 (m, 1H), 8.04-8.07 (m, 1H), 7.93-7.97 (m, 2H), 7.56-7.80 (m,2H), and 2.72 (s, 3H). ESI-MS (m/z): Calcd. for C₁₉H₁₅BrFN₃O₃S₄: 597.9(M+1); found: 597.8.

EXAMPLE 404-[S-(3-Bromophenyl)-N-(sulfonyl-2-methyl-5-nitro-benzene)-sulfoxamino]-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

The title compound was prepared following the same procedure describedfor Example 38: step b. Reaction of4-[S-(3-bromophenyl)-sulfoxamino]-5-methylsulfanyl-thiophene-2-carbamicacid tert-butyl ester (10 mg, 0.02 mmol, as prepared in Example 24: stepj), 4-methyl-3-nitro-benzenesulfonyl chloride (10 mg, 0.04 mmol), and2,6-lutidine (25 μL, 0.21 mmol) in THF (2 mL), followed by analogouswork up and purification as described in Example 38: step b, provided2.0 mg of the title compound 4-[S-(3-Bromophenyl)-N-(sulfonyl-2-methyl-5-nitro-benzene)-sulfoxamino]-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate. ¹H-NMR (CD₃OD): δ 8.34-8.46 (m, 3H), 8.11-8.14 (m,1H), 8.05 (dm, 1H, J=8.1 Hz), 7.95 (dm, 1H, J=8.0 Hz), 7.65-7.68 (m,1H), 7.59 (t, 1H, J=8.1 Hz), 2.89 (s, 3H), and 2.65 (s, 3H). ESI-MS(m/z): Calcd. for C₁₉H₁₇BrN₄O₅S₄: 588.9 (M+1); found: 588.9.

EXAMPLE 414-[S-(3-Bromophenyl)-N-(sulfonyl-5-methanesulfonyl-2-methyl-benzene)-sulfoxamino]-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

The title compound was prepared following the same procedure describedfor Example 38: step b. Reaction of4-[S-(3-bromophenyl)-sulfoxamino]-5-methylsulfanyl-thiophene-2-carbamicacid tert-butyl ester (10 mg, 0.02 mmol, as prepared in Example 24: stepj), 5-methanesulfonyl-2-methyl-benzenesulfonyl chloride (11 mg, 0.04mmol), and 2,6-lutidine (25 μL, 0.21 mmol) in THF (2 mL), followed byanalogous work up and purification as described in Example 38: step b,provided 1.0 mg of the title compound. ¹H-NMR (CD₃OD): δ 8.35 (s, 1H),8.15-8.17 (m, 1H), 8.03-8.08 (m, 2H), 7.95-7.98 (m, 1H), 7.73 (d, 1H,J=8.1 Hz), 7.68 (d, 1H, J=7.9 Hz), 7.60 (t, 1H, J=8.1 Hz), 3.14 (s, 3H),2.88 (s, 3H), and 2.65 (s, 3H). ESI-MS (m/z): Calcd. for C₂₀H₂₀BrN₃O₅S₅:621.9 (M+1); found: 621.9.

EXAMPLE 42 4-[S-(3-Bromophenyl)-N-(sulfonyl-5-bromo-4-chloro3-pyridine)-sulfoxamino]-5-methylsulfanyl-thiophene-2-carboxamidinebistrifluoroacetate

The title compound was prepared following the same procedure describedfor Example 38: step b. Reaction of4-[S-(3-bromophenyl)-sulfoxamino]-5-methylsulfanyl-thiophene-2-carbamicacid tert-butyl ester (10 mg, 0.02 mmol, as prepared in Example 24: stepj), 5-bromo-6-chloro-pyridine-3-sulfonyl chloride (12 mg, 0.04 mmol),and 2,6-lutidine (25 μL, 0.21 mmol) in THF (2 mL), followed by analogouswork up and purification as described in Example 38: step b, provided2.0 mg of the title compound4-[S-(3-bromophenyl)-N-(sulfonyl-5-bromo-4-chloro3-pyridine)-sulfoxamino]-5-methylsulfanyl-thiophene-2-carboxamidinebistrifluoroacetate. ¹H-NMR (CD₃OD): δ 8.77 (d, 1H, J=2.2 Hz), 8.49 (d,1H, J=2.2 Hz), 8.39 (s, 1H), 8.16-8.17 (m, 1H), 8.07 (dm, 1H, J=8.1 Hz),7.98 (dm, 1H, J=8.1 Hz), 7.62 (t, 1H, J=8.1 Hz), and 2.74 (s, 3H).ESI-MS (m/z): Calcd. for C₁₇H₁₃Br₂ClN₄O₃S₄: 642.8 (M+1); found: 642.8.

EXAMPLE 434-[S-(3-Bromophenyl)-N-[sulfonyl-7-(4-methyl-3,4-dihydro-2H-benzo[1,4]oxazine)]-sulfoxamino]-5-methylsulfanyl-thiophene-2-carboxamidinebistrifluoroacetate

The title compound was prepared following the same procedure describedfor Example 38: step b. Reaction of4-[S-(3-bromophenyl)-sulfoxamino]-5-methylsulfanyl-thiophene-2-carbamicacid tert-butyl ester (10 mg, 0.02 mm ol, as prepared in Example 24:step j), 4-methyl-3,4-dihydro-2H-benzo[1,4]oxazine-7-sulfonyl chloride(10 mg, 0.04 mmol), and 2,6-lutidine (25 μL, 0.21 mmol) in THF (2 mL),followed by analogous work up and purification as described in Example38: step b, provided 2.6 mg of the title compound4-[S-(3-bromophenyl)-N-[sulfonyl-7-(4-methyl-3,4-dihydro-2H-benzo[1,4]oxazine)]-sulfoxamino]-5-methylsulfanyl-thiophene-2-carboxamidinebistrifluoroacetate. ¹H-NMR (CD₃OD): δ 8.25 (s, 1H), 8.07 (t, 1H, J=1.7Hz), 7.96-7.80 (m, 1H), 7.89-7.92 (m, 1H), 7.54, (t, 1H, J=8.0 Hz), 7.08(dd, 1H, J=8.4, 2.1 Hz), 7.00 (d, 1H, J=2.3 Hz), 6.72 (d, 1H, J=8.4 Hz),4.30-4.35 (m, 2H), 3.48-3.72 (m, 2H), 2.90 (s, 3H), and 2.71 (s, 3H).ESI-MS (m/z): Calcd. for C₂₁H₂₁BrN₄O₄S₄: 600.9 (M+1); found: 600.9.

EXAMPLE 444-[S-(3-Bromophenyl)-N-(sulfonyl-3-guanidinobenzene)-sulfoxamino]-5-methylsulfanyl-thiophene-2-carboxamidinebistrifluoroacetate

4-[S-(3-Bromophenyl)-N-(6-cyano-3-pyridinecarboxamido)-sulfoxamino]-5-methylsulfanyl-thiophene-2-carbamicacid tert-butyl ester (10 mg, 0.016 mmol, prepared in Example 34: stepb) and N,N′-di-Boc-S-methylisothiourea (15 mg, 0.05 mmol) were dissolvedin AcOH/MeOH (1:15, 3 ml). The solution was heated at 50° C. for 24 hand then concentrated in vacuo. The residue was dissolved in EtOAc andwashed with water and brine. The EtOAc layer was removed in vacuo andthe residue was redissolved in TFA/DCM (1:1, 4 mL). After 1 h at RT, thesolvents were evaporated and the crude product was purified usingRP-HPLC as described in Example 38: step b to provide 2.0 mg of thetitle compound4-[S-(3-bromophenyl)-N-(sulfonyl-3-guanidinobenzene)-sulfoxamino]-5-methylsulfanyl-thiophene-2-carboxamidinebistrifluoroacetate. ¹H-NMR (CD₃OD): δ 8.41 (s, 1H), 8.21 (t, 1H, J=1.7Hz), 8.08 (ddd, 1H, J=7.9, 1.9, 0.9 Hz), 7.96 (ddd, 1H, J=7.9, 1.9, 0.9Hz), 7.89 (ddd, 1H, 7.9, 1.9, 1.0 Hz), 7.80-7.82 (m, 1H), 7.67 (t, 1H,7.9 Hz), 7.54-7.62 (m, 2H), and 2.76 (s, 3H). ESI-MS (m/z): Calcd. forC₁₉H₁BrN₆O₃S₄: 586.9 (M+1); found: 586.8.

EXAMPLE 45 4-[S-(3-Bromophenyl)-N-(sulfonyl-3-methanesulfonylbenzene)-sulfoxamino]-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

EXAMPLE 45a 3-Methanesulfonyl-benzenesulfonyl chloride

3-Methanesulfonyl-benzenesulfonyl chloride was prepared according to apreviously described procedure (Tetrahedron 59 (2003) 1317-1325).3-Methanesulfonyl-phenylamine (1 gm, 4.8 mmol) was dissolved in CH₃CN(40 mL). The solution was cooled in an ice bath (0-5° C.) and 4 mL ofacetic acid and 2 mL of concentrated HCl were added. To the mixture wasadded NaNO₂ (397 mg, 5.76 mmol, in 3 mL water) over 10 min at 5° C.After stirring 20 min, SO₂ gas was bubbled in over 30 min (˜200 drops)keeping the reaction mixture <7° C. A solution of CuCl₂ (840 mg, 6.24mmol) in water (2.5 mL) was added and the mixture was allowed to warmand stir for 16 h at RT. The mixture was concentrated in vacuo and theremaining mixture was diluted with 1N HCl and extracted with EtOAc(3×100 mL). The combined organic layer was washed with brine, dried(MgSO₄), and evaporated in vacuo to provide 1.2 gm of3-methanesulfonyl-benzenesulfonyl chloride as a pale yellow solid.¹H-NMR (CDCl₃): δ 8.62 (t, 1H, J=1.6 Hz), 8.33-8.36 (m, 2H), 7.92t, 1H,J=8.0 Hz), 7.28 (s, 1H), and 3.18 (s, 3H).

EXAMPLE 45b 4-[S-(3-Bromophenyl)-N-(sulfonyl-3-methanesulfonylbenzene)-sulfoxamino]-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

The title compound was prepared following the same procedure describedfor Example 37. Reaction of4-[S-(3-bromophenyl)-sulfoxamino]-5-methylsulfanyl-thiophene-2-carbamicacid tert-butyl ester (33 mg, 0.066 mmol, as prepared in Example 24:step j), 3-methanesulfonyl-benzenesulfonyl chloride (88 mg, 0.35 mmol,as prepared in Example 45: step a), and 2,6-lutidine (500 μL) in THF (2mL), followed by analogous work up and purification as described inExample 38: step b, provided 2.5 mg of the title compound4-[S-(3-bromophenyl)-N-(sulfonyl-3-methanesulfonylbenzene)-sulfoxamino]-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate. ¹H-NMR (CD₃OD): δ 8.34-8.36 (m, 2H), 8.19-5-8.24 (m,2H), 8.17 (t, 1H, J=1.9 Hz), 8.05 (ddd, 1H, J=8.1, 1.9, 0.9 Hz), 7.96(ddd, 1H, J=8.0, 1.9, 0.9 Hz), 7.83 (t, 1H, J=7.9 Hz), 7.59 (t, 1H, 8.1Hz), 3.19 (s, 3H), and 2.69 (s, 3H). ESI-MS (m/z): Calcd. forC₁₉H₁₈BrN₃O₅S₅: 607.9 (M+1); found: 607.9.

EXAMPLE 46 4-[S-[3-(4-guanidino-6-methyl-phenyl)phenyl]-N-(3-nitrobenzene-sulfonyl)sulfoximino]-5-methylsulfanyl-thiophene-2-carboxamidinebistrifluoroacetate

EXAMPLE 46a 2′-Methyl-4′-nitro-biphenyl-3-sulfinic acid methyl ester

A solution of 3-bromobenzene methyl sulfinate (541 mg, 2.3 mmol),4,4,5,5-tetramethyl-2-(2-methyl-4-nitro-phenyl)-[1,3,2]dioxaborolane(484 mg, 1.84 mmol), cesium carbonate (900 mg, 2.76 mmol), andPd(dppf)Cl₂ (145 mg, 0.18 mmol) was stirred in DMF at 80° C. for 4 hunder argon. The mixture was partitioned between EtOAc (100 mL) and aqNH₄Cl (30 mL) and the layers were separated. The organic layer wasfurther washed with water (4×30 mL), brine (30 mL), and was dried overNa₂SO₄. Concentration of the solution followed by purification of theresidue via silica gel chromatography (2-10% EtOAc in hexanes) yieldedthe product as a colorless oil (300 mg, 56%). ¹H NMR (CDCl₃): δ 8.19 (m,1H), 8.12 (ddd, 1H, J=0.6, 2.5, 8.4 Hz), 7.77 (ddd, 1H, J=1.2, 1.8, 7.8Hz), 7.65-7.71 (m, 2H), 7.54 (ddd, 1H, J=1.2, 1.8, 7.6 Hz), 7.41 (d, 1H,J=8.4 Hz), 6.65 (s, 1H), 3.58 (s, 3H), 2.38 (s, 3H).

EXAMPLE 46b 4′-tert-Butoxycarbonylamino-2′-methyl-biphenyl-3-sulfinicacid. methyl ester

A mixture of 2′-methyl-4′-nitro-biphenyl-3-sulfinic acid methyl ester(Example 46, step a 200 mg, 0.69 mmol)) and palladium (10% on carbon,100 mg) in MeOH (10 mL) was stirred under a hydrogen atmosphere (1 atmvia balloon) for 2 h. Di-tert-butyl dicarbonate (358 mg, 1.24 mmol) wasadded and the reaction was stirred for 3 h at RT. The mixture wasfiltered through celite and then was partitioned between EtOAc (100 mL)and water (30 mL). The layers were separated and the organic layer wasfurther washed with water (4×30 μL), brine (30 mL), and was dried overNa₂SO₄. Concentration of the solution followed by purification of theresidue via silica gel chromatography (5-10% EtOAc in hexanes) yieldedthe product as a colorless oil (191 mg, 77%). ¹H NMR(CDCl₃): δ7.68 (ddd,1H, J=1.2, 1.6, 7.6 Hz), 7.66 (m, 1H), 7.60 (dt, 1H, J=0.6, 7.6 Hz),7.51 (ddd, 1H, J=1.2, 1.6, 7.6 Hz), 7.37 (br s, 1H), 7.24 (dd, 1H, J2.2, 8.4 Hz), 7.17 (d, 1H, J=8.2 Hz), 6.57 (br s, 1H), 3.56 (s, 3H),2.26 (s, 3H), 1.51 (s, 9H). C₁₉H₂₃NO₄S: 362.1 (M+1) found: 262.0((M+1)-Boc).

EXAMPLE 46c[3′-(2-Chloro-5-cyano-thiophene-3-sulfinyl)-biphenyl-4-yl]-carbamic acidtert-butyl ester

To a solution of4′-tert-Butoxycarbonylamino-2′-methyl-biphenyl-3-sulfinic acid methylester in THF (Example 46, step b 350 mg, 0.97 mmol) was added a solutionof 4-(5-chloro-thiophene-2-carbonitrile) magnesium chloride (prepared asin Example 24: step e, 0.5M, 2 mL, 1 mmol) at −78° C. The solution wasallowed to warm to −20° C. over 30 min. Additional4-(5-chloro-thiophene-2-carbonitrile) magnesium chloride (4 mL) wasadded, the solution was stirred for 1 h, and an additional amount ofthiophene-grignard was added (2 mL). After stirring at −20 for 1 h, thereaction was quenched with NaHCO₃ (30 mL), and EtOAc (80 mL) was added.The layers were separated and the organic layer was washed with water(2×30 mL), brine (40 mL), and was dried over Na₂SO₄. The solution wasconcentrated in vacuo and the residue was purified by silica gel flashchromatography to yield the product (380 mg, 83%). ¹H NMR (CDCl₃): δ7.66 (ddd, 1H, J=1.4, 1.8, 7.6 Hz), 7.65 (s, 1H), 7.60 (t, 1H, J=1.6Hz), 7.57 (t, 1H, J=7.6 Hz), 7.47 (dt, 1H, J=1.4, 7.6 Hz), 7.36 (br s,1H), 7.22 (dd, 1H, J=2.2, 8.4 Hz), 7.13 (d, 1H, J=8.4 Hz), 6.51 (br s,1H), 2.22 (s, 3H), 1.53 (s, 9H). C₁₉H₂₃NO₄S: 362.1 (M+1) found: 262.0((M+1)-Boc). C₂₃H₂₁ClN₂O₃S₂: 473.1 (M+1) found: 417.0 ((M+1)-tBu), 373.0((M+1)-Boc).

EXAMPLE 46d 4-[S-[3-(4-carbamic acid tert-butyl ester-6-methylphenyl)phenyl]-N-3-nitro phenylsulfoximino]-5-chloro-thiophene-2-carbonitrile

To a suspension of[3′-(2-Chloro-5-cyano-thiophene-3-sulfinyl)-biphenyl-4-yl]-carbamic acidtert-butyl ester (Example 46, step c 380 mg, 0.8 mmol) and3-nitrophenylsulfonyl-iodinane (646 mg, 1.6 mmol) in acetonitrile (4 mL)was added copper (II) triflate (58 mg, 016 mmol). The reaction wasstirred for 5 min and the reaction turned brown. TLC analysis indicatedthat a decomposition might be occurring so the reaction was quenchedwith aq NaHCO₃ (2 mL). The solution was partitioned between EtOAc (100mL) and NaHCO₃ (30 mL) and the layers were separated. The organic layerwas washed with water (3×20 μL) and brine (30 mL). The organic solutionwas dried over Na₂SO₄, concentrated in vacuo, and the residue waspurified via silica gel flash chromatography to yield the product (156mg, 14%). ¹H NMR (CDCl₃): δ 8.84 (t, 1H, J=1.8 Hz), 8.42 (ddd, 1H,J=1.0, 2.2, 8.2 Hz), 8.34 (ddd, 1H, J=1.0, 1.6, 7.8 Hz), 8.06 (s, 1H),8.02 (m, 1H), 8.00 (m, 1H), 7.74 (t, 1H, J=8.1 Hz), 7.67 (m, 1H), 7.39(br s, 1H), 7.26 (dd, 1H, J=2.2, 8.2 Hz), 7.11 (d, 1H, J=8.2 Hz), 6.63(br s, 1H), 2.22 (s, 3H), 1.54 (s, 9H). C₁₉H₂₃NO₄S: 362.1 (M+1) found:262.0 ((M+1)-Boc).

EXAMPLE 46e 4-[S-[3-(4-guanidino-6-methyl-phenyl)phenyl]-N-3-nitrophenyl sulfoximino]-5-chloro-thiophene-2-carbonitrile

To a solution of 4-[S-[3-(4-carbamic acid tert-butyl ester-6-methylphenyl)phenyl]-N-3-nitro phenylsulfoximino]-5-chloro-thiophene-2-carbonitrile (Example 46, step d 46mg, 0.068 mmol) in DCM (2 mL) was added TFA (2 mL) and the solution wasstirred for 30 min at RT. The solvent was removed in vacuo and theresidue was taken up in EtOAc (23 mL). The organic layer was washed withNaHCO₃ (2×10 mL), brine (10 mL), and was dried over Na₂SO₄. The solventwas evaporated in vacuo and a portion of the residue (30 mg, 0.52 mmol)was dissolved in DCM (5 mL) and cooled to 0° C. Mercuric (II) chloride(41 mg, 0.15 mmol) was added followed by dropwise addition of1,3-Bis(tert-butoxycarbonyl)2-methyl-2-thiopseudourea (0.25M in DCM, 250uL, 0.63 mmol). The reaction warmed to RT over 30 min and was completeby TLC analysis. The solution was transferred to a silica gel column andwas eluted with a 5-20% gradient of EtOAc in hexanes to yield theproduct (36 mg, 84%). C₃₅H₃₅ClN₆O₉S₃: 815.1 (M+1); found: 814.6.

EXAMPLE 46f 4-[S-[3-(4-guanidino-6-methyl-phenyl)phenyl]-N-(3-nitrobenzene-sulfonyl)sulfoximino]-5-methylsulfanyl-thiophene-2-carboxamidinebistrifluoroacetate

To a solution of 4-[S-[3-(4-guanidino-6-methyl-phenyl)phenyl]-N-3-nitrophenyl sulfoximino]-5-chloro-thiophene-2-carbonitrile (Example 46, stepe; 36 mg, 0.044 mmol) in THF at −78° C. was added a solution of NaSMe(0.25M, 528 uL, 0.132 mmol) in MeOH. The reaction was allowed to warm toRT over 30 min and was stirred for an additional hr at RT. Ethyl acetate(30 mL) and aqueous NaHCO₃ (10 mL) were added and the layers wereseparated. The organic layer was washed with water (10 mL), brine (10mL), and was dried over Na₂SO₄. The solution was concentrated and theresidue was dissolved in methanolic ammonia (7N, 20 mL). Ammoniumformate (500 mg) was added and the reaction was heated at 40° C. for 12h. The solution was concentrated and the residue was dissolved in 1:1TFA/DCM (10 mL). After stirring for 1 h at RT, the solution wasconcentrated and the resulting residue was purified by RP-HPLC (10-55%acetonitrile in 0.1% TFA/water over 40 min.) to afford the titlecompound (6 mg, 26%) as a colorless glassy solid. ¹H NMR (CD₃OD): 67 ¹HNMR (CD₃OD): δ 8.61 (m, 1H), 8.48 (ddd, 1H, J=1.0, 2.3, 8.2 Hz), 8.43(s, 1H), 8.30 (ddd, 1H, J=1.0, 1.8, 7.9 Hz), 8.08 (m, 1H), 8.02 (m, 1H),7.83 (t, 1H, J=8.1 Hz), 7.77 (m, 1H), 7.73 (m, 1H), 7.35 (d, 1H, J=8.1Hz), 7.29 (m, 1H), 7.24 (m, 1H), 2.70 (s, 3H), 2.29 (s, 3H).C₂₆H₂₅N₇O₅S₄: 644.1 (M+1); found: 644.0.

EXAMPLE 47[3-Methyl-2-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-5-(2-trimethylsilanyl-ethoxycarbonylamino)-phenyl]-carbamicacid 2-trimethylsilanyl-ethyl ester

To a 0° C. solution of[3-Methyl-2-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-5-(2-trimethylsilanyl-ethoxycarbonylamino)-phenyl]-carbamicacid 2-trimethylsilanyl-ethyl ester (synthesis described in WO03099805)195 mg, 0.5 mmol) and pyridine (200 uL, 2.5 mmol) in DCM (10 mL) wasadded a solution of trimethylsilylethyl chloroformate (0.4 M in toluene,1.5 mL, 0.6 mmol) over 5 min. After stirring for 30 min, ethyl acetate(80 mL) and aqueous NaHCO₃ (20 mL) were added and the layers wereseparated. The organic layer was washed with aqueous citric acid (3×20mL), aqueous NaHCO₃ (20 mL), brine (20 mL), and was dried over Na₂SO₄.The solution was concentrated in vacuo and the residue was purified viasilica gel flash chromatography (5-15% EtOAc in hexanes) yielding theproduct (190 mg, 71%) as an oil. ¹H NMR (CDCl₃): δ 9.18 (s, 1H), 7.93(d, 1H, J=2.0 Hz), 7.27 (br s, 1H), 6.62 (s, 1H), 4.27 (m, 2H), 4.09 (m,4H), 2.50 (s, 3H), 1.37 (s, 9H), 1.06 (m, 4H), 0.09 (s, 9H), 0.07 (s,9H).

EXAMPLE 484-[S-([6-Methyl-4-(2-trimethylsilanyl-ethoxycarbonylamino)-biphenyl-2-yl]-carbamicacid 2-trimethylsilanyl-ethyl ester)-N-sulfony-4-analinesulfoximino]-5-methylsulfanyl-thiophene-2-carbamic acid tert-butyl ester

The procedure outlined in Example 18, step c was followed using4-[S-(3-Bromophenyl)-N-sulfonyl-3-analinesulfoximino]-5-methylsulfanyl-thiophene-2-carbamic acid tert-butyl ester(Example 33: step b; 101 mg, 0.16 mmol),[3-Methyl-2-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-5-(2-trimethylsilanyl-ethoxycarbonylamino)-phenyl]-carbamicacid 2-trimethylsilanyl-ethyl ester (190 mg, 0.35 mmol), and saturatedNaHCO₃ (2 mL), tetrakis(triphenylphosphine)palladium (0) (60 mg, 0.054mmol), and dimethoxyethane (4 mL). Analogous purification yielded theproduct (78 mg, 50%). ¹H NMR (CDCl₃): δ 7.9-8.05 (m, 3H), 7.69 (m, 1H),7.67 (m, 1H), 7.60 (m, 1H), 7.44 (m, 1H), 7.28 (br s, 1H), 6.72 (m, 1H),6.57 (m, 2H), 6.08 (br m, 1H), 4.28 (m, 2H), 4.10 (m, 2H), 2.52 (br d,3H), 1.93 (br d, 3H), 1.52 (s, 9H), 1.08 (m, 2H), 0.92 (m, 2H), 0.08 (s,9H), −0.02 (br d, 9H). C₄₂H₅₈N₆O₉S₄Si₂: 975.3 (M+1); found: 932.8((M+1)-CO₂).

EXAMPLE 49

Tablet Preparation

Tablets containing 25.0, 50.0, and 100.0 mg, respectively, of an activecompound are prepared as illustrated below: TABLET FOR DOSES CONTAININGFROM 25-100 MG OF THE ACTIVE COMPOUND Amount-mg Active Compound 25.050.0 100.00 Microcrystalline cellulose 37.25 100.0 200.0 Modified foodcorn starch 37.25 4.25 8.5 Magnesium stearate 0.50 0.75 1.5

All of the active compound, cellulose, and a portion of the cornstarchare mixed and granulated to 10% corn starch paste. The resultinggranulation is sieved, dried and blended with the remainder of the cornstarch and the magnesium stearate. The resulting granulation is thencompressed into tablets containing 25.0, 50.0, and 100.0 mg,respectively, of active ingredient per tablet.

EXAMPLE 50

Intravenous Solution Preparation

An intravenous dosage form of the above-indicated active compounds isprepared as follows: Active Compound 0.5-10.0 mg Sodium Citrate 5-50 mgCitric Acid 1-15 mg Sodium Chloride 1-8 mg Water for Injection (USP)q.s. to 1 ml

Utilizing the above quantities, the active compound is dissolved at roomtemperature in a previously prepared solution of sodium chloride, citricacid, and sodium citrate in Water for Injection (USP, see page 1636 ofUnited States Pharmacopeia/National Formulary for 1995, published byUnited States Pharmacopeial Convention, Inc., Rockville, Md. (1994).

EXAMPLE 51

In Vitro Inhibition of C1s

Reagents: All buffer salts were obtained from Sigma Chemical Company(St. Louis, Mo.), and were of the highest purity available. DTNB waspurchased from Pierce (Rockford, Ill.). Z-Gly-Arg-S-Bzl was purchasedfrom Enzyme Systems Products (Livermore, Calif.). Activated human C1swas purchased from Calbiochem (La Jolla, Calif.).

K_(i) Determinations: All assays were based on the ability of the testcompound to inhibit the C1 s-catalyzed hydrolysis of the substrateZ-Gly-Arg-S-Bzl, which was observed via a secondary reaction with5,5′-dithio-bis(2-nitrobenzoic acid) (DTNB). In a typical K_(i)determination, substrate was prepared in DMSO, and diluted into an assaybuffer consisting of 50 mM HEPES, 200 mM NaCl, pH 7.5, 0.05%n-octyl-β-D-glucopyranoside. Substrate solutions were prepared at aconcentration of 45 μM (K_(m)=190 μM) with DTNB at a concentration of200 μM in assay buffer. Test compounds were prepared as a 10 μM solutionin DMSO. Dilutions were prepared in DMSO yielding 7 final concentrationsencompassing a 700-fold concentration range. Purified activated C1s wasdiluted into assay buffer for a working concentration of 66 nM.

In a typical K_(i) determination, into each well of a 96-well plate waspipetted 280 μL of substrate solution, 10 μL of test compound solution,and the plate allowed to thermally equilibrate at 37° C. for 15 minutes.Reactions were initiated by the addition of a 10 μL aliquot of theenzyme, and the absorbance increase at 405 nm was continuously recordedfor 15 minutes in a Molecular Devices plate reader. Final DMSOconcentration was 4.3%. Final reagent concentrations were: [C1 s]=2.3nM, [Z-Gly-Arg-S-Bzl]=45 μM, [DTNB]=200 μM. The ratio of the velocity(rate of change in absorbance as a function of time) for a samplecontaining no test compound was divided by the velocity of a samplecontaining test compound, and was plotted as a function of test compoundconcentration. The data were fit to a linear regression, and the valueof the slope of the line calculated. The inverse of the slope was theexperimentally determined K_(i) value.

EXAMPLE 52

In Vitro Inhibition of MASP-2

Reagents: All buffer salts were obtained from Sigma Chemical Company(St. Louis, Mo.), and were of the highest purity available. DTNB waspurchased from Pierce (Rockford, Ill.). Z-Gly-Arg-S-Bzl was purchasedfrom Enzyme Systems Products (Livermore, Calif.). Autoactivated 2-chainhuman MASP-2 (His-tag, Cys300-Phe686) was produced in-house from aBaculovirus expression system in insect cells.

K_(i) Determinations: All assays were based on the ability of the testcompound to inhibit the MASP-2-catalyzed hydrolysis of the substrateZ-Gly-Arg-S-Bzl, which was observed via a secondary reaction with5,5′-dithio-bis(2-nitrobenzoic acid) (DTNB). In a typical K_(i)determination, substrate was prepared in DMSO, and diluted into an assaybuffer consisting of 50 mM HEPES, 200 mM NaCl, pH 7.5, 0.05%n-octyl-β-D-glucopyranoside. Substrate solutions were prepared at aconcentration of 45 μM (K_(m)=8.6 μM) with DTNB at a concentration of200 μM in assay buffer. Test compounds were prepared as a 10 μM finalconcentration in assay buffer. Dilutions of test compounds were preparedin assay buffer yielding at least 7 final concentrations encompassing a700-fold concentration range. Purified activated MASP-2 was diluted intoassay buffer for a working concentration of 30 nM.

In a typical K_(i) determination, into each well of a 96-well plate waspipetted 280 μL of substrate solution followed by 10 μL of test compoundsolution, and the plate was allowed to thermally equilibrate at 37° C.for 10 minutes. Reactions were initiated by the addition of a 10 μLaliquot of the enzyme, and the absorbance increase at 405 nm wascontinuously recorded for 15 minutes in a Molecular Devices platereader. Final reagent concentrations were: [MASP-2]=1.0 nM,[Z-Gly-Arg-S-Bzl]=45 μM, [DTNB]=200 μM. The ratio of the velocity (rateof change in absorbance as a function of time) for a sample containingno test compound was divided by the velocity of a sample containing testcompound, and was plotted as a function of test compound concentration.The data were fit to a linear regression, and the value of the slope ofthe line calculated. The inverse of the slope was the experimentallydetermined apparent K_(i) value (K_(i) app). The K_(i) app was correctedfor true K_(i) from the relationship between the substrate concentration[S] and the substrate Km, where K_(i)=K_(i) app ×(1/(1+[S]/Km)).

Complement Inhibition Data

The following compounds have Ki values in the range of 0.008 to 6.0micromolar (μM) for C1 s: Examples 3-22, 25-28, 30-46.

The compound of Example 46 has a Ki value of 0.010 μM for C1 s. Thecompound of Example 18 has a Ki value of 0.011 μM for C1s and 0.44 μMfor MASP-2. The results indicate that the compounds of the presentinvention are inhibitors of complement, specifically C1s.

It will be understood to those of ordinary skill in the art that theinvention as described herein can be performed within a wide andequivalent range of conditions, formulations, and other parameterswithout affecting the scope of the invention or any embodiment thereof.All patents and publications cited herein are fully incorporated byreference into this text in their entirety.

1. A racemic or homochiral compound of Formula I:

or a solvate, hydrate, pharmaceutically acceptable salt, or prodrugthereof; wherein: Z is —CO—, —SO₂—, —SO₂CH₂—, —COCH₂—, —CONH—, or adirect bond wherein the carbonyl carbon or the sulfur is bonded to thenitrogen; Q is C₁₋₄ alkyl, halo, amino, C₁₋₆ -alkylthio, C₂₋₆alkenylthio, C₁₋₆ alkoxy, trifluoromethyl, methylsulfonyl, orbenzylthio; R¹ is hydrogen, C₁₋₄ alkyl, aryl, heteroaryl, benzo fusedheteroaryl, benzo fused heterocyclyl, any of which except hydrogen isoptionally substituted with one or two substituents independentlyselected from: guanidinyl, halogen, —CF₃, —CN, —NO₂, —NR_(d)COR_(e),—CONR_(d)R_(e), —NR_(d)SO₂R_(e), —SO₂NR_(d)R_(e), —NR_(d)CONHR_(e),—R_(d), —NR_(d)R_(e), —CO₂R_(d), —SO₂R_(d), or heterocyclyl which may besubstituted with one R_(d); R² is hydrogen, halogen, aryl or heteroaryl,wherein the aryl or heteroaryl are optionally substituted with up tothree substituents independently selected from: C(1-4)alkyl,—NR_(f)R_(g), guanidinyl; A is aryl or heteroaryl; R_(a), R_(b) R_(c),R_(d) R_(e), R_(f) and R_(g) are independently hydrogen, C₁₋₄ alkyl,C₆₋₁₀ aryl, C₁₋₄ hydroxyalkyl, C₁₋₄ aminoalkyl,mono(C₁₋₄)alkylamino(C₂₋₆)alkyl, di(C₁₋₄)alkylamino(C₂₋₆)alkyl,carboxy(C₁₋₄)alkyl, cyano, nitro, amino, C₁₋₄ alkoxy, hydroxy, or—CO₂R^(w), wherein R^(w) is hydrogen, hydroxy, C₁₋₄ alkoxy, cyano, C₁₋₄alkoxycarbonyl, C₁₋₄ alkyl, C₃₋₈ cycloalkyl, phenyl, or benzyl.
 2. Acompound of claim 1, wherein: Q is —SC₍₁₋₄₎alkyl; A is phenyl.
 3. Acompound of claim 1, wherein: Q is —SC₍₁₋₄₎alkyl; A is phenyl; R¹ ishydrogen, C₁₋₄ alkyl, aryl, heteroaryl, benzo fused heteroaryl, benzofused heterocyclyl, any of which except hydrogen is optionallysubstituted with one or two substituents independently selected from:guanidinyl, halogen, —CF₃, —CN, —NO₂, NR_(d)COR_(e), NR_(d)SO₂R_(e),NR_(d)CONHR_(e), R_(d), NH₂, CO₂R_(e), SO₂R_(d), heterocyclyl.
 4. Acompound of claim 1, wherein: Q is —SC₍₁₋₄₎alkyl; A is phenyl; R_(a),R_(b), and R_(c) are hydrogens; R¹ is hydrogen, C₁₋₄ alkyl, phenyl,pyridyl, imidazolyl, thiazolyl, furanyl, thienyl, benzothiazolyl,pyrazolyl, pyrimidinyl, 3,4-Dihydro-2H-benzo[1,4]oxazine,benzimidazolyl, benzofuranyl, indolyl, benzothiophenyl, or 1,3,4oxadiazolyl, any of which except hydrogen is optionally substituted withone or two substituents independently selected from: guanidinyl,halogen, —CF₃, —CN, —NO₂, NR_(d)COR_(e), NR_(d)SO₂R_(e),NR_(d)CONHR_(e), R_(d), NH₂, CO₂R_(e), SO₂R_(d), heterocyclyl.
 5. Acompound selected from the group consisting of the following:4-[S-(3-Bromophenyl)-N-(2-nitrobenzene-sulfonyl)sulfoxamino]-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate;4-[S-(3-Bromophenyl)-N-(3-acetamidobenzene-sulfonyl)sulfoxamino]-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate;4-[S-(3-Bromophenyl)-N-(3-{N,N-bismethanesulfonyl}aminobenzene-sulfonyl)sulfoxamino]-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate;4-[S-(3-Bromophenyl)-N-(3-ureidobenzene-sulfonyl)sulfoxamino]-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate;4-[S-(3-Bromophenyl)-N-(3-methanesulfonamidobenzene-sulfonyl)sulfoxamino]-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate;4-[S-(3-Bromophenyl)-N-{3-(5-methyl-[1,3,4]oxadiazol-2-yl)-benzene-sulfonyl}sulfoxamino]-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate;4-[S-(3-Bromophenyl)-N-{3-(oxazol-5-yl-benzene-sulfonyl}sulfoxamino]-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate; 4-[S-(3-Bromo-benzenesulfonyl)-N-(m-sulfonyl benzoicacid)-sulfoxamino]-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate; 4-[S-(3-Bromo-benzenesulfonyl)-N-(p-sulfonyl benzoicacid)-sulfoxamino]-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate;4-[S-(3-Bromophenyl)-N-Tosylsulfoximino]-5-methylsulfanyl-thiophene--2-carboxamidinetrifluoroacetate;5-Bromo-4[S-(3-Bromophenyl)-N-Tosylsulfoximino]-thiophene-2-carboxamidinetrifluoroacetate;4-[S-(3-Bromophenyl)-N-Nosylsulfoximino]-5-methylsulfanyl-thiophene-2-amidinetrifluoroacetate; 4-[S-(3-Bromophenyl)-N-sulfonyl-3-nitro-benzenesulfoximino]-5-methylsulfanyl-thiophene-2-amidine trifluoroacetate;4-[S-(3-Bromophenyl)-N-sulfonyl-4-aminophenylsulfoximino]-5-methylsulfanyl-thiophene-2-amidinetrifluoroacetate; 4-[S-(3-Bromophenyl)-N-sulfonyl-3-analinesulfoximino]-5-methylsulfanyl-thiophene-2-amidine trifluoroacetate;4-[S-(3-Bromophenyl)-N-(sulfonyl-3-phenylcarbonitrile)-sulfoxamino]-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate;4-[S-(3-Bromophenyl)-N-(sulfonyl-3-benzamide)-sulfoxamino]-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate;4-[S-(3-Bromophenyl)-N-(sulfonyl-3-trifluoromethylbenzene)-sulfoxamino]-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate;4-[S-(3-Bromophenyl)-N-(sulfonyl-2-methyl-5-nitro-benzene)-sulfoxamino]-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate;4-[S-(3-Bromophenyl)-N-(sulfonyl-5-methanesulfonyl-2-methyl-benzene)-sulfoxamino]-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate;4-[S-(3-Bromophenyl)-N-(sulfonyl-3-guanidinobenzene)-sulfoxamino]-5-methylsulfanyl-thiophene-2-carboxamidinebistrifluoroacetate; and4-[S-(3-Bromophenyl)-N-(sulfonyl-3-methanesulfonylbenzene)-sulfoxamino]-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate.
 6. A compound which is:4-[S-(3-Bromophenyl)-N-p-tolyl-formamide]-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate.
 7. A compound selected from the group consisting ofthe following:4-[S-(3-Bromophenyl)-N-benzamide]-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate;4-[S-(3-Bromophenyl)-N-3-nitro-benzamide]-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate;4-[S-(3-Bromophenyl)-N-3-amino-benzamide]-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate;4-[S-(3-Bromophenyl)-N-(6-cyano-3-pyridinecarboxamido)-sulfoxamino]-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate; and4-[S-(3-Bromophenyl)-N-(acyl-3-pyridine-4-carboxamide)-sulfoxamino]-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate.
 8. A compound selected from the group consisting ofthe following:4-[S-(3-Bromophenyl)-N-(phenylmethane-sulfonyl)sulfoxamino]-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate;4-[S-(3-Bromophenyl)-N-(methanesulfonyl)-sulfoxamino]-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate; and4-[S-(3-Bromophenyl)-N-({2-aminophenyl}methane-sulfonyl)sulfoxamino]-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate.
 9. A compound selected from the group consisting ofthe following:4-[S-[3-(2-Amino-4-guanidino-6-methyl-phenyl)phenyl]-N-(3-ureidobenzene-sulfonyl)sulfoxamino]-5-methylsulfanyl-thiophene-2-carboxamidinebistrifluoroacetate;4-[S-[3-(2-Tolylphenyl)phenyl]-N-Tosylsulfoximino]-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate;4-[S-[3-(2-amino-4-guanidino-6-methyl-phenyl)phenyl]-N-(4-ureidobenzene-sulfonyl)sulfoxamino]-5-methylsulfanyl-thiophene-2-carboxamidinebistrifluoroacetate; and4-[S-[3-(4-guanidino-6-methyl-phenyl)phenyl]-N-(3-nitrobenzene-sulfonyl)sulfoximino]-5-methylsulfanyl-thiophene-2-carboxamidinebistrifluoroacetate.
 10. A compound selected from the group consistingof the following:4-[S-(3-Bromophenyl)-N-(2-pyridinesulfonyl)-sulfoxamino]-5-methylsulfanyl-thiophene-2-carboxamidinebis trifluoroacetate; 4-[S-(3-Bromophenyl)-N-(m-sulfonylpyridyl)-sulfoxamino]-5-methylsulfanyl-thiophene-2-carboxamidine bistrifluoroacetate;4-[S-(3-Bromophenyl)-N-sulfonyl-3-N-(5-Methanesulfonyl-4-methyl-thiazol-2-yl)-acetamidesulfoximino]-5-methylsulfanyl-thiophene-2-amidine trifluoroacetate;4-[S-(3-Bromophenyl)-N-(sulfonyl-5-bromo-4-chloro3-pyridine)-sulfoxamino]-5-methylsulfanyl-thiophene-2-carboxamidinebistrifluoroacetate; and4-[S-(3-Bromophenyl)-N-[sulfonyl-7-(4-methyl-3,4-dihydro-2H-benzo[1,4]oxazine)]-sulfoxamino]-5-methylsulfanyl-thiophene-2-carboxamidinebistrifluoroacetate.
 11. A compound selected from the group consistingof the following:4-[S-(3-Bromophenyl)-N-(phenyl)-sulfoxamino]-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate;4-[S-(3-Bromophenyl)-sulfoximino]-5-methylsulfanyl-thiophene-2-carbamicacid tert-butyl ester; and4-(3-Bromo-benzenesulfoxamine)-5-methylsulfanyl-thiophene-2-carboxamidine.12. A compound which is:4-(3-Bromo-benzenesulfoxamineacetamide)-5-methylsulfanyl-thiophene-2-carboxamidine.13. A pharmaceutical composition, comprising a compound of claim 1 and apharmaceutically-acceptable carrier or diluent.
 14. A method fortreating the symptoms of an acute or chronic disorder mediated by theclassical pathway or the MBL pathway of the complement cascade,comprising administering to a mammal in need of such treatment atherapeutically effective amount of a conjugated complement inhibitor ofclaim
 1. 15. The method of claim 14, wherein said disorder isinflammation, tissue damage, or an autoimmune disease.
 16. The method ofclaim 15, wherein said inflammation or tissue damage arises followingstroke, myocardial infarction, hemorrhagic shock or surgery, or acombination thereof.
 17. The method of claim 14, wherein disorder isintestinal inflammation of Crohn's disease, restenosis or psoriasis. 18.The method of claim 14, wherein said compound is administered to amammal before, during or after the transplant of an organ or a graft.19. The method of claim 14, wherein said compound is administered to amammal before, during or after (1) treatment of said mammal with IL-2,(2) bone marrow transplantation in said mammal or (3) onset ofpancreatitis in said mammal, in an amount effective to reduce thetoxicity and side-effects of the IL-2 treatment, bone marrowtransplantation or pancreatitis.
 20. The method of claim 14, whereinsaid disorder is an autoimmune disease.
 21. The method of claim 14,wherein said disorder is Addison's disease, Type I diabetes mellitus,Hashimoto's thyroiditis, glomerulonephritis and cutaneous lesions ofsystemic lupus erythematosus, other glomerulonephritides, bullouspemphigoid, dermatitis herpetiformis, Goodpasture's syndrome, Graves'disease, myasthenia gravis, insulin resistance, autoimmune hemolyticanemia, autoimmune thrombocytopenic purpura, immune-complex-inducedvasculitis glomerulonephritis, type II collagen-induced arthritis,rheumatoid arthritis or allergic neuritis.
 22. The method of claim 14,wherein said disorder is myasthenia gravis (MG), rheumatoid arthritis,or systemic lupus erythematosus.
 23. The method of claim 14, whereinsaid disorder is a neurodegenerative disease.
 24. The method of claim23, wherein said neurodegenerative disease is multiple sclerosis (MS),Guillain-Barré syndrome (GBS), Miller-Fisher syndrome (MFS), Alzheimer'sdisease (AD) or variant Creutzfeldt-Jakob disease (vCJD).
 25. The methodof claim 14, wherein said disorder is adult respiratory distresssyndrome.
 26. The method of claim 14, wherein said disorder is septicshock.
 27. The method of claim 14, wherein said disorder is hereditaryangioedema, paroxysmal nocturnal hemoglobinuria, wound healing, braintrauma, asthma, hemodialysis, infection, dermatosis, inflammatory boweldisease, osteoporosis, osteoarthritis, thermal injury (burns andfrostbite), hemolytic anemia or post pump syndrome in cardiopulmonarybypass.
 28. A method of reducing rejection of a transplant or graft inan individual, comprising administering a compound of claim 1 to theindividual.
 29. The method of claim 28, wherein the individual receivesa transplant or graft as part of a therapy for a disorder selected fromthe group consisting of heart failure, diabetes, stroke, Parkinson'sdisease, Alzheimer's disease, liver disease, kidney disease, burns, andwounds.
 30. The method of claim 29, wherein the cells of the celltransplantation are stem cells, primary cells, cells derived from tissueculture, pancreatic islet cells, cells expressing insulin, cellsexpressing glucose-modulating hormones, or cells expressing factorsuseful for the treatment of diabetes.
 31. A method for preventingcomplement activation in an organ in an organ preservation solution,comprising contacting the organ with a conjugated complement inhibitorof claim
 1. 32. A method for preventing complement activation inresponse to insertion of a medical device into an individual, comprisingcontacting the device with a conjugated complement inhibitor of claim 1.33. The method of claim 32, wherein the medical device is a stent,prosthesis, an artificial organ, or an artificial joint.
 34. A processfor the preparation of a compound of Formula I comprising:

converting 4-Bromo-5-chloro-thiophene-2-carbonitrile to a compound ofFormula I.
 35. The process of claim 34, further comprising:

reacting sulfoximine (1-4) with a nucleophile, Q-M, where M is a metalsuch as an alkali, allows replacement of the leaving group; wherein Lvis a leaving group such as Br, Cl, F, or SO₂Me.
 36. The process of claim35 further comprising:

oxidizing sulfoxide (1-3) to sulfoximine (1-4) by a substitutedsulfonylimino iodinane, wherein reactions are carried out in thepresence of an aprotic solvent such as acetonitrile, and a lewis acidsuch as copper (II) trifluoromethane sulfonate.
 37. The process of claim36 further comprising:

treating 4-bromo-5-chloro-thiophene-2-carbonitrile (1-2) with isopropylmagnesium chloride, followed by a sulfinic methyl ester, such asmeta-bromo benzene sulfinic methyl ester, to give the sulfoxide (1-3).